UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 1 of 206 PROTOCOL PS0009  AMENDMENT 4  
A PHASE 3, MULTICENT ER, RANDOMIZED, DOUB LE-BLIND, 
PLACEBO - AND ACTIVE COMPARATOR -CONTROLLE D, 
PARALLEL -GROUP STUDY TO EVALUATE TH E EFFICACY 
AND SAFETY OF BIMEKI ZUMAB IN ADULT SUBJE CTS WITH 
MODERATE TO SEVERE C HRONIC PLAQUE PSORIA SIS 
PHASE 3  
EudraCT Number: 2016 -003425 -42 
IND Number: 128707  
Sponsor:  
UCB Biopharma SPRL  
Allée de la Recherche 60  
1070 Brussels  
BELGIUM  
Protocol/Amendment number  Date  Type of 
amendment  
Final Protocol  15 Aug 2017  Not applicable  
Protocol Amendment 1  19 Sep 2017  Not applicable  
Protocol Amendment 2  15 Oct 2017  Not applicable  
Protocol Amendment 3  06 Apr 2018  Substantial  
Protocol Amendment  4 21 May 2019  Nonsubstantial  
Confidential Material  
Confidential  
This document is the property of UCB and may not – in full or in part – be passed on, 
reproduced, published, or otherwise used without the express permission of UCB.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 2 of 206 STUDY CONTACT INFORMATIO N 
Sponsor  
UCB Biopharma SPRL  
Allée de la Recherche 60  
1070 Brussels, BELGIUM  
Sponsor Study Physician  
Name:  , MD, PhD  
Address:  UCB Biosciences, 8010 Arco Corporation Drive, Raleigh, NC 27617  
Phone:   
Fax:  
Clinical Project Manager  
Name:   
Address:  UCB Biosciences, 8010 Arco Corporation Drive, Raleigh, NC 27617  
Phone:   
Fax:   
Clinical Trial Biostatistician  
Name:   
Address:  UCB Biosciences, 8010 Arco Corporation Drive, Raleigh, NC 27617  
Phone:   
Fax:  
Clinical Monitoring Contract Research Organization  
Name:  PAREXEL International (IRL) Limited -Ireland  
Address:  Ireland Limited at 70 Sir John Rogerson’s Quay, Dublin 2, Ireland  
Phone:  +353 (1) 477 3171  
Fax: +353 (1) 477 3308  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 3 of 206 SERIOUS ADVERSE EVENT REPORTING  
Serious adverse event reporting (24h)  
Fax Europe and Rest of the World: +32 2 386 24 21  
USA and Canada:  +1 800 880 6949  
 or +1 866 890 3175  
Email  Global:  DS_ICT@ucb.com  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 4 of 206 TABLE OF CONTENTS  
LIST OF ABBREVIATION S ................................ ................................ ................................ .. 10 
1 SUMMARY  ................................ ................................ ................................ .....................  14 
2 INTRODUCTION  ................................ ................................ ................................ ...........  15 
2.1 Psoriasis  ................................ ................................ ................................ .......................  15 
2.1.1  Global epidemiology of psoriasis  ................................ ................................ ........  15 
2.1.2  Current treatments for psoriasis  ................................ ................................ ...........  16 
2.2 Bimekizumab  ................................ ................................ ................................ ...............  18 
2.2.1  Clinical  ................................ ................................ ................................ .................  18 
2.2.1.1  Completed studie s ................................ ................................ .....................  18 
2.2.1.2  Ongoing studies  ................................ ................................ .........................  20 
2.2.2  Nonclinical  ................................ ................................ ................................ ...........  20 
3 STUDY OBJECTIVE(S)  ................................ ................................ ................................ . 21 
3.1 Primary objective  ................................ ................................ ................................ .........  21 
3.2 Secondary objectives  ................................ ................................ ................................ ... 21 
3.3 Other objectives  ................................ ................................ ................................ ...........  21 
4 STUDY VARIABLES  ................................ ................................ ................................ ..... 22 
4.1 Primary efficacy  variables  ................................ ................................ ...........................  22 
4.2 Secondary variables  ................................ ................................ ................................ ..... 22 
4.2.1  Secondary efficacy variables  ................................ ................................ ...............  22 
4.2.2  Secondary safety variables  ................................ ................................ ..................  22 
4.3 Other variables  ................................ ................................ ................................ .............  22 
4.3.1  Other effica cy variable(s)  ................................ ................................ ....................  23 
4.3.2  Other safety variables  ................................ ................................ ..........................  24 
4.3.3  Pharmacokinetic variable  ................................ ................................ .....................  24 
4.3.4  Pharmacogenomic variables  ................................ ................................ ................  24 
4.3.5  Immunological variable  ................................ ................................ .......................  24 
5 STUDY DESIGN  ................................ ................................ ................................ .............  25 
5.1 Study description  ................................ ................................ ................................ .........  25 
5.2 Study periods  ................................ ................................ ................................ ...............  25 
5.2.1  Screening Period  ................................ ................................ ................................ .. 25 
5.2.2  Initial Treatment Period  ................................ ................................ .......................  25 
5.2.3  Maintenance Treatment Period  ................................ ................................ ............  26 
5.2.4 Safety Follow -Up ................................ ................................ ................................ . 26 
5.2.5  Premature End of Treatment  ................................ ................................ ................  26 
5.3 Study duration per subject  ................................ ................................ ...........................  26 
5.4 Planned number of subjects and site(s)  ................................ ................................ ........  27 
5.5 Anticipated regions and countries  ................................ ................................ ................  27 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 5 of 206 5.6 Schedule of study assessments ................................ ................................ .....................  27 
5.7 Schematic diagram  ................................ ................................ ................................ ....... 33 
5.8 Rationale fo r study design and selection of dose  ................................ .........................  35 
5.8.1  Study design  ................................ ................................ ................................ .........  35 
5.8.2  Dose selection  ................................ ................................ ................................ ...... 35 
6 SELECTION AND WITHDRAWAL OF SUBJEC TS ................................ ...................  35 
6.1 Inclusion criteria  ................................ ................................ ................................ ..........  35 
6.2 Exclusion criteria  ................................ ................................ ................................ .........  36 
6.3 Withdrawal criteria  ................................ ................................ ................................ ...... 39 
6.3.1  Potentia l drug -induced liver injury IMP discontinuation criteria  ........................  41 
7 STUDY TREATMENT(S)  ................................ ................................ ..............................  42 
7.1 Description of investigational medicinal product(s)  ................................ ....................  42 
7.2 Treatment(s) to be administered  ................................ ................................ ..................  42 
7.3 Packaging  ................................ ................................ ................................ .....................  44 
7.4 Labeling  ................................ ................................ ................................ .......................  44 
7.5 Handling and storage requirements  ................................ ................................ .............  44 
7.6 Drug accountability  ................................ ................................ ................................ ...... 44 
7.7 Procedures for monitoring subject compliance  ................................ ............................  45 
7.8 Concomitant medication(s)/treatment(s)  ................................ ................................ ..... 45 
7.8.1  Permitted concomitant treatments (medications and therapies)  ..........................  45 
7.8.1.1  Topical medications  ................................ ................................ ..................  45 
7.8.1.2  Other medications  ................................ ................................ ......................  45 
7.8.2  Prohibited concomitant treatments (medications and therapies)  .........................  46 
7.8.2.1  Vaccines  ................................ ................................ ................................ .... 47 
7.9 Blinding ................................ ................................ ................................ ........................  47 
7.9.1  Procedures for maintaining and breaking the treatment blind  .............................  48 
7.9.1.1  Maintenance of IMP blind  ................................ ................................ .........  48 
7.9.1.2  Breaking the treatment blind in an  emergency situation  ...........................  48 
7.10  Randomization and numbering of subjects  ................................ ................................ .. 48 
8 STUDY PROCEDURES BY VISIT  ................................ ................................ ...............  48 
8.1 Screening Visit (2 to 5 Weeks)  ................................ ................................ ....................  49 
8.2 Initial Treatment Period  ................................ ................................ ...............................  50 
8.2.1  Baseline Visit  ................................ ................................ ................................ ....... 50 
8.2.2  Week  1 Visit (±3  days relative to Baseline)  ................................ ........................  51 
8.2.3  Week  2 Visit (±3  days relative to Baseline)  ................................ ........................  52 
8.2.4  Week  4 Visit (±3  days relative to Baseline)  ................................ ........................  53 
8.2.5  Week  8 Visit (±3  days relative to Baseline)  ................................ ........................  54 
8.2.6  Week  12 Visit (±3  days relative to Baseline)  ................................ ......................  55 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 6 of 206 8.2.7  Week  16 Visit (±3  days relative to Baseline)  ................................ ......................  56 
8.3 Maintenance Treatment Period  ................................ ................................ ....................  57 
8.3.1  Week  20 Visit (±3  days relative to Baseline)  ................................ ......................  57 
8.3.2  Week  24 Visit (±3  days relative to Baseline)  ................................ ......................  57 
8.3.3  Week  28 Visit (±7  days relative to Baseline)  ................................ ......................  58 
8.3.4  Week  32 Visit (±7  days relative to Baseline)  ................................ ......................  59 
8.3.5  Week  36 Visit (±7  days relative to Baseline)  ................................ ......................  60 
8.3.6  Week  40 Visit (±7  days relative to Baseline)  ................................ ......................  60 
8.3.7  Week  44 Visit (±7  days relative to Baseline)  ................................ ......................  61 
8.3.8  Week  48 Visit (±7  days relative to Baseline)  ................................ ......................  62 
8.3.9  Week  52 Visit (±7  days relative to Baseline)  ................................ ......................  62 
8.4 Premature End of Treatment Visit  ................................ ................................ ...............  64 
8.5 Safety Follow -Up Visit (20 weeks after last dose, ±7 days)  ................................ ........  64 
8.6 Unscheduled Visit  ................................ ................................ ................................ ........  65 
9 ASSESSMENT OF EFFICA CY ................................ ................................ ......................  65 
9.1 Psoriasis Area and Severity Index  ................................ ................................ ...............  65 
9.2 Investigator’s Global Assessment  ................................ ................................ ................  66 
9.3 Dermatology Life Quality Index  ................................ ................................ ..................  66 
9.4 Patient Health Questionnaire 9  ................................ ................................ ....................  67 
9.5 Scalp IGA ................................ ................................ ................................ .....................  67 
9.6 mNAPSI  ................................ ................................ ................................ .......................  67 
9.7 pp-IGA ................................ ................................ ................................ .........................  68 
9.8 Euro Quality of Life 5 -Dimensions, 3 -Level  ................................ ...............................  68 
9.9 36-Item Short Form Health Survey ................................ ................................ ..............  68 
9.10  Patient Global Assessment of psoriasis  ................................ ................................ ....... 69 
9.11  Patient Symptom Diary responses  ................................ ................................ ...............  69 
9.12  PASE questionnaire  ................................ ................................ ................................ ..... 69 
9.13  PGADA for arthritis visual analog scale  ................................ ................................ ..... 70 
9.14  HAQ -DI score  ................................ ................................ ................................ ..............  70 
9.15  WPAI -SHP V2.0  ................................ ................................ ................................ ..........  70 
9.16  Photographs ................................ ................................ ................................ ..................  71 
10 ASSESSMENT OF PHARMA COKINETIC AND PHARMA COGENOMIC 
VARIABLE(S)  ................................ ................................ ................................ ................  71 
10.1  Pharmacokinetic variables  ................................ ................................ ...........................  71 
10.2  Pharmacogenomic variables  ................................ ................................ ........................  71 
11 ASSESSMENT OF IMMUNO LOGICAL VARIABLE(S)  ................................ ............  72 
12 ASSESSMENT OF SAFETY  ................................ ................................ ..........................  72 
12.1  Adverse events  ................................ ................................ ................................ .............  72 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 7 of 206 12.1.1  Definitions  ................................ ................................ ................................ ...........  72 
12.1.1.1  Adverse eve nt ................................ ................................ ............................  72 
12.1.1.2  Serious adverse event  ................................ ................................ ................  73 
12.1.1.1  Adverse events of special interest  ................................ .............................  74 
12.1.1.2  Other safety topics of interest  ................................ ................................ .... 74 
12.1.2  Procedures for reporting and recording adverse events  ................................ ....... 74 
12.1.2.1  Description of adverse events  ................................ ................................ .... 74 
12.1.2.2  Rule for repetition of an adverse event ................................ ......................  75 
12.1.2.3  Additional procedures for reporting serious adverse events  .....................  75 
12.1.3  Follow up of adverse events  ................................ ................................ ................  76 
12.1.4 Pregnancy  ................................ ................................ ................................ ............  76 
12.1.5  Suspected transmission of an infectious agent via a medicinal product  ..............  77 
12.1.6  Overdose of investigational medicinal product  ................................ ...................  77 
12.1.7  Safety signal detection  ................................ ................................ .........................  77 
12.2  Laboratory measurements  ................................ ................................ ............................  78 
12.2.1  Evaluation of PDILI  ................................ ................................ ............................  79 
12.2.1.1  Consultation with Medical Monitor and local hepatologist  ......................  83 
12.2.1.2  Immediate action: determination of IMP discontinuation  .........................  83 
12.2.1.3  Testing: identification/exclusion of alternative etiology  ...........................  83 
12.2.1.4  Follow -up evaluation  ................................ ................................ .................  85 
12.3  Other safety measurements  ................................ ................................ ..........................  86 
12.3.1  Assessment and management of TB and TB risk factors  ................................ .... 86 
12.3.1.1  Tuberculosis assessment by IGRA  ................................ ............................  89 
12.3.1.2  Chest x -ray for tuberculosis  ................................ ................................ ...... 89 
12.3.1.3  Tuberculosis questionnaire  ................................ ................................ ........  89 
12.3.1.4  Tuberculosis management  ................................ ................................ .........  89 
12.3.2  Pregnancy testing  ................................ ................................ ................................ . 90 
12.3.3  Vital signs  ................................ ................................ ................................ ............  90 
12.3.4  12-lead electrocardiograms  ................................ ................................ ..................  90 
12.3.5  Physical examination  ................................ ................................ ...........................  90 
12.3.6  Height and body weight  ................................ ................................ .......................  91 
12.3.7  Assessment of suicidal ideation and behavior  ................................ .....................  91 
12.4  Other study measurements  ................................ ................................ ...........................  91 
12.4.1  Demographic information  ................................ ................................ ....................  91 
12.4.2  Medical history  ................................ ................................ ................................ .... 91 
12.4.3  Psoriasis  history  ................................ ................................ ................................ ... 91 
12.4.4  Data Monitoring and Adjudication Committees  ................................ ..................  91 
13 STUDY MANAGEMENT AND  ADMINISTRATION  ................................ .................  92 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 8 of 206 13.1  Adherence to protocol  ................................ ................................ ................................ .. 92 
13.2  Monitor ing ................................ ................................ ................................ ...................  92 
13.2.1  Definition of source data  ................................ ................................ .....................  92 
13.2.2  Source data verification  ................................ ................................ .......................  93 
13.3  Data handling  ................................ ................................ ................................ ...............  93 
13.3.1  Case Report Form completion  ................................ ................................ .............  93 
13.3.2  Database entry and reconciliation  ................................ ................................ ........  93 
13.3.3  Subject Screening and Enrollment log/Subject Identification Code list ..............  93 
13.4  Termination of the study  ................................ ................................ ..............................  94 
13.5  Archiving and data retention  ................................ ................................ ........................  94 
13.6  Audit and inspection  ................................ ................................ ................................ .... 94 
13.7  Good Clinical Practice  ................................ ................................ ................................ . 95 
14 STATISTICS  ................................ ................................ ................................ ...................  95 
14.1  Definition of analysis sets  ................................ ................................ ............................  95 
14.2  General statistical considerations  ................................ ................................ .................  95 
14.3  Planned efficacy analyses  ................................ ................................ ............................  97 
14.3.1  Analysis of the primary efficacy variable  ................................ ............................  97 
14.3.1.1  Sensitivity analyses  ................................ ................................ ...................  98 
14.3.2  Other efficacy analyses  ................................ ................................ ........................  99 
14.3.2.1  Analysis of the secondary efficacy variables  ................................ ............  99 
14.3.2.2  Analysis of the other efficacy variables  ................................ ..................  100 
14.4  Subgroup analyses  ................................ ................................ ................................ ..... 101 
14.5  Planned safety and other analyses ................................ ................................ ..............  101 
14.5.1  Safety analyses  ................................ ................................ ................................ ... 101 
14.5.2  Pharmac okinetic analyses  ................................ ................................ ..................  101 
14.5.3  Immunogenicity analyses  ................................ ................................ ..................  101 
14.6  Handling of protocol deviations ................................ ................................ .................  102 
14.7  Handling of dropouts or missing data  ................................ ................................ ........  102 
14.8  Planned interim analysis and data monitoring  ................................ ...........................  103 
14.9  Determination of sample size  ................................ ................................ .....................  103 
15 ETHICS AND REGULATOR Y REQUIREMENTS  ................................ ....................  104 
15.1  Informed consent  ................................ ................................ ................................ ....... 104 
15.2  Subject identification cards  ................................ ................................ ........................  105 
15.3  Institutional Review Boards and Independent Ethics Committees  ............................  105 
15.4  Subject privacy ................................ ................................ ................................ ...........  105 
15.5  Protocol amendments  ................................ ................................ ................................ . 106 
16 FINANCE, INSURANCE, AND PUBLICATION  ................................ .......................  106 
17 REFERENCES  ................................ ................................ ................................ ..............  106 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 9 of 206 18 APPENDICES  ................................ ................................ ................................ ...............  109 
18.1  Protocol Amendment 1  ................................ ................................ ..............................  109 
18.2  Protocol Amendment 2  ................................ ................................ ..............................  138 
18.3  Protoco l Amendment 3  ................................ ................................ ..............................  160 
18.4  Protocol Amendment 4  ................................ ................................ ..............................  201 
19 DECLARATION AND SIGN ATURE OF INVESTIGATO R ................................ ..... 205 
20 SPONSOR DECLARATION  ................................ ................................ ........................  206 
 
LIST OF TABLES  
Table  5‒1:  Schedule of study assessments ................................ ................................ .........  28 
Table  7‒1:  Dosing scheme  ................................ ................................ ................................ . 43 
Table  7‒2:  Prohibited psoriasis medications ................................ ................................ ...... 46 
Table  9‒1:  Body areas for calculation of percent BSA for PASI  ................................ ...... 65 
Table  9‒2:  Five-point IGA  ................................ ................................ ................................ . 66 
Table  9‒3:  Scalp IGA ................................ ................................ ................................ .........  67 
Table  9‒4:  pp-IGA ................................ ................................ ................................ .............  68 
Table  12‒1:  Anticipated serious adverse events for the population of subjects with 
moderate to severe chronic plaque psoriasis  ................................ ....................  74 
Table  12‒2:  Laboratory measurements  ................................ ................................ ................  78 
Table  12‒3:  Required investigations and follow up for PDILI ................................ ............  80 
Table  12‒4:  PDILI laboratory measurements  ................................ ................................ ...... 84 
Table  12‒5:  PDILI information to be collected  ................................ ................................ ... 85 
 
LIST OF FIGURES  
Figure  5‒1:  Schematic diagram  ................................ ................................ ...........................  34 
Figure  12-1: Schematic diagram of TB test results and study eligibility  .............................  88 
Figure  14-1: Sequence of testing  ................................ ................................ ..........................  97 
 
  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 10 of 206 LIST OF ABBREVIATION S 
AE adverse event  
AESI  adverse event of special interest  
ALP  alkaline phosphatase  
ALT  alanine aminotransferase  
AMS  Active Medication Set  
ANCOVA  analysis of covariance  
AST  aspartate aminotransferase  
axSpA  axial spondyloarthritis  
BA bioavailability  
BP blood pressure  
BSA  body surface area  
cAMP  cyclic adenosine monophosphate  
CDC  Centers for Disease Control  
CDMS  clinical data management system  
CI confidence interval  
CMH  Cochran -Mantel -Haenszel  
CPM  Clinical Project Manager  
CPMP  Committee for Proprietary Medicinal Products  
CRO  contract research organization  
CSR  Clinical Study Report  
CTCAE  Common Terminology Criteria for Adverse Events  
CV cardiovascular  
DLQI  Dermatology Life Quality Index  
DMC  Data Monitoring Committee  
ECG  electrocardiogram  
eCRF  electronic Case Report Form  
eC-SSRS  electronic Columbia Suicide Severity Rating Scale  
ePRO  electronic patient -reported outcome  
EQ-5D-3L Euro -Quality of Life 5 -Dimensions, 3 levels  
FAS Full Analysis Set  
GCP  Good Clinical Practice  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 11 of 206 GI gastrointestinal  
GMP  Good Manufacturing Practices  
HAQ -DI Health Assessment Questionnaire -Disability Index  
HBcAb  anti-hepatitis B core antibody  
HBsAg  anti-hepatitis B surface antigen  
HCP  healthcare practitioner  
HCV  hepatitis C virus  
HCV Ab  hepatitis C antibody  
HIV human immunodeficiency virus  
HLT  High Level Term  
IB Investigator’s Brochure  
IBD inflammatory bowel disease  
ICF Informed Consent Form  
ICH International Council for Harmonisation  
IEC Independent Ethics Committee  
Ig immunoglobulin  
IGA Investigator’s Global Assessment  
IGRA  interferon -gamma release assay  
IL interleukin  
IMP investigational medicinal product  
IRB Institutional Review Board  
IRT interactive response technology  
iv intravenous  
LOCF  last observation carried forward  
LTB  latent tuberculosis  
LTBI  latent tuberculosis infection  
mAb  monoclonal antibody  
MAR  missing at random  
MCMC  Markov -Chain Monte Carlo  
MCS  Mental Component Summary  
MedDRA  Medical Dictionary for Regulatory Activities  
MI multiple imputation  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 12 of 206 mNAPSI  Modified Nail Psoriasis Severity Index Score  
NRI Nonresponder imputation  
NSAID  non-steroidal anti -inflammatory drugs  
NTMB  nontuberculous mycobacterium  
PASE  Psoriatic Arthritis Screening and Evaluation  
PASI  Psoriasis Area Severity Index  
PCS Physical Component Summary  
PD pharmacodynamics  
PDE4  phosphodiesterase 4  
PDILI  potential drug -induced liver injury  
PEOT  Premature End of Treatment  
PFS prefilled syringe  
PGADA  Patient's Global Assessment of Disease Activity  
PHQ -9 Patient Health Questionnaire  
PK pharmacokinetics  
PK-PPS Pharmacokinetics Per -Protocol Set  
pp-IGA palmoplantar Investigator’s Global Assessment  
PPS Per-Protocol Set  
PRO  patient -reported outcome  
PS Patient Safety  
PsA psoriatic arthritis  
PSO psoriasis  
Q4W  every 4 weeks  
QOL  quality of life  
RS Randomized Set  
SAE  serious adverse event  
SAP Statistical Analysis Plan  
sc subcutaneous  
scalp IGA  scalp -specific IGA  
SD standard deviation  
SF-36 Short Form 36 -item Health Survey  
SFU Safety Follow -Up 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 13 of 206 SOP Standard Operating Procedure  
SS Safety Set  
TB tuberculosis  
TEAE  treatment -emergent adverse event  
TNF  tumor necrosis factor  
ULN  upper limit of normal  
VAS  visual analog scale  
WBC  white blood cell  
WPAI -SHP Work Productivity and Activity Impairment Questionnaire -specific health 
problem  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 14 of 206 1 SUMMARY  
This is a Phase 3, multicenter, randomized, double -blind, placebo - and active 
comparator -controlled, parallel -group, study  to evaluate the efficacy, safety, and 
pharmacokinetics (PK) of bimekizumab compared with placebo and ustekinumab in adult 
subjects with moderate to severe chronic plaque psoriasis (PSO).  
The study population consists of adult subjects (≥18 years of age) w ith a diagnosis of moderate 
to severe chronic plaque PSO (Baseline Psoriasis Area and Severity Index [PASI] ≥12 and body 
surface area [BSA] affected by PSO ≥10% and Investigator’s Global Assessment [IGA] score ≥3 
[on a 5 -point scale]) who are a candidate f or ustekinumab, or for systemic PSO therapy and/or 
phototherapy.  
Approximately 750 subjects will be screened in order to have 560 subjects randomized in the 
study. For each subject, the study will last a maximum of 73 weeks and will consist of 4 periods, 
a Screening Period (2 to 5 weeks), a double -blind, placebo - and active comparator -controlled 
Initial Treatment Period (16 weeks), a double -blind, active comparator -controlled Maintenance 
Treatment Period (36 weeks), and a Safety Follow -Up (SFU) Period (20 w eeks after the final 
dose of investigational medicinal product (IMP). After the 36 -week Maintenance Treatment 
Period, eligible subjects will be allowed to enroll in an open -label study.  
Eligible subjects will be randomized 4:2:1 to receive the following bl inded IMP regimens:  
 Bimekizumab 320mg administered subcutaneously (sc) every 4 weeks (Q4W)  
 Ustekinumab (45mg or 90mg, depending on subject weight) administered sc at Baseline and 
4 weeks later, followed by ustekinumab sc every 12 weeks  
 Placebo administered  sc Q4W for 16 weeks during the Initial Treatment Period, followed by 
bimekizumab 320mg administered sc Q4W during the Maintenance Treatment Period  
Approximately 320 subjects will be randomized to bimekizumab 320mg, 160 subjects will be 
randomized to ustek inumab, and approximately 80 subjects will be randomized to placebo. 
Investigational medicinal product will be administered in the clinic at Baseline and Q4W 
thereafter, until Week  16 (Initial Treatment Period). Additional nondosing study visits will occur  
at Week  1 and Week  2. At Week  16, subjects will enter the Maintenance Treatment Period. The 
Maintenance Treatment Period will include Q4W dosing for subjects receiving bimekizumab and 
Q12W dosing for subjects receiving ustekinumab.  
At Week  52, all subject s enrolling in the open -label study will undergo the Week  52 study 
assessments before receiving their first treatment dose in the open -label study. All subjects not 
enrolling in the open -label study will have the Week  52 study assessments and will enter th e 
SFU Period.  
Subjects withdrawing early from the study will undergo the Premature End of Treatment (PEOT) 
Visit assessments and will enter the SFU Period.  
The primary objective of the study is to compare the efficacy of bimekizumab administered sc 
for 16  weeks versus placebo in the treatment of subjects with moderate to severe chronic plaque 
PSO. The secondary objectives of the study are listed in Section  3.2. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 15 of 206 The co -primary efficacy variables are the PASI90 response (defined as a subject that achieves 
90% reduction from Baseline in the PASI score) at Week  16 and the IGA response (defined as 
Clear or Almost Clear with at least a 2 -category improvement relative to Baseline) at Week  16. 
The secondary efficacy variables are listed in Section  4.2. 
Pharmacokinetic variables are listed in Section  4.3.3 . Pharmacogenomic variables are listed in 
Section  4.3.4 . Immunological variables are listed in Section  4.3.5 . 
Pharmacokinetic, genomic, genetic, proteomic, and immunological variables will be evaluated to 
assess their relationship to treatment response.  
Safety variables to be assessed are adverse events (AEs), vital signs, electrocardiograms (ECGs), 
physical examination, and measurements of laboratory parameters.  
2 INTRODUCTION  
2.1 Psoriasis  
Psoriasi s is a common, chronic inflammatory disease characterized by a series of linked cellular 
changes in the skin: hyperplasia of epidermal keratinocytes, vascular hyperplasia and ectasia, and 
infiltration of T lymphocytes, neutrophils, and other types of leuko cytes in affected skin. Though 
the pathophysiology of PSO is not fully understood, the importance of T -cells and inflammatory 
cytokines has been demonstrated by the clinical benefit provided by therapies directed at these 
targets (Krueger and Ellis, 2005).  
There are a variety of forms including plaque, guttate, inverse, pustular, and erythrodermic. 
Plaque PSO is the most common, comprising approximately 80% to 90% of all cases. 
Approximately 17% of those with PSO have moderate to severe disease (Kurd et al,  2008).  
In addition to the impact on skin, PSO has a multitude of psychosocial and emotional effects on 
patients, including increased self -consciousness, frustration, fatigue, depression, and suicidal 
ideation. As a result, patients frequently report sleeping problems, difficulties at work, problems 
interacting with family members, disrupted leisure activities, and sexual difficulties 
(Dowlatshahi et al, 2014; Gottlieb, 2005; Mukhtar et al, 2004; Ortonne, 2004; Krueger et al, 
2001).  
A number of comorbi dities have been associated with PSO, especially with more severe PSO. 
Psoriatic arthritis (PsA), cardiovascular (CV) disease, metabolic syndrome, chronic pulmonary 
disease, peptic ulcer disease, renal disease, and diabetes have all been demonstrated to ha ve an 
increased prevalence in PSO patients (Yeung et al, 2013; Christophers et al, 2010; Gisondi et al, 
2007; Gelfand et al, 2006).  
2.1.1  Global epidemiology of psoriasis  
Psoriasis affects approximately 3% of the US adult population (Rachakonda et al, 2014; Kurd  
and Gelfand, 2009) and its onset can begin at any age (Augustin et al, 2010; Icen et al, 2009). 
The reported worldwide incidence and prevalence of PSO varies greatly depending on age, 
gender, ethnicity, and geography primarily due to genetic and environme ntal factors. Estimates 
of incidence and prevalence include all types of PSO. Plaque PSO is the most common form of 
the disease therefore reported estimates of the magnitude of this condition are likely weighted 
heavily by this subtype. Both the incidence and prevalence of PSO are higher among Caucasians 
and those living in higher latitudes. Psoriasis affects approximately 2% to 4% of the population 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 16 of 206 of western countries. Geographical differences are also influenced by case definition, study 
design, and the definition of prevalence (Parisi et al, 2013; Langley et al, 2005; Raychaudhuri 
and Gross, 2000).  
2.1.2  Current treatments for psoriasis  
Therapy for patients with PSO varies according to the severity of disease. Limited or mild 
disease is often treated with topi cal therapies such as corticosteroids and vitamin D analogs. 
Patients with more severe disease are often treated with phototherapy, methotrexate, 
cyclosporine, the oral phosphodiesterase 4 (PDE4) inhibitor apremilast, or biologic agents, such 
as tumor necr osis factor (TNF) antagonists, interleukin (IL) 12/23 inhibitors, IL -23p19 inhibitors 
and IL -17A inhibitors. The effectiveness of TNF inhibitors in the treatment of PSO has been 
demonstrated in many Phase 3 clinical studies and has led to the approval of m ultiple TNF 
inhibitors for use in patients with moderate to severe PSO. Interleukin inhibitors approved for 
this indication include the IL -12/23 antagonist ustekinumab, the IL -23p19 antagonist 
guselkumab, the IL -17A inhibitors secukinumab and ixekizumab, a nd the IL -17 receptor 
antagonist brodalumab.  
Standard therapies for PSO are listed below:  
 Topical steroids (eg, triamcinolone, mometasone, clobetasol, betamethasone, hydrocortisone) 
are generally used as first -line treatment of PSO. High -strength steroids  are typically 
reserved for use on the arms and legs. Areas such as the face and skin folds (axillary, 
inguinal regions, etc) are usually treated with a low potency steroid. Chronic use of topical 
steroids can lead to corticosteroid -related side effects an d is generally discouraged.  
 Vitamin D analogs (eg, calcipotriol and tacalcitol) are commonly used to treat mild to 
moderate PSO, and work best within the mild patients. They are safe but lack efficacy for 
more severe disease.  
 Phototherapy is a frequent opt ion for moderate to severe patients, but the inconvenience of 
multiple treatment visits and varying efficacy limits its use in the market.  
 Methotrexate is a systemic immunosuppressant and is used in moderate to severe PSO 
patients. Toxicity concerns, parti cularly in older patients, are a major drawback.  
 Cyclosporine is a systemic immunosuppressant used in patients with severe, recalcitrant, 
PSO who have failed at least one systemic therapy or in whom other systemic therapies are 
contraindicated. In recommen ded dosages cyclosporine can cause systemic hypertension and 
nephrotoxicity, therefore, renal function must be monitored during therapy.  
 Apremilast is an oral small -molecule inhibitor of PDE4 that is also approved for treatment of 
adults with moderate to s evere plaque PSO. Phosphodiesterase 4 inhibitors work 
intracellularly to modulate a network of proinflammatory and anti -inflammatory mediators. 
Phosphodiesterase 4 is a cyclic adenosine monophosphate (cAMP) -specific PDE and the 
dominant PDE in inflammatory  cells. Phosphodiesterase 4 inhibition elevates intracellular 
cAMP levels, which in turn down -regulates the inflammatory response by modulating the 
expression of TNFα, IL -23, IL -17, and other inflammatory cytokines.  
 Biologics, including TNFα inhibitors (ad alimumab, etanercept, and infliximab), 
IL-12/23  inhibitors (ustekinumab), the IL -23p19 antagonist (guselkumab), the IL -17A 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 17 of 206 inhibitors (secukinumab and ixekizumab), and the IL -17 receptor antagonist brodalumab are 
the treatment options of choice for patient s with moderate to severe plaque PSO who are 
candidates for systemic therapy or phototherapy. These products are injected sc or delivered 
via intravenous (iv) infusion.  Different from the traditional systemic drugs that impact the 
entire immune system, bi ologics target specific parts of the immune system and offer reduced 
multi -organ toxicity and adverse effects associated with traditional treatments.  
 TNFα inhibitors, while effective, come with boxed warnings including the risk of serious 
infections and re ports of lymphoma and malignancy in children and adolescent patients. 
The efficacy of TNFα inhibitors in treating PSO is attributed to their inhibition of 
Th17 -T cells.  
 Ustekinumab has been approved in the US and the EU for the treatment of patients with 
moderate to severe plaque PSO who are candidates for phototherapy or systemic therapy. 
Ustekinumab is a human immunoglobulin (Ig) G1κ monoclonal antibody that binds with 
specificity to the p40 protein subunit used by both the IL -12 and IL -23 cytokines, 
naturally occurring cytokines that are involved in inflammatory and immune responses, 
such as natural killer cell activation and CD4+ T -cell differentiation and activation.  
 Secukinumab and ixekizumab have been approved in the US and the EU for the treatment 
of moderate to severe plaque PSO in adult patients who are candidates for systemic 
therapy or phototherapy. Secukinumab is a human IgG1 monoclonal antibody that 
selectively binds to the interleukin -17A (IL -17A) cytokine and inhibits its interaction 
with th e IL-17 receptor. Ixekizumab is a humanized IgG4 monoclonal antibody that 
selectively binds with the interleukin 17A (IL -17A) cytokine and inhibits its interaction 
with the IL -17 receptor. IL -17A is a naturally occurring cytokine that is involved in 
normal  inflammatory and immune responses. Both drugs inhibit the release of 
proinflammatory cytokines and chemokines.  
 Guselkumab has been approved in the US and EU for the treatment of adult patients with 
moderate to severe plaque PSO who are candidates for syst emic therapy or phototherapy. 
It is a human monoclonal IgG1λ antibody that selectively binds to the p19 subunit of 
interleukin 23 (IL -23) and inhibits its interaction with the IL -23 receptor. IL -23 is a 
naturally occurring cytokine that is involved in norm al inflammatory and immune 
responses. Guselkumab inhibits the release of proinflammatory cytokines and 
chemokines.  
 Brodalumab has been approved in the US for the treatment of moderate to severe plaque 
psoriasis in adult patients who are candidates for syst emic therapy or phototherapy and 
have failed to respond or have lost response to other systemic therapies. In the EU, 
brodalumab is indicated for the treatment of moderate to severe plaque PSO in adult 
patients who are candidates for systemic therapy. Brod alumab is a human monoclonal 
IgG2 antibody that selectively binds to human IL -17RA and inhibits its interactions with 
cytokines IL -17A, IL -17F, IL -17C, IL -17A/F heterodimer and IL -25. Blocking IL -17RA 
inhibits IL -17 cytokine -induced responses including the  release of proinflammatory 
cytokines and chemokines. Brodalumab has a black box warning regarding suicidal 
ideation and behavior.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 18 of 206 2.2 Bimekizumab  
Bimekizumab (UCB4940) is an engineered, humanized full length monoclonal antibody (mAb) 
of immunoglobulin (Ig) G1  subclass of approximately 150,000 Daltons which is expressed in a 
genetically engineered Chinese hamster ovary cell line. Bimekizumab has high affinity for 
human IL -17A and human IL -17F and selectively and potently inhibits the activity of both 
isoforms i n vitro. Interleukin -17A and IL -17F are key proinflammatory cytokines believed to 
play important roles in autoimmune and inflammatory diseases. Bimekizumab is being 
developed for the treatment of patients with inflammatory diseases such as PsA, PSO, and ax ial 
spondyloarthritis (axSpA).  
While anti -IL-17A antibodies have demonstrated efficacy in patients with PSO, PsA. and 
ankylosing spondylitis, as yet, no therapeutic approach selectively and potently inhibits the 
activity of both IL -17A and IL -17F isoforms in vitro. Bimekizumab is an engineered, 
humanized, full -length IgG1 mAb which has been designed to inhibit the activity of IL -17A and 
IL-17F subtypes of IL -17. This property makes bimekizumab distinct from the other IL -17-
targeting agents, like secukinumab  and ixekizumab (selective anti -IL-17-A mAb), or brodalumab 
(anti-IL-17 receptor mAb).  
Overexpression of IL -17A, IL -17C, and IL -17F in lesion tissue suggests that broader IL -17 
blockade may be more beneficial in the treatment of plaque PSO. However, blocki ng all IL -17 
isoforms (including the IL -17E isoform, also known as IL -25) may not be the optimal approach. 
The role of IL -25 in PSO and other IL -17 mediated diseases has not been well established, 
however it has been suggested that IL -25 may play a benefic ial role in inflammatory conditions 
associated with type 1 T helper (Th -1) mediated immune responses, such as PSO (as opposed to 
type 2 T helper (Th -2) mediated) (Valizadeh et al, 2015). Thus, it can be hypothesized that 
inhibition of both IL -17A and IL -17F is associated with additional benefits in PSO compared to 
the selective IL -17A inhibition or a broader IL -17 blockade.  
2.2.1  Clinical  
2.2.1.1  Completed studies  
Five clinical studies of bimekizumab have been completed: UP0008 in 39 subjects with mild to 
moderate plaque  PSO, RA0124 in 30 healthy volunteers, PA0007 in 53 subjects with PsA, 
UP0031 in 12 healthy volunteers, and UP0042 in 48 healthy volunteers.  
UP0008 was a Phase 1, single ascending dose study in adults with mild to moderate PSO 
affecting ≤5% BSA. In this b linded study, single doses of up to 640mg (approximately 8mg/kg 
in an 80kg adult) were evaluated without any safety concerns. A total of 26 subjects with PSO 
with less than 5% of body surface involvement were treated with a range of single iv doses from 
8 to 640mg. There were no clinically relevant safety findings identified at any dose and all doses 
were well tolerated. The pre -specified exploratory assessment of disease activity showed 
clinically relevant and statistically significant improvements at the higher doses studied.  
RA0124 was a Phase 1, open -label, parallel -group, single -dose study in healthy subjects. The 
primary objective of this study was to determine the absolute bioavailability (BA) of single sc 
doses of bimekizumab (80mg and 160mg). The se condary objectives were to evaluate the dose 
proportionality of bimekizumab 80mg and 160mg sc, and to evaluate the safety and tolerability 
of these sc doses and 160mg given by iv infusion. In RA0124, the absolute BA was similar for 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 19 of 206 the 2 doses tested (0.65 6 and 0.631 for the bimekizumab 80mg and 160mg sc doses, 
respectively). The PK of bimekizumab was linear in the tested dose range and the median t 1/2 
following sc administration was similar to that following iv administration (27.81 days and 28.25 
days for  bimekizumab 160mg sc and 160mg iv, respectively).  
Bimekizumab has also been investigated in a Phase 1b, proof of concept, randomized, placebo 
controlled, multiple dose study (PA0007). The primary objective of PA0007 was to assess the 
safety and PK of multiple dose administration of iv bimekizumab in subjects with PsA. Four 
active doses and a placebo were tested. Drug was administered as a loading dose at Week  0, and 
2 additional doses were administered at Week  3 and Week  6. In each treatment group, sub jects 
received a total of 3 doses of bimekizumab, administered every 3 weeks as shown below:  
 80mg loading dose followed by 40mg at Weeks 3 and 6  
 160mg loading dose followed by 80mg at Weeks 3 and 6  
 240mg loading dose followed by 160 mg at Weeks 3 and 6  
 560mg loading dose followed by 320mg at Weeks 3 and 6  
The results of this study demonstrated that all doses of bimekizumab were well tolerated and 
there were no unexpected clinically relevant safety findings.  
Infections (mostly nasopharyngitis) were the most commonly reported events in both the active 
treatment and the placebo group. None of the infections were considered serious or required 
treatment with antibiotics. Two subjects in the active treatment group experienced 1  local 
candida infection each (oroph arhyngitis and vulvovaginitis, respectively) that were non -serious 
and resolved with topical therapy. There was a potential reduction in mean neutrophil count in 
the active treatment group, although this drop was not clinically relevant and a clear relatio nship 
with dose or time was not evident. Some increases in liver function tests were reported, but none 
had a convincing relationship to exposure to IMP. The exploratory analysis showed clinically 
relevant improvement in activity of PsA and in skin involve ment in those subjects with 
concomitant active psoriatic lesions.  
UP0031 was a Phase 1, open -label, parallel -group, randomized, single -dose study to evaluate the 
BA, PK, and tolerability of 2 different formulations of bimekizumab in healthy subjects. Subje cts 
receiving Formulation  A ( ) were administered two  1mL injections of 80mg each 
of bimekizumab and subjects receiving Formulation  B ) were administered a 
single injection of bimekizumab 160mg given as a 1mL injection. Six subj ects were randomized 
to each bimekizumab formulation. The geometric means (GeoMeans) for area under the curve  
were similar between bimekizumab 2x80mg and 1x160mg groups and the relative BA for 
Formulation  B vs Formulation  A was 96.1% (95% confidence inter val [CI]: 72.7%, 127.0%). 
Administration of the 2 formulations of bimekizumab used in this study identified no new safety 
issues. There were no treatment -emergent adverse events (TEAEs) leading to discontinuation, 
and no serious adverse events (SAEs) or fa talities were reported. The only preferred term 
experienced by more than 1 subject in either treatment group was injection site pain (5  subjects 
[83.3%] and 3 subjects [50%] in the 2x80mg and 1x160mg groups, respectively). The most 
frequently reported TEAE  considered related to the IMP was injection site pain, experienced by 
5 subjects [83.3%] and 3 subjects [50.0%] in the 2x80mg and 1x160mg groups, respectively. 
There were no clinically significant laboratory values reported in the study.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 20 of 206 UP0042 was a rand omized double -blind, placebo -controlled, single -dose, parallel -group study to 
evaluate the safety, tolerability, and PK of bimekizumab administered as an sc injection to 
Japanese and Caucasian healthy subjects. This study demonstrated that the PK profiles following 
single administration of 80mg, 160mg, and 320mg with an sc injection were dose proportional 
with a linear elimination in both Japanese and Caucasian subjects and that the PK profiles of 
Japanese and Caucasian subjects were considered to be genera lly similar. A single dose of 
bimekizumab (80mg, 160mg, or 320mg) administered as an sc injection was generally safe and 
well tolerated in healthy Japanese and Caucasian subjects and no major differences in safety 
findings were observed between Japanese an d Caucasian subjects.  
2.2.1.2  Ongoing studies  
Four additional studies of bimekizumab in the treatment of PSO are ongoing .  
 PS0010 is a Phase 2b, double -blind, placebo -controlled, dose ranging study to evaluate the 
safety, efficacy, PK, and pharmacodynamics (PD) of  bimekizumab in adult subjects with 
moderate to severe chronic plaque PSO.  
 PS0011 is a long -term extension study for subjects who completed PS0010 to assess the 
long-term safety, tolerability, and efficacy of bimekizumab.  
 PS0016 is a Phase 2a, subject -blind, investigator -blind study to evaluate the time course of 
PD response, safety, and PK of bimekizumab in adult subjects with moderate to severe 
chronic plaque PSO.  
 PS0018 is a long -term extension study for eligible subjects from PS0016 to assess the safety , 
tolerability, and efficacy of bimekizumab.  
Bimekizumab is also being evaluated in the treatment of other indications (eg, PsA, axSpA, 
hidradenitis suppurativa). Additional information on the clinical data for bimekizumab is 
available in the current versi on of the Investigator’s Brochure (IB).  
2.2.2  Nonclinical  
Parallel inhibition of IL -17A and IL -17F has been shown to be efficacious in a variety of animal 
models of inflammatory disease. Intravenously administered bimekizumab was well tolerated in 
repeat dose to xicology studies in Cynomolgus monkeys with a no adverse effect level of 
200mg/kg/week. The findings of note in toxicity studies were diarrhea related to infectious 
enteritis (observed in the single dose study) and asymptomatic mild colonic ulceration in a  
proportion of animals (in the repeat dose study); this latter finding was not associated with 
hematology abnormalities. Data suggest that bimekizumab has induced primary lesions to the 
mucosa associated lymphoid tissue via a pharmacologically -related mech anism. In a second 
repeat -dose study, none of the minor apoptosis/necrosis findings observed in gut associated 
lymph nodes were revealed. In animals given the highest dose of bimekizumab in the study 
(20mg/kg/week), a slightly higher number of protozoa ( Balantidium coli ) was observed in the 
cecum and colon as compared to the control animals and low dose animals. Therefore, gut 
associated lymph node lesions observed in the first study are considered to be accidental and/or 
linked to exaggerated pharmacology and proliferation of Balantidium coli  and is considered the 
consequence of a change in local mucosal immunity. To date, similar findings have not been 
seen in studies in humans.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 21 of 206 Additional information on the nonclinical data for bimekizumab is available in  the current 
version of the IB.  
3 STUDY OBJECTIVE(S)  
3.1 Primary objective  
The primary objective of the study is to compare the efficacy of bimekizumab administered sc 
for 16 weeks versus placebo in the treatment of subjects with moderate to severe chronic plaqu e 
PSO.  
3.2 Secondary objectives  
The secondary objectives of the study are to:  
 Evaluate the efficacy of bimekizumab compared to placebo at achieving complete clearance 
(PASI100) after 16 weeks of treatment  
 Evaluate the efficacy of bimekizumab compared to placeb o after 4 weeks of treatment  
 Evaluate the efficacy of bimekizumab compared to ustekinumab after 4 weeks, 12 weeks, 16 
weeks, and 52  weeks of treatment  
 Evaluate the change in itch, pain, and scaling of bimekizumab compared to placebo after 
16 weeks of treatment as reported by subjects using the Patient Symptom Diary  
 Evaluate the change in psoriatic scalp disease of bimekizumab compared to placebo after 
16 weeks of treatment in subjects with scalp PSO at Baseline  
 Assess TEAEs, SAEs, and TEAEs leading to withdrawal adjusted by duration of subject 
exposure to study treatment  
3.3 Other objectives  
The other objectives of the study are to demonstrate the effects of  bimekizumab on aspects of the 
disease:  
 Assess the efficacy of bimekizumab over time  
 Assess the change of skin -related quality of life (QOL)  
 Assess the change of general health -related QOL  
 Assess the change in nail PSO over time in subjects with nail PSO a t Baseline  
 Assess the change in scalp PSO over time in subjects with scalp PSO at Baseline  
 Assess the change in palmoplantar PSO over time in subjects with palmoplantar PSO at 
Baseline  
 Assess the change in physical function (as measured by the Health Assessment 
Questionnaire -Disability Index  [HAQ -DI]) over time in subjects with PsA at Baseline  
 Assess the symptoms of PsA as measured by the Psoriatic Arthritis Screening and Evaluation  
(PASE) questionnaire  
 Assess the change of patient -reported joint sympt oms in subjects with PsA at Baseline  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 22 of 206  Assess the change in symptoms of PSO as reported by subjects using the Patient Symptom 
Diary (all items) through Week  16 
 Assess depression  
 Assess the PK of bimekizumab  
 Assess the immunogenicity of bimekizumab  
 Assess wor k productivity  
 Assess the effect of bimekizumab on gene and protein expression, and explore the 
relationship between genomic, genetic, and proteomic biomarkers and disease biology, drug 
treatment and inflammatory and immune responses (from consenting subje cts who agree to 
participate in the biomarker substudy)  
 Assess the safety and tolerability of bimekizumab  
4 STUDY VARIABLES  
4.1 Primary efficacy variables  
The co -primary efficacy variables are the PASI90 response (defined as a subject that achieves 
90% reduction  from Baseline in the PASI score) at Week  16 and the IGA response (defined as 
Clear or Almost Clear with at least a 2 -category improvement relative to Baseline) at Week  16. 
4.2 Secondary variables  
4.2.1  Secondary efficacy variables  
The secondary efficacy variables a re: 
 PASI100 response at Week  16 
 PASI75 response at Week  4 
 Patient Symptom Diary responses for itch, pain, and scaling at Week  16 
 Scalp IGA response (Clear or Almost Clear with at least a 2-category improvement from 
Baseline ) at Week 16 for subjects with scalp PSO at Baseline  
 PASI90 response at Week  12 and 52  
 IGA response at Week  12 and 52  
4.2.2  Secondary safety variables  
 TEAEs adjusted by duration of subject exposure to study treatment  
 SAEs adjusted by duration of subject exposure to study treatment  
 TEAEs leadi ng to withdrawal adjusted by duration of subject exposure to study treatment  
4.3 Other variables  
The other variables are listed below and will be evaluated according to the planned assessments 
(Table  5‒1). 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 23 of 206 4.3.1  Other efficacy variable(s)  
The other efficacy variable s are listed below and will be evaluated according to the planned 
assessments ( Table  5‒1). This excludes the timepoints for the primary and secondary variables 
specified above in Section  4.1 and Section  4.2.1 , respectively.  
Change from Baseline variables evaluated during the Initial Treatment Period are relative to the  
Baseline (first dose) Visit. For subjects who switch treatment at the Week  16 Visit, change from 
Baseline variables during the Maintenance Treatment Period may be evaluated relative to both 
the Baseline (first dose) Visit and the Week  16 Visit.  
For simpli city, “change from Baseline” is used below for all such variables. Greater detail on the 
definition of Baseline for different summaries will be provided in the Statistical Analysis Plan 
(SAP). Unless otherwise stated PASI responders will be calculated rela tive to the Baseline Visit 
(first dose).  
The other efficacy variables are:  
 PASI50, PASI75, PASI90, and PASI100 response  
 Time to PASI75, PASI90, and PASI100 response during the Initial Period  
 Absolute and percent change from Baseline in PASI score  
 IGA respo nse (Clear  with at least a 2 -category improvement from Baseline )  
 IGA response (Clear or Almost Clear with at least 2 category improvement relative to 
Baseline)  
 Shift from Baseline in IGA score  
 Absolute and percent change from Baseline in the BSA affected by PSO  
 Absolute and percent change from Baseline in the product of IGA and BSA (IGAxBSA)  
 Change from Baseline in Dermatology Life Quality Index (DLQI)  
 Percent of subjects achieving a DLQI total score of 0 or 1  
 Percent of subjects achieving a minimal clinically important difference (improvement from 
Baseline of 4 or more) in the DLQI  
 Change from Baseline in the Patient's Global Assessment of Disease Activity (PGADA) for 
the arthritis visual analog scale (VAS) in subjects with PsA at Baseline  
 Change fro m Baseline in Patient Global Assessment of PSO score  
 Patient Symptom Diary responses  
 Scalp -specific Investigator’s Global Assessment (scalp IGA) response (Clear or Almost 
Clear  with at least a 2 -category improvement from Baseline ) for subjects with scalp PSO at 
Baseline  
 Change from Baseline in Modified Nail Psoriasis Severity Index (mNAPSI) score for 
subjects with nail PSO at Baseline  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 24 of 206  Palmoplantar Investigator’s Global Assessment (pp -IGA) response (Clear or Almost Clear) 
for subjects with palmoplantar PSO at Baseline  
 Change from Baseline in the HAQ -DI for subjects with PsA at Baseline  
 Change from Baseline in the PASE questionnaire scores (function score, symptom score, and 
total score)  
 Shift from Baseline in PASE score suggestive of PsA (<47 versus ≥47)  
 Change from Baseline in Short Form 36 -item Health Survey (SF -36) Physical Component 
Summary (PCS) score, and Mental Component Summary (MCS) score, and individual 
domains  
 Responses to Euro -Quality of Life 5 -Dimensions, 3 levels  (EQ-5D-3L), absolute and changes  
from Baseline in EQ -5D-3L VAS scores  
 Change from baseline in Patient Health Questionnaire (PHQ) -9 scores  
 Change from Baseline in Work Productivity and Activity Impairment Questionnaire -specific 
health problem (WPAI -SHP) V2.0 adapted to PSO scores  
4.3.2  Other s afety variables  
Safety variables to be assessed are:  
 Severity and frequency of AEs  
 Change from Baseline in vital signs  
 ECG results  
 Change from Baseline in clinical laboratory values (chemistry, hematology, and urinalysis)  
Physical examination findings cons idered clinically significant changes since the physical 
examination at the Screening Visit will be recorded as AEs.  
4.3.3  Pharmacokinetic variable  
The PK variable is the plasma concentration of bimekizumab.  
4.3.4  Pharmacogenomic variables  
Additional blood samples wil l be collected from subjects who consent to participate in the 
substudy at specific time points and stored at -80°C for up to 20 years.  
Genomic, genetic, epigenetic, proteins, and metabolite biomarkers may be measured to evaluate 
the relationship with resp onse to treatment with bimekizumab, PSO disease biology, and 
inflammatory and immune response processes. The nature and format of these tentative substudy 
analyses will be determined when the results of the main study are made available.  
The candidate expl oratory variables are the blood or blood derivative (eg, serum) concentrations 
of cytokines and chemokines of relevance to IL -17A/F signaling pathway and PSO biology. 
Additional variables may include but will not be limited to serum complement concentratio ns. 
4.3.5  Immunological variable  
The immunological variable is the anti bimekizumab antibody level prior to and following IMP.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 25 of 206 5 STUDY DESIGN  
5.1 Study description  
PS0009 is a randomized, double -blind, placebo - and active comparator -controlled study to 
evaluate the efficacy and safety of bimekizumab administered sc to subjects with PSO. To be 
eligible to participate in this study, subjects must be adults with a diagnosis of moderate to 
severe plaque PSO (PASI ≥12 and BSA ≥10% and IGA score ≥3 [on a 5 -point scale]) wh o are a 
candidate for ustekinumab, or for systemic PSO therapy and/or phototherapy. Subjects may have 
been previously exposed to a biologic therapy (see Exclusion Criterion # 23). 
5.2 Study periods  
This study will include 4 periods, a Screening Period (2 to 5 w eeks), an Initial Treatment Period 
(16 weeks), a Maintenance Treatment Period (36 weeks), and a SFU Period (20 weeks after the 
final dose of IMP). After completion of the Maintenance Treatment Period, eligible subjects will 
be allowed to enroll in an open -label study. Subjects enrolling into the open -label study will not 
have the PS0009 SFU Visit.  
5.2.1  Screening Period  
The Screening Period will last 2 weeks, but can be extended up to a total of 5 weeks  in cases 
where a laboratory assessment needs to be repeated or to allow washout of prohibited 
medications. During this time, eligible subjects will be informed about the study and sign the 
Informed Consent Form (ICF), laboratory data (hematology, urine, and biochemistry tests) will 
be obtained, and the doses of med ications used to treat PsA, will be verified as stable. The 
Screening Period will also enable washout of any medications not permitted for use during the 
study.  Subjects who require prophylaxis for latent tuberculosis (LTB) infection must be on 
treatment for at least 8 weeks prior to their first dose of IMP. These subjects may be rescreened 
once they have completed the first 8 weeks of prophylaxis treatment.  
One rescreening may be allowed after consultation with the Medical Monitor.  
The assessments to be p erformed at the Screening Visit are presented in Table  5‒1. 
5.2.2  Initial Treatment Period  
During the 16 -week Initial Treatment Period, approximately 560 subj ects will be randomized 
4:2:1 to receive the following blinded IMP regimens:  
 Bimekizumab 320mg administered sc Q4W (320 subjects)  
 Ustekinumab (160 subjects):  
 For subjects weighing ≤100kg (220lbs) at Baseline, 45mg sc initially and 4 weeks later  
 For subject s weighing >100kg (220lbs) at Baseline, 90mg sc initially and 4 weeks later  
 Placebo administered sc Q4W (80 subjects)  
Investigational medicinal product will be administered in the clinic by sc injection at the time 
points specified in the schedule of asses sments ( Table  5‒1). 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 26 of 206 Subjects withdrawing early from the study will undergo the PEOT Visit assessments and will 
enter the SFU Period. Subjects withdrawi ng early from the study will not be eligible for 
inclusion in the open -label study.  
Subjects will be followed in a double -blind fashion. Subjects may receive placebo injections at 
certain visits in order to blind the IMP.  
The assessments to be performed at  each Treatment Period Visit are presented in Table  5‒1. 
5.2.3  Maintenance Treatment Period  
After the 16 -week Initial Treatment Period, subjects will enter t he 36 -week Maintenance 
Treatment Period. The Maintenance Treatment Period will start at Week  16 and subjects will 
return to the clinic Q4W through Week  52. 
Treatment during the Maintenance Treatment Period will be based on initial treatment, per the 
follow ing rules:  
 Subjects in the bimekizumab 320mg treatment arm will continue to receive bimekizumab 
320mg Q4W.  
 Subjects in the ustekinumab treatment arm will continue on ustekinumab (subjects weighing 
≤100kg [220lbs] at Baseline will receive 45mg sc every 12 w eeks; subjects weighing >100kg 
[220lbs] at Baseline will receive 90mg sc every 12 weeks).  
 Subjects in the placebo arm will receive bimekizumab 320mg Q4W.  
Subjects may receive placebo injections at certain visits in order to blind the IMP (see 
Section  7.2). 
At the end of the Maintenance Treatment Period, all subjects enrolling in the open -label study 
will, after signing a new ICF, undergo the Week  52 study assessments and then receive their first 
dose of bimekizumab in the open -label study. All subjects not enrolling in the open -label study 
will have the Week  52 study assessments and will enter the SFU Period.  
The assessments at each Maintenanc e Treatment Period Visit are presented in Table  5‒1. 
5.2.4  Safety Follow -Up 
All subjects not continuing in the open -label study, including those withdrawn fr om IMP, will 
have a SFU Visit 20 weeks after their final dose of IMP.  
The assessments for the SFU are presented in Table  5‒1. 
5.2.5  Premature End of Treatment  
Subjects withdrawing early from the study will undergo PEOT Visit assessments ( see 
Section  8.4) and will enter the SFU Period.  
5.3 Study duration per su bject  
For each subject, the study will last a maximum of up to 73 weeks, as follows:  
 Screening Period: 2 to 5 weeks  
 Double -blind, placebo - and active comparator -controlled Initial Treatment Period: 16 weeks  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 27 of 206  Double -blind, active comparator -controlled Maintenance Treatment Period: 36 weeks  
 Safety Follow -Up Period: a SFU Visit is planned 20 weeks after the final dose of IMP (for 
subjects not enrolling in the open -label study)  
After the 36 -week Maintenance Treatment Period, subjects will be allowed to enr oll in an open -
label study, in which case subjects will undergo the Week  52 study assessments before receiving 
their first open -label IMP dose. The SFU Visit will not be required for subjects who enroll in the 
open -label study.  
The end of the study is defi ned as the date of the last visit of the last subject in the study.  
5.4 Planned number of subjects and site(s)  
Approximately 750  subjects will be screened in order to have 560 subjects randomized in the 
study. There will be approximately 320 subjects in the bi mekizumab 320mg treatment arm, 160 
subjects in the ustekinumab treatment arm, and 80 subjects in the placebo treatment arm. The 
planned number of study sites is approximately 100. Every eligible subject who signs an ICF will 
be randomized.  
5.5 Anticipated regi ons and countries  
The regions planned for study conduct are North America, Western Europe, Central/Eastern 
Europe, and Asia/Australia , with possible extension to other regions and countries.  
5.6 Schedule of study assessments  
The schedule of study assessments i s presented in Table  5‒1. At each visit, all study assessments 
should be performed prior to administration of IMP.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 28 of 206 Table  5‒1: Schedule of study assessments  
Visita/ 
Week  
 
Protocol activity  
Screening  Initial Treatment Period  
(weeks after first dose)  Maintenance Treatment Period  
(weeks after first dose)  
SFUb Baseline 
(first dose)  
1 2 4 8 12 16 20 24 28 32 36 40 44 48 52/ 
PEOT  
Informed consentc X               Xd   
Inclusion/exclusion  X X                 
Urine drug screen  X                X  
Demographic data  X                  
Psoriasis history  X                  
Significant past medical history and 
concomitant diseases  X Xe                 
Physical examf, g X X     X   X   X    X X 
Height   X                 
Body weight   X     X   X   X    X  
Vital signsh X X X X X X X X X X X X X X X X X X 
Hematology and biochemistry  X X X X X X X X X X  X  X  X X X 
Urinalysis  X X      X  X  X  X  X X X 
ECG  X      X      X     X  
Pregnancy testingi X X   X X X X X X X X X X X X X X 
Hepatitis B and C testingj X                  
HIV testingk X                  
Chest x -rayl X                  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 29 of 206 Table  5‒1: Schedule of study assessments  
Visita/ 
Week  
 
Protocol activity  
Screening  Initial Treatment Period  
(weeks after first dose)  Maintenance Treatment Period  
(weeks after first dose)  
SFUb Baseline 
(first dose)  
1 2 4 8 12 16 20 24 28 32 36 40 44 48 52/ 
PEOT  
IGRA Tuberculosis test  X               X   
Tuberculosis questionnaire  X X     X   X   X    X X 
Blood sample for bimekizumab 
plasma concentrationsm  X X X X X X X   X   X   X X 
Blood sample for anti - 
bimekizumab antibodiesm  X   X X X X   X   X   X X 
Blood sample genomic, proteomic, 
metabolomics, and candidate 
biomarker analysesc,m  X X   X X X         X  
Blood sample genetic/epigenetic 
analysisc,m  X               X  
PASI  X X X X X X X X X X X X X X X X X X 
IGA X X X X X X X X X X X X X X X X X X 
Percentage of BSA  X X X X X X X X X X X X X X X X X X 
DLQI   X X X X X X X   X   X   X  
PHQ -9 X X   X X X X X X X X X X X X X  
eC-SSRS  X X X X X X X X X X X X X X X X X X 
Patient Symptom Diary (daily)  X X X X X X X  X           
scalp IGA   X Xn Xn Xn Xn Xn Xn   Xn   Xn   Xn  
mNAPSI   X   Xo Xo Xo Xo   Xo   Xo   Xo  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 30 of 206 Table  5‒1: Schedule of study assessments  
Visita/ 
Week  
 
Protocol activity  
Screening  Initial Treatment Period  
(weeks after first dose)  Maintenance Treatment Period  
(weeks after first dose)  
SFUb Baseline 
(first dose)  
1 2 4 8 12 16 20 24 28 32 36 40 44 48 52/ 
PEOT  
pp-IGA  X   Xp Xp Xp Xp   Xp   Xp   Xp  
EQ-5D-3L  X   X X X X   X   X   X  
SF-36  X   X X X X   X   X   X  
Patient Global Assessment of 
psoriasisq           X   X   X  
PASE   X               X  
PGADAr  X    X  X X   X   X   X  
HAQ -DIr  X   X X X X   X   X   X  
WPAI -SHP V2.0   X      X  X    X   X  
Photographs of skin and nails 
(subset of sites)   X X X X X X X   X   X   X  
Concomitant medication  X X X X X X X X X X X X X X X X X X 
Adverse events  X X X X X X X X X X X X X X X X X X 
IRTs,t X X X X X X X X X X X X X X X X X X 
Bimekizumab, ustekinumab, or 
placebo administrations,t  X   X X X X X X X X X X X X   
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 31 of 206 Table  5‒1: Schedule of study assessments  
Visita/ 
Week  
 
Protocol activity  
Screening  Initial Treatment Period  
(weeks after first dose)  Maintenance Treatment Period  
(weeks after first dose)  
SFUb Baseline 
(first dose)  
1 2 4 8 12 16 20 24 28 32 36 40 44 48 52/ 
PEOT  
BSA=body surface area; CV=cardiovascular; DLQI=Dermatology Life Quality Index; ECG=electrocardiogram; eC -SSRS=electronic Columbia Suicide 
Severity Rating Scale; eCRF=electronic Case Report Form; EQ -5D-3L=Euro -Quality of Life 5 -Dimensions 3 -level; GI=gastro intestinal; HAQ -DI=Health 
Assessment Questionnaire -Disability Index; HCV=hepatitis C virus; HIV=human immunodeficiency virus; ICF=Informed Consent Form; IGA=Investigator’s 
Global Assessment; IGRA=interferon -gamma release assay; IMP=investigational medicina l product; IRT=interactive response technology; 
mNAPSI=Modified Nail Psoriasis Severity Index Score; PASE=Psoriatic Arthritis Screening and Evaluation;  PASI=Psoriasis Area Severity Index; 
PEOT=Premature End of Treatment; PGADA=Patient’s Global Assessment o f Disease Activity; PHQ -9=Patient Health Questionnaire 9; pp -
IGA=palmoplantar Investigator’s Global Assessment; PsA=psoriatic arthritis; SF -36=Short Form 36 -item Health Survey; SFU=Safety Follow -Up; scalp 
IGA=scalp -specific Investigator’s Global Assessment ; TB=tuberculosis; WPAI -SHP=Work Productivity and Activity Impairment Questionnaire -specific 
health problem  
a Visit windows of ±3 days from the first dose to the Week 24 visit. Visit windows of ±7 days from the Week 28 visit to the Week 52 visit. The SFU Visit 
window is ±7 days from last dose.  
b The SFU Visit will occur 20 weeks after the final dosefor subjects who do not enroll in the open -label study.  
c All genomic, proteomic, and metabolomics s amples will be stored at -80°C at the central biorepository for up to 20 years.  
d A separate ICF is required to be completed for the open -label study.  
e Ensure no significant changes in medical history.  
f Includes evaluation of signs and symptoms of active  TB and risk for exposure to TB.  
g The physical examination will be performed as per Section  12.3.5 . 
h Vital signs (sitting systolic and diastolic bl ood pressure, pulse rate, and body temperature) are to be measured prior to blood sampling, and prior to dosing, 
where applicable.  
i Pregnancy testing will consist of serum testing at the Screening. The pregnancy test will be urine at all other visits.  
j Subjects who have evidence of or test positive for hepatitis B by any of the following criteria: 1) positive for hepatitis B s urface antigen (HBsAg+); 2) positive 
for anti -hepatitis B core antibody (HBcAb+) are excluded. A positive test for HCV is defined a s: 1) positive for hepatitis C antibody (anti -HCV Ab), and 2) 
positive via a confirmatory test for HCV (for example, HCV polymerase chain reaction) are also excluded. Subjects will also b e tested for anti -hepatitis  B 
surface antibody.  
k The HIV test result s will not be recorded in the eCRF.  
l Screening chest x -ray must occur within 3 months prior to Screening Visit.  
m All blood samples taken prior to dosing.  
n The scalp IGA will only be assessed for those subjects with scalp involvement (scalp IGA score >0)  at Baseline.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 32 of 206 o The mNAPSI will be assessed only in subjects with nail involvement (mNAPSI score >0) at Baseline.  
p The pp -IGA will only be assessed in subjects with palmoplantar involvement (pp -IGA score >0) at Baseline.  
q The Patient Global Assessment of  psoriasis will be performed as part of the patient symptoms diary on a weekly basis from baseline through the initial 
treatment period. During the Maintenance Treatment Period this assessment will be completed at the specified clinic visits.  
r The PGADA and HAQ -DI are assessed for all subjects at Baseline. At all subsequent visits, the PGADA and HAQ -DI are assessed only for subjects with PsA 
at Baseline (defined as a past medical history of PsA or PASE ≥47).  
s IMP administration is based on randomization.  
t The dosing window is ±3 days relative to the scheduled dosing visit through Week 24. The dosing window is ±7 days from Week 2 8 through the end of the 
study.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 33 of 206 5.7 Schematic diagram  
The study schematic diagram for PS 0009 is presented in Figure  5‒1. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 34 of 206 Figure  5‒1: Schematic diagram  
Placebo
Bimekizumab 
320mg Q4W
UstekinumabScreening
N=80
N=320
N=160Initial Treatment Period
Week 16
Co-primary Endpoint: 
PASI90 Response and IGA ResponseBimekizumab 
extension study
to evaluate response 
to treatment and 
long-term safety
SFU Visit
20 Weeks after last 
dose for subjects not 
enrolling in extension 
study
RandomizationUstekinumabMaintenance Treatment Period
52 Baseline           Bimekizumab 320mg Q4WN=560           Bimekizumab 320mg Q4W
 
IGA=Investigator’s Global Assessment; N=number; PASI=Psoriasis Area Severity Index; Q4W=every 4 weeks; SFU=Safety Follow -Up 
Note: At Week 24 and all following visits, subjects on continuous treatment with the same IMP for at least 12 weeks with a persistent IGA score ≥3 over at least 
a 4-week period are defined as nonresponders and should discontinue IMP.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 35 of 206 5.8 Rationale for study design and selection of dose  
5.8.1  Study design  
A randomized, double -blind, placebo - and active -controlled study design has been selected to 
demonstrate efficacy and safety of bimkeizumab for regulatory approval. The study population 
will include adults with moderate to severe chronic plaque PSO and allow subjects who have 
received previous biologic treatment as well as those who are biologic treatment naïve. The 
primary efficacy outcome measures (based on PASI and IGA) and other efficacy assessments 
included in this study are consisten t with those used for other PSO studies and are considered 
appropriate for establishing efficacy of bimekizumab. An initial treatment period of 16 weeks 
will be used to demonstrate the efficacy of bimekizumab over PBO and ustekinumab. The study 
duration ex tends beyond the initial treatment period (to 52 weeks) to collect information on 
dosing beyond initial treatment.  
5.8.2  Dose selection  
Bimekizumab doses ranging from 64mg to 480mg were evaluated in the Phase 2b multicenter, 
randomized, double -blind, placebo -controlled, parallel -group, dose -ranging study PS0010. 
Bimekizumab 320mg was found to have an acceptable safety profile, only required 2 injections 
per treatment administration, and achieved significant PASI responses at Week 12 (summarized 
in the IB). Furthe rmore, data from the Phase 2a multicenter, randomized, subject -blind, 
investigator -blind study PS0016 and PK/PD modeling in this PSO population indicates improved 
responses through Week 16. Therefore, a bimekizumab dose of 320mg Q4W was selected for 
this s tudy.  
6 SELECTION AND WITHDR AWAL OF SUBJECTS  
6.1 Inclusion criteria  
To be eligible to participate in this study, all of the following criteria must be met at Screening 
and at the Baseline Visit:  
1. Subject has provided informed consent.  
2. Subject is considered relia ble and capable of adhering to the protocol (eg, able to understand 
and complete diaries), visit schedule, or medication intake according to the judgment of the 
Investigator.  
3. Male or female at least 18 years of age.  
4. Chronic plaque PSO for at least 6 months  prior to the Screening Visit.  
5. PASI ≥12 and BSA affected by PSO ≥10% and IGA score ≥3 on a 5 -point scale.  
6a. Subject is a candidate for systemic PSO therapy and/or phototherapy.  
7. Subject must be considered, in the opinion of the Investigator, to be a su itable candidate for 
treatment with ustekinumab per regional labeling and has no contraindications to receive 
ustekinumab as per the local label.  
8. Female subjects must be:  
 Postmenopausal: Menopause is defined as 12 consecutive months of amenorrhea, for 
which there is no other obvious pathological or physiological cause.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 36 of 206  Permanently sterilized (eg, tubal occlusion, hysterectomy, bilateral salpingectomy)  
 Or, if of childbearing potential (and engaged in sexual activity that could result in 
procreation), must  be willing to use a highly effective method of contraception 
throughout the duration of the study until 20 weeks after last administration of IMP, and 
have a negative pregnancy test at Visit 1 (Screening) and immediately prior to first dose. 
The following  methods are considered highly effective when used consistently and 
correctly:  
o Combined (estrogen and progestogen) hormonal contraception associated with 
inhibition of ovulation (oral, intravaginal, or transdermal)  
o Progestogen -only hormonal contraception a ssociated with inhibition of ovulation 
(oral, injectable, implantable)  
o Intrauterine device  
o Intrauterine hormone -releasing system  
o Vasectomised partner  
o Abstinence as a form of birth control is generally not allowed in the study unless 
abstinence is in acco rdance with a subject’s preferred and common lifestyle. Study 
personnel must confirm the continued use of abstinence is still in accordance with the 
subject’s lifestyle at regular intervals during the study.  
9. Subject agrees not to change their usual sun exposure during the course of the study and to 
use ultraviolet A/ultraviolet B sunscreens if unavoidable exposure occurs.  
6.2 Exclusion criteria  
Subjects are not permitted to enroll in the study if any of the following criteria are met:  
1. Female subject who is breastfeeding, pregnant, or plans to become pregnant during the study 
or within 20 weeks following the final dose of IMP.  
2. Subject previously participated in a bimekizumab clinical study who received at least 1 dose 
of the IMP (including placebo).  
3a. Subje ct is currently participating in another study of a medication (systemic) under 
investigation. Subject must be washed out of the medication for 12 weeks or at least 5 half -
lives prior to the Baseline Visit, whichever is greater.  
4a. Subject is currently pa rticipating in another study of a topical medication under investigation. 
Subject must be washed out of the medication for 4 weeks prior to the Baseline Visit.  
5a. Subject is currently, or was within the 4 weeks prior to the Baseline Visit, participating i n 
another study of a medical device under investigation.  
6. Subject has a known hypersensitivity to any excipients of bimekizumab or ustekinumab.  
7. Subject has a form of PSO other than chronic plaque -type (eg, pustular, erythrodermic and 
guttate PSO, or d rug-induced PSO).  
8. Subject has an active infection or history of infection(s) as follows:  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 37 of 206  Any active infection (except common cold) within 14 days prior to Baseline  
 A serious infection, defined as requiring hospitalization or iv anti -infective(s) within 2 
months prior to the Baseline Visit  
 A history of opportunistic, recurrent, or chronic infections that, in the opinion of the 
Investigator, might cause this study to be detrimental to the subject. Opportunistic 
infections are infections caused by uncommon pathogens (eg, pneumocystis jirovicii, 
cryptococcosis) or unusually severe infections caused by common pathogens (eg, 
cytomegalovirus, herpes zoster)  
9. Subject has concurrent acute or chronic viral hepatitis B or C or human immunodeficiency 
virus (HIV) in fection. Subjects who have evidence of, or tested positive for hepatitis B or 
hepatitis C are excluded. A positive test for the hepatitis B virus is defined as: 1) positive for 
hepatitis B surface antigen (HBsAg+) or 2) positive for anti -hepatitis B core a ntibody 
(HBcAb+). A positive test for the hepatitis C virus (HCV) is defined as: 1) positive for 
hepatitis C antibody (anti -HCV Ab), and 2) positive via a confirmatory test for HCV (for 
example, HCV polymerase chain reaction).  
10. Subject has received any live (includes attenuated) vaccination within the 8 weeks prior to 
the Baseline visit (eg, inactivated influenza and pneumococcal vaccines are allowed but nasal 
influenza vaccination is not permitted).  
11. Subject has received Bacillus Calmette -Guerin vacc inations within 1 year prior to the 
Baseline Visit.  
12. Subject has known tuberculosis (TB) infection, is at high risk of acquiring TB infection, or 
has current or history of nontuberculous mycobacterium (NTMB) infection. A subject with 
LTB (a positive int erferon -gamma release assay [IGRA] and diagnosis confirmed by TB 
specialist) may be rescreened once and enrolled after receiving at least 8 weeks of 
appropriate LTB infection therapy and if no evidence of therapy -related hepatotoxicity has 
occurred prior t o the first injection (alanine aminotransferase [ALT)/aspartate 
aminotransferase [AST) remain ≤3 times the upper limit of normal [ULN]).  
Subject has a past history of active TB involving any organ system unless adequately treated 
according to World Health Organization/Centers for Disease Control (CDC) therapeutic 
guidance and proven to be fully recovered upon consult with a TB specialist.  
Refer to Section  12.3.1  for details on determining full TB exclusion criteria.  
13. Subject has a history of a lymphoproliferative disorder including lymphoma or current signs 
and symptoms suggestive of lymphoproliferative disease.  
14a. Subject has any active malignancy  or history of malignancy within 5 years prior to the 
Screening Visit EXCEPT treated and considered cured cutaneous squamous or basal cell 
carcinoma, or in situ cervical cancer.  
15. Subject has a diagnosis of inflammatory conditions other than PSO or PsA, including but not 
limited to rheumatoid arthritis, sarcoidosis, or systemic lupus erythematosus. Subjects with a 
diagnosis of Crohn’s disease or ulcerative colitis are allowed as long as they have no active 
symptomatic disease at Screening or Baseline.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 38 of 206 16. Subject has had major surgery (including joint surgery) within the 3 months prior to the 
Baseline Visit, or has planned major surgery within 6 months after entering the study.  
17a. Subject has any systemic disease (ie, cardiovascular, neurological, renal,  liver, metabolic, 
gastrointestinal, hematological, immunological, etc.) considered by the Investigator to be 
uncontrolled, unstable, or likely to progress to a clinically significant degree during the 
course of the study.  
18. Subject has had myocardial in farction or stroke within the 6 months prior to the Screening 
Visit.  
19. Subject has laboratory abnormalities at Screening, including any of the following:  
a. ≥3.0x ULN of any of the following: ALT, AST, alkaline phosphatase (ALP); or >ULN 
total bilirubin (≥1.5xULN total bilirubin if known Gilbert’s syndrome).  
b. White blood cell (WBC) count <3.00x103/μL 
c. Absolute neutrophil count <1.5x103/μL 
d. Lymphocyte count <500 cells/ μL 
e. Hemoglobin <8.5g/dL  
f. Any other laboratory abnormality, which, in the opinion of the Investigator, will prevent 
the subject from completing the study or will interfere with the interpretation of the study 
results  
Individual screening tests for which the r esults are in error, borderline, or indeterminate 
for inclusion in the study can be repeated once for confirmation  during the Screening 
Period . Upon retesting, subjects whose results remain outside this threshold should not be 
randomized.  
20. Subject has a ny other condition, including medical or psychiatric, which, in the Investigator's 
judgment, would make the subject unsuitable for inclusion in the study.  
21. Subject has had previous exposure to ustekinumab.  
22. Criterion deleted  
23. Subject has experienc ed primary failure (no response within 12 weeks) to 1 or more IL -17 
biologic response modifier (eg, brodalumab, ixekizumab, secukinumab) OR more than 1 
biologic response modifier other than an IL -17. 
24. Subject is taking PsA medications other than stable doses (ie, stable for at least 1 week prior 
to the Screening Visit) of nonsteroidal anti -inflammatory drugs (NSAIDs) or analgesics (see 
Section  7.8.1.2 ). 
25. Subject has a history of chronic alcohol or drug abuse within 6 months prior to Screening as 
evaluated by the Investigator based on medical history, site interview, and/or results of th e 
specified urine drug screen.  
26. Presence of active suicidal ideation, or positive suicide behavior using the "Screening" 
version of the electronic Columbia Suicide Severity Rating Scale (eC -SSRS) and with either 
of the following criteria:  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 39 of 206  History of a s uicide attempt within the 5 years prior to the Screening Visit. Subjects with 
a history of a suicide attempt more than 5 years ago should be evaluated by a mental 
healthcare practitioner (HCP) before enrolling into the study.  
 Suicidal ideation in the past month prior to the Screening Visit as indicated by a positive 
response ("Yes") to either Question 4 or Question 5 of the "Screening" version of the 
eC-SSRS.  
27a. Subject has presence of moderately severe major depression or severe major depression, 
indicat ed by a score of ≥15 using the screening PHQ -9. Medication used to treat depression 
should be stable for 8 weeks prior to baseline.  
28. Subject is a member of Investigator site personnel directly affiliated with this study and/or 
their immediate families. Immediate family is defined as a spouse, parent, child, or sibling, 
whether biological or legally adopted.  
29. Subject is a UCB employee or employee of third -party organizations involved in the study.  
30. Subject is taking or has taken prohibited psoriasis  medications without meeting the 
mandatory washout period relative to the Baseline Visit ( Table  7‒2). 
6.3 Withdrawal criteria  
Subjects are free to withdraw  from the study at any time, without prejudice to their continued 
care. Subjects who withdraw from the study should complete the PEOT Visit (see Section  8.4). 
Subjects should be withdrawn from the study and will be encouraged to come back for the SFU 
Visit 20  weeks after final dose of IMP if the subject withdraws his/her consent or the Sponsor or 
a regulatory agency requests withdrawal of the subject.  
A subject should be withdrawn from IMP and will be asked to come back for the SFU visit 
20 weeks after final dose of IMP  if any of the following events occur:  
1. Subject develops an illness that in the opinion of the Investigator would interfere with his/her  
continued participation if the risk of continuing IMP outweighs the potential benefit.  
2. Subject develops erythrodermic, guttate, or pustular form of PSO.  
3. Criterion deleted  
4. Subject is noncompliant with the study procedures or medications in the opinion of the 
Investigator.  
5. Subject uses prohibited concomitant medications, with the exception of topicals, as defined 
in this protocol ( Section  7.8.2 ), that may present a risk to the safety of the subject or the 
integrity of the study data, in the opinion of the Investigator and/or the Medical Monitor.  
6. Subject has a clinical laboratory value meeting any of the following criteria:  
a. Hepatotoxicity as described in  Section  6.3.1  
b. A laboratory value meeting any of the following criteria:  
◦ Absolute neutrophil count <1.0x103/μL 
◦ Absolute lymphocyte count <0.2x103/μL 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 40 of 206 Subjects may remain in the study if the result is transient. A retest is required within 1 to 
2 weeks at a scheduled or unscheduled visit. If the repeat absolute neutrophil count or 
absolute lymphocyte count is still below the allowable values, the subjec t must be 
withdrawn. If the repeat absolute neutrophil count or absolute lymphocyte count is above 
the allowable values, the subject may continue in the study.  
7. The subject experiences a severe AE, an SAE, or a clinically significant change in a 
laboratory value that, in the opinion of the Investigator, merits the discontinuation of the 
investigational product and appropriate measures being taken.  
8. At Week 24 and all following visits, subjects on continuous treatment with the same IMP for 
at least 12 weeks wi th a persistent IGA score ≥3 over at least a 4 -week period are defined as 
nonresponders and should discontinue IMP.  
9. There is confirmation of a pregnancy during the study, as evidenced by a positive pregnancy 
test (see Section  12.1.4  for more information regarding pregnancies).  
10. A subject considered as having either a suspected new LTB infection or who develops active 
TB or NTMB infection during the stu dy (including but not limited to, conversion 
demonstrated by IGRA or other diagnostic means) must be immediately discontinued from 
IMP and a PEOT Visit must be scheduled as soon as possible, but not later than the next 
regular visit.  
The subject must be pe rmanently withdrawn if further examinations result in a diagnosis of 
active TB, or if the subject is diagnosed with latent TB infection (LTBI) with no initiation of 
prophylactic treatment, prematurely discontinues prophylactic treatment, or, in the opinion  of 
the Investigator or Sponsor, is noncompliant with prophylactic TB therapy.  
Confirmed active TB is an SAE and must be captured on an SAE Report Form and provided 
to the Sponsor in accordance with SAE reporting requirements. As with all SAEs, periodic 
follow-up reports should be completed as per protocol requirements until such time as the TB 
infection resolves.  
Additional information on TB policies is provided in Section  12.3.1 . 
11. Subjects with newly diagnosed inflammatory bowel disease (IBD) or with IBD flares during 
the study must:  
 Be referred, as appropriate, to a health care professional treating IBD, such as a 
gastroenterologist  
 Discontinue IMP and be followed -up until resolution of active IBD symptoms  
If IBD flares increase in severity or frequency during the study, the Investigator should use 
clinical judgement in deciding whether the subject should continue in the study and contact 
the Medical Monitor and UCB study physician to confirm the subject’s suitability for 
continued participation in the study.  
12. Subjects must be referred  immediately to a mental health care professional and may be 
withdrawn from the study based upon the Investigator’s judgment of benefit/risk for:  
 Active suicidal ideation as indicated by a positive response (“Yes”) to Question 4 of the 
“Since Last Visit” version of the eC -SSRS.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 41 of 206  Moderately severe major depression as indicated by a PHQ -9 score of 15 to 19 if this 
represents an increase of 3 points compared to last visit.  
13. Subjects must be referred immediately to a mental healthcare professional and must be 
withdrawn in case of:  
 Active suicidal ideation as indicated by a positive response (“ Yes”) to Question 5 of the 
“Since Last Visit” version of the eC -SSRS  
 Any suicidal behavior since last visit.  
 Severe major depression as indicated by a PHQ -9 score ≥20.  
The mental health consultation must be recorded in source documentation.  
Investigators s hould attempt to obtain information on subjects in the case of withdrawal or 
discontinuation. For subjects considered as lost to follow -up, the Investigator should make an 
effort (at least 1 phone call and 1 written message to the subject), and document hi s/her effort 
(date and summary of the phone call and copy of the written message in the source documents), 
to complete the final evaluation. All results of these evaluations and observations, together with a 
narrative description of the reason(s) for remov ing the subject, must be recorded in the source 
documents. The electronic Case Report Form (eCRF) must document the primary reason for 
withdrawal or discontinuation.  
Investigators should contact the Medical Monitor, whenever possible, to discuss the withdr awal 
of a subject in advance.  
6.3.1  Potential drug -induced liver injury IMP discontinuation criteria  
Subjects with potential drug -induced liver injury (PDILI) must be assessed to determine if IMP 
must be discontinued. In addition, all concomitant medications and  herbal supplements that are 
not medically necessary should also be discontinued.  
The PDILI criteria below require immediate and permanent discontinuation of IMP for subjects 
with either of the following:  
 ALT or AST ≥ 8xULN  
 ALT or AST ≥3xULN and coexisting  total bilirubin ≥2xULN  
The PDILI criterion below requires immediate discontinuation of IMP for:  
 Subjects with ALT or AST ≥3xULN who exhibit temporally associated symptoms of 
hepatitis or hypersensitivity. Hepatitis symptoms include fatigue, nausea, vomiti ng, right 
upper quadrant pain or tenderness. Hypersensitivity symptoms include fever (without clear 
alternative cause), rash, or eosinophilia (ie, >5%).  
If a nondrug -related cause for the symptoms can be confirmed, these subjects may resume 
IMP administrat ion after discussion with the responsible UCB physician, but only when the 
requirements for rechallenge with IMP as provided in Section  12.2.1.2.1  are followed.  
The PDILI criterion below allows for subjects to continue on IMP at the discretion of the 
Investigator.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 42 of 206  Subjects with ALT or AST ≥5xULN and <8xULN, total bilirubin <2xULN, and no 
eosinophilia (ie, ≤5%), with no fever, rash, or symptoms of he patitis (eg, fatigue, nausea, 
vomiting, right upper quadrant pain or tenderness).  
Evaluation of PDILI must be initiated as described in Section  12.2.1  with repeat tests 
performed in two weeks. Upon re -test, if ALT or AST values have reduced to <5xULN, the 
subject can continue with the study. However, if ALT or AST remains ≥5xULN and 
<8xULN after re -test, IMP should be temporarily withheld and subject should undergo a 
repeat test in two weeks. If ALT or AST values remain ≥5xULN even after the second re -
test, then the subject should be permanently withdrawn from the study and should be 
followed for possible drug -induced liver injury.  
If subjects are unab le to comply with the applicable monitoring schedule, IMP must be 
discontinued immediately.  
Investigators should attempt to obtain information on subjects in the case of IMP discontinuation 
to complete the final evaluation. Subjects with PDILI should not b e withdrawn from the study 
until investigation and monitoring are complete. All results of these evaluations and 
observations, as well as the reason(s) for IMP discontinuation and subject withdrawal (if 
applicable), must be recorded in the source documents . The eCRF must document the primary 
reason for IMP discontinuation.  
7 STUDY TREATMENT(S)  
7.1 Description of investigational medicinal product(s)  
The IMPs used in this study are bimekizumab, ustekinumab, and placebo.  
 Bimekizumab will be supplied in a  
 for sc 
injection.  
 Placebo will be supplied as 0.9% sodium chloride aqueous solution (physiological saline, 
preservative free) of pharmacopo eia (USP/Ph.Eur) quality in a 1mL PFS for sc injection.  
 Ustekinumab is commercially available and will be supplied in a 0.5mL PFS at a 
concentration of 45mg/0.5mL.  
Further details of the IMPs and their specifications are provided in the IMP Handling Manual.  
7.2 Treatment(s) to be administered  
Unblinded study staff will be responsible for preparation of the clinical trial material, including 
recording the administration information on source documents, and administration of the IMP as 
sc injections. The un blinded personnel will not be involved in the study in any way other than 
assuring the medication is taken from the correct kit and administering the drug to the subjects.  
Suitable areas for sc injections are the lateral abdominal wall, upper outer thigh, or upper arm. 
During each dosing visit, each of the injections should be administered at a separate injection 
site. Injection sites should be rotated at each visit and injections should not be given into a PSO 
plaque or areas where the skin is tender, brui sed, erythematous, or indurated. The injection 
should last approximately 10 to 15 seconds.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 43 of 206 An IMP Handling Manual will be provided to each site containing instructions regarding drug 
preparation and dosing.  
Double -blind Initial Treatment Period dosing  
Beca use of differences in the dosing schedule between bimekizumab and ustekinumab, all 
subjects will receive 2 injections sc Q4W based on the following dosing scheme:  
 Subjects randomized to receive placebo will receive 2 placebo injections sc Q4W.  
 Subjects ran domized to receive bimekizumab 320mg Q4W will receive 2 bimekizumab 
160mg injections sc Q4W.  
 Subjects randomized to receive ustekinumab will receive ustekinumab sc at Baseline and 
Week  4, followed by placebo (2 placebo injections sc) at Week  8 and Week  12. Because 
ustekinumab dosing is based on weight, on ustekinumab treatment weeks subjects ≤100kg 
(220lbs) at Baseline will receive 1 ustekinumab 45mg sc injection and 1 placebo injection 
and subjects >100kg (220lbs) at Baseline will receive 2 ustekinumab 45m g sc injections.  
Maintenance Treatment Period dosing  
Investigational medicinal product treatment during the Maintenance Treatment Period will be 
based on initial treatment as described in Section  5.2.3 . 
 Subjects who received bimekizumab or placebo in the Initial Treatment Period will receive 
2 bimekizumab 160mg injections sc Q4W.  
 Subjects randomized to receive ustekinumab will have received ustekinumab sc at Baseline 
and Week  4, and will continue to receive ustekinumab sc every 12 weeks (Weeks 16, 28, and 
40). Subjects will receive placebo (2 placebo injections sc) on non -ustekinum ab treatment 
weeks (Weeks 20, 24, 32, 36, 44, and 48). Because ustekinumab dosing is based on weight, 
on ustekinumab treatment weeks subjects ≤100kg (220lbs) at Baseline will receive 
1 ustekinumab 45mg sc injection and 1 placebo injection and subjects >100 kg (220lbs) at 
Baseline will receive 2 ustekinumab 45mg sc injections.  
The dosing scheme is depicted in Table  7‒1.  
Table  7‒1: Dosing scheme  
Week  
Dose Assignment  Baseline 
(first 
dose)  4 8 12 16 20 24 28 32 36 40 44 48 
Bimekizumab 
320mg Q4W  ●● ●● ●● ●● ●● ●● ●● ●● ●● ●● ●● ●● ●● 
Ustekinumab 45mg 
(subjects ≤100kg)  ▲○ ▲○ ○○ ○○ ▲○ ○○ ○○ ▲○ ○○ ○○ ▲○ ○○ ○○ 
Ustekinumab 90mg 
(subjects >100kg)  ▲▲  ▲▲  ○○ ○○ ▲▲  ○○ ○○ ▲▲  ○○ ○○ ▲▲  ○○ ○○ 
Placebo/ 
bimekizumab 
320mg Q4W  ○○ ○○ ○○ ○○ ●● ●● ●● ●● ●● ●● ●● ●● ●● 
Q4W=every 4 weeks  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 44 of 206 Notes: A bimekizumab 160mg injection is depicted by a black circle ( ●). A placebo injection is depicted by a white 
circle (○). A  ustekinumab  45mg injection is depicted by a black triangle ( ▲). 
7.3 Packaging  
Bimekizumab, ustekinumab, and placebo will be packaged and labeled according to Good 
Manufacturing Practice  (GMP) guidelines and applicable laws or regulations. They will be 
suitably packaged in such a way as to protect the product from deterioration during transport and 
storage. Further information regarding storage and transport conditions are provided in the  IMP 
Handling Manual.  
7.4 Labeling  
Bimekizumab, ustekinumab, and placebo will be labeled in accordance with the current 
International Council for Harmonisation (ICH) guidelines on Good Clinical Practice (GCP) and 
GMP and will include any locally required statements. If necessary, labels will be translated into 
the local language.  
7.5 Handling and storage requirements  
Refer to the IMP Handling Manual for the storage conditions of the IMP.  
The Investigator (or designee) is responsible for the safe and proper sto rage of IMP at the site. 
Investigational medicinal product stored by the Investigator is to be kept in a secured area with 
limited access according to the storage conditions mentioned on the label.  
Appropriate storage conditions must be ensured either by c ontrolling the temperature (eg, room, 
refrigeration unit) or by completion of a temperature log in accordance with local requirements 
on a regular basis (eg, once a week), showing actual and minimum/maximum temperatures 
reached over the time interval.  
In case an out of range temperature is noted, it must be immediately reported as per instructions 
contained in the IMP Handling Manual.  
The IMP will be shipped to the study sites in temperature controlled containers. Out -of-range 
shipping or storage conditions  must be brought to the attention of the sponsor or designee, 
immediately. Authorization to use any out -of-range IMP must be documented and received prior 
to dispensing or administering the IMP at the study site.  
7.6 Drug accountability  
A Drug Accountability f orm will be used to record IMP dispensing and return information on a 
by subject basis and will serve as source documentation during the course of the study. Details of 
any IMP lost, damaged (eg, due to breakage or wastage), not used, partially used, dispo sed of at 
the study site, or returned to the sponsor or designee must also be recorded on the appropriate 
forms. All supplies and pharmacy documentation must be made available throughout the study 
for UCB (or designee) to review.  
In order to maintain the b lind, all IMP documentation (eg, shipping receipts, drug accountability 
logs, Interactive Response Technology [IRT] randomization materials) must be maintained and 
accessed by unblinded, trained site personnel only. Designated, unblinded site personnel mus t be 
appropriately trained and licensed (per country guidelines) to administer injections.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 45 of 206 Unblinded study staff will be delegated the responsibility to receive, inventory and destroy the 
used kits. The packaging identifies each kit by a unique number, but  due to the commercial 
packaging of the comparator, the unblinded study staff will be responsible in order to maintain 
the blind. Unblinded study staff will be responsible for preparation (breaking tamper proof 
sticker on kit, etc) of the clinical trial ma terial, including recording the administration 
information on source document.  
The Investigator (or designee) is responsible for retaining all used, unused, and partially used 
containers of IMP until returned or destroyed.  
The Investigator may assign some of the Investigator’s duties for drug accountability at the study 
site to an appropriate pharmacist/designee.  
The Investigator must ensure that the IMP is used only in accordance with the protocol.  
Periodically, and/or after completion of the clinical phas e of the study, all used (including empty 
containers)/partially used, unused, damaged, and/or expired IMP must be reconciled and either 
destroyed at the site according to local laws, regulations, and UCB Standard Operating 
Procedures (SOPs) or returned to UCB (or designee). Investigational medicinal product intended 
for the study cannot be used for any other purpose than that described in this protocol.  
7.7 Procedures for monitoring subject compliance  
Investigational medicinal product will be administered in th e clinic and compliance will be 
determined at the visit by study personnel. Drug accountability must be recorded on the Drug 
Accountability Form.  
7.8 Concomitant medication(s)/treatment(s)  
Any treatment administered from the time of informed consent to the fin al study visit will be 
considered concomitant medication. This includes medications that were started before the study 
and are ongoing during the study.  
7.8.1  Permitted concomitant treatments (medications and therapies)  
7.8.1.1  Topical medications  
Subjects may continue to use topical moisturizers or emollients, bath oils, or oatmeal bath 
preparations for skin conditions during the study, as needed. Over -the-counter shampoos for the 
treatment of PSO of the scalp are also permitted.  
Mild and low potency topical steroids wi ll be permitted for use limited to the face, axilla, and/or 
genitalia, as needed. These topical medications should not be used within approximately 24 
hours prior to study visits requiring IGA and PASI measures.  
7.8.1.2  Other medications  
Subjects who are already r eceiving an established NSAID regimen for PsA or symptoms of 
arthritis and have been on a stable dose for at least 1 week prior to the Screening Visit may 
continue their use during the study. However, initiation of, or increase in dosage of NSAIDs 
during t he study (especially in subjects with a history of gastrointestinal (GI) intolerance to 
NSAIDs or a history of GI ulceration) should not occur prior to Week  16 and should not happen 
within 2 weeks of the Week  52 Visit.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 46 of 206 Subjects may take mild pain relievers  (acetaminophen/paracetamol, mild opiates) as needed for 
arthritis pain but preferably not within 24 hours of the Baseline and Week  52 Visits.  
Intra -articular steroid injections of any joint and hyaluronic acid injections are allowed after 
Week  16. 
Subjects who are receiving an established  regimen for depression should remain on stable dosing 
prior to Baseline and throughout the study.  
7.8.2  Prohibited concomitant treatments (medications and therapies)  
Table  7‒2 presents the list of prohibited PSO medications.  
Table  7‒2: Prohibited psoriasis medications  
Drug  Washout period relative to Baseline Visit  
Topicals except for those permitted ( Section  7.8.1.1 )  2 weeks  
Systemic retinoids  3 months  
Systemic treatment (non-biological):  
systemic immunosuppressant agents (eg, methotrexate, 
cyclosporine, azathioprine, thioguanine)  
fumaric acid esters specifically used for the treatment 
of PSO   
systemic corticosteroids  
phototherapy  1 month  
Anti-TNFs:  
etanercept (including  biosimilar)  
infliximab (including biosimilar), golimumab, 
certolizumab pegol, adalimumab (including biosimilar)   
1 month for etanercept  
3 months for everything other than 
etanercept  
Other biologics and other systemic therapies, eg:  
ustekinumab  Any exposure for ustekinumab  
apremilast, tofacitinib  2 weeks for apremilast and tofacitinib  
alefacept, efalizumab, guselkumab  3 months for alefacept, efalizumab, and 
guselkumab  
tildrakizumab, risankizumab  5 months for tildrakizumab and 
risankizumab  
briakinumab  6 months for briakinumab  
rituximab  12 months for rituximab  
Anti-IL-17 therapy:  
secukinumab  
ixekizumab  
brodalumab  3 months  
(bimekizumab is excluded per exclusion 
criteria)  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 47 of 206 Table  7‒2: Prohibited psoriasis medications  
Drug  Washout period relative to Baseline Visit  
Any other antipsoriatic agent (systemic) under investigation 
(or approved after the protocol is approved)  3 months or 5 half -lives, whichever is 
greater  
Any other antipsoriatic agent (topical) under investigation  1 month  
IL-17=interleukin 17; PSO=psoriasis; TNF=tumor necrosis factor  
Subjects who take prohibited medica tions may be withdrawn from IMP but followed until the 
SFU. The decision to withdraw a subject for taking prohibited medications should be made in 
consultation with the Medical Monitor.  
7.8.2.1  Vaccines  
Administration of live (including attenuated) vaccines is not  allowed during the conduct of the 
study and for 20 weeks after the final dose of IMP (see Exclusion Criterion # 10, Section  6.2). 
Administration of i nactivated vaccines is allowed during the study at the discretion of the 
Investigator.  
7.9 Blinding  
Due to differences in presentation between the bimekizumab and ustekinumab, special 
precautions will be taken to ensure study blinding and study sites will have  blinded and 
unblinded personnel.  
All Sponsor and Investigator site personnel involved in the study will be blinded to the 
randomized IMP assignment with the following exceptions:  
 Unblinded study staff will be responsible for preparation (breaking tamper p roof sticker on 
kit, etc) of the clinical trial material, including recording the administration information on 
source documents, and administration of the IMP as sc injections. The unblinded personnel 
will not be involved in the study in any way other tha n assuring the medication is taken from 
the correct kit and administering the drug to the subjects.  
 Bioanalytical staff analyzing blood samples for bimekizumab and anti -bimekizumab 
antibody determination.  
During the study the Sponsor will provide blinded a nd unblinded site monitors for the purposes 
of verifying safety, efficacy, and drug administration and documentation records. Unblinded 
study site personnel need to be available in order to resolve queries. Study monitors and study 
site personnel, blinded to treatment assignment, will not discuss or have access to any drug 
related information.  
Study sites will be required to have a written blinding plan in place, signed by the Principal 
Investigator, which will detail the site’s steps for ensuring that the double -blind nature of the 
study is maintained. Sites will be instructed to keep study subjects blind to the IMP as detailed in 
the site blinding plan.  
Further details are provided in the study manual and site blinding plan.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 48 of 206 7.9.1  Procedures for maintaining and breaking the treatment blind  
7.9.1.1  Maintenance of IMP blind  
All subject treatment details (bimekizumab, ustekinumab, or placebo) will be allocated and 
maintained by the IRT system.  
7.9.1.2  Breaking the treatment blind in an emergency situation  
The integrity of this clin ical study must be maintained by observing the treatment blind. In the 
event of an emergency for which the appropriate treatment for a subject cannot be made without 
knowing the treatment assignment, it will be possible to determine to which treatment arm and 
dose the subject has been allocated by contacting the IRT. All sites will be provided with details 
of how to contact the system for code breaking at the start of the study. The Medical Monitor or 
equivalent should be consulted prior to unblinding, when ever possible.  
The Clinical Project Manager (CPM) will be informed immediately via the IRT when a code is 
broken, but will remain blinded to specific treatment information. Any unblinding of the IMP 
performed by the Investigator must be recorded in the sou rce documents and on the Study 
Termination eCRF page.  
7.10 Randomization and numbering of subjects  
An IRT will be used for assigning eligible subjects to a treatment regimen based on a 
predetermined production randomization and/or packaging schedule provided by  UCB (or 
designee). The randomization schedule will be produced by the IRT vendor. The IRT will 
generate individual assignments for subject kits of IMP, as appropriate, according to the visit 
schedule. Subject treatment assignment will be stratified by reg ion (North America, Western 
Europe, Central/Eastern Europe, and Asia/Australia) and prior biologic exposure (yes/no).  
At Screening, each subject will be assigned a 5 -digit number that serves as the subject identifier 
throughout the study. The subject numbe r will be required in all communication between the 
Investigator or designee and the IRT regarding a particular subject.  
At the Baseline Visit, a subject will be randomized into the study. The Investigator or designee 
will use the IRT for randomization. Th e IRT will automatically inform the Investigator or 
designee of the subject’s identification number. The IRT will allocate kit numbers to the subject 
based on the subject number during the course of the study. The kits are blinded.  
Subject numbers and kit numbers will be tracked via the IRT.  
8 STUDY PROCEDURES BY VISIT  
Table  5‒1 (Schedule of study assessments) provides a general overview of study assessment s. A 
list of procedures to be completed at each visit is described below.  
 From the Week 1 visit to the Week 24 visit, visit windows of ±3 days on either side of the 
scheduled dosing are permitted; however, the Investigator should try to keep the subjects o n 
the original dosing schedule. From the Week 28 visit to the Week 52 visit, visit windows are 
±7 days. Changes to the dosing schedule outside of the visit window must be discussed with 
the Medical Monitor.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 49 of 206  The dosing window is ±3 days relative to the sche duled dosing visit through Week 24. The 
dosing window is ±7 days relative to the scheduled dosing visit from Week 28 through the 
end of the study.  
 For the SFU Visit (20 weeks after the last dose), the visit window is ±7  days  relative to the 
scheduled visi t date.  
8.1 Screening Visit (2 to 5 Weeks)  
Prior to any study specific activities, subjects will be asked to read, sign, and date an ICF that has 
been approved by the Sponsor and an Institutional Review Board (IRB)/Independent Ethics 
Committee (IEC), and that complies with regulatory requirements. Subjects will be given 
adequate time to consider any information concerning the study given to them by the Investigator 
or designee. As part of the informed consent procedure, subjects will be given the opportunity to  
ask the Investigator any questions regarding potential risks and benefits of participation in the 
study.  
Where local regulations permit, subjects will also be given the option to participate in the 
genomics, genetics, and proteomics substudy. Subjects agr eeing to participate in the substudy 
will be required to complete a separate ICF. The ICF must be signed prior to collecting any 
samples for the substudy. The substudy will only be conducted where ethically accepted and 
authorized by the regulatory agencie s. Refusal to participate in the substudy will not affect a 
subject’s ability to participate in the main PS0009 study.  
The following procedures/assessments will be performed at the Screening Visit:  
 Informed consent  
 Inclusion/exclusion  
 Urine drug screen  
 Demographic data (age, gender, race and ethnicity [ according to local regulations ]) 
 Psoriasis history including the date of onset and past treatments  
 Significant past medical history including clinically relevant past or coexisting medical 
conditions and s urgeries  
 Physical exam including evaluation of signs and symptoms of active TB and risk for 
exposure to TB  
 Vital signs (sitting systolic and diastolic blood pressure [BP), pulse rate, and body 
temperature) should be obtained prior to blood sampling  
 Collection of blood and urine samples for the following clinical laboratory tests:  
 Hematology and biochemistry  
 Urinalysis  
 Serum pregnancy test  
 Hepatitis B and Hepatitis C  
 HIV 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 50 of 206  IGRA Tuberculosis test  
 Record 12 -lead ECG  
 Chest x -ray (not necessary if performed  within 3 months prior to Screening Visit and report 
is available)  
 Tuberculosis questionnaire  
 PASI  
 IGA 
 Percentage of BSA  
 PHQ -9 
 eC-SSRS  
 Patient Symptom Diary (daily)  
 Concomitant medication  
 AEs 
 Confirm subject eligibility and contact IRT  
8.2 Initial Treatment Pe riod 
8.2.1  Baseline Visit  
The following procedures/assessments will be performed/recorded prior to administration of 
IMP:  
 Inclusion/exclusion  
 Significant past medical history and concomitant diseases to ensure no significant changes 
since screening  
 Physical exam  including evaluation of signs and symptoms of active TB and risk for 
exposure to TB  
 Height  
 Body weight  
 Vital signs (sitting systolic and diastolic BP, pulse rate, and body temperature) should be 
obtained prior to blood sampling  
 Collection of blood and urine samples for the following clinical laboratory tests should be 
obtained prior to dosing:  
 Hematology and biochemistry  
 Urinalysis  
 Urine pregnancy test  
 Bimekizumab plasma concentrations  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 51 of 206  Anti-bimekizumab antibodies  
 Genomic, proteomic, metabolomics, and candidate biomarker  analyses (participating 
subjects only)  
 Genetic/epigenetic analysis (participating subjects only)  
 Tuberculosis questionnaire  
 PASI  
 IGA 
 Percentage of BSA  
 DLQI  
 PHQ -9 
 eC-SSRS  
 Patient Symptom Diary (daily)  
 scalp IGA  
 mNAPSI  
 pp-IGA 
 EQ-5D-3L 
 SF-36 
 PASE  
 PGADA  
 HAQ -DI 
 WPAI -SHP V2.0  
 Photographs of skin and nails (participating centers only)  
 Concomitant medication  
 AEs 
 Contact IRT  
After completion of the above -mentioned procedures, bimekizumab, ustekinumab, or placebo 
administration will occur.  
8.2.2  Week  1 Visit ( ±3 days relative to Baseline)  
The following procedures/assessments will be performed/recorded:  
 Vital signs (sitting systolic and diastolic BP, pulse rate, and body temperature) should be 
obtained prior to blood sampling  
 Collection of blood and urine  samples for the following clinical laboratory tests should be 
obtained prior to dosing:  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 52 of 206  Hematology and biochemistry  
 Bimekizumab plasma concentrations  
 Genomic, proteomic, metabolomics, and candidate biomarker  analyses  
 PASI  
 IGA 
 Percentage of BSA  
 DLQI  
 eC-SSRS 
 Patient Symptom Diary (daily)  
 scalp IGA for subjects with scalp involvement at Baseline  
 Photographs of skin and nails (participating centers only)  
 Concomitant medication  
 AEs 
 Contact IRT  
8.2.3  Week  2 Visit ( ±3 days relative to Baseline)  
The following procedures/assessments will be performed/recorded:  
 Vital signs (sitting systolic and diastolic BP, pulse rate, and body temperature) should be 
obtained prior to blood sampling  
 Collection of blood and urine samples for the following clinical laboratory test s should be 
obtained prior to dosing:  
 Hematology and biochemistry  
 Bimekizumab plasma concentrations  
 PASI  
 IGA 
 Percentage of BSA  
 DLQI  
 eC-SSRS  
 Patient Symptom Diary (daily)  
 scalp IGA for subjects with scalp involvement at Baseline  
 Photographs of skin and nails (participating centers only)  
 Concomitant medication  
 AEs 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 53 of 206  Contact IRT  
8.2.4  Week  4 Visit ( ±3 days relative to Baseline)  
The following procedures/assessments will be performed/recorded prior to administration of 
IMP:  
 Vital signs (sitting systolic and diastoli c BP, pulse rate, and body temperature) should be 
obtained prior to blood sampling  
 Collection of blood and urine samples for the following clinical laboratory tests should be 
obtained prior to dosing:  
 Hematology and biochemistry  
 Urine pregnancy test  
 Bimeki zumab plasma concentrations  
 Anti-bimekizumab antibodies  
 PASI  
 IGA 
 Percentage of BSA  
 DLQI  
 PHQ -9 
 eC-SSRS  
 Patient Symptom Diary (daily)  
 scalp IGA for subjects with scalp involvement at Baseline  
 mNAPSI for subjects with nail involvement at Baseline  
 pp-IGA for s ubjects with palmoplantar involvement at Baseline  
 EQ-5D-3L 
 SF-36 
 PGADA (only for subjects with PsA)  
 HAQ -DI (only for subjects with PsA)  
 Photographs of skin and nails (participating centers only)  
 Concomitant medication  
 AEs 
 Contact IRT  
After completion of the above -mentioned procedures, administration of bimekizumab, 
ustekinumab, or placebo will occur.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 54 of 206 8.2.5  Week  8 Visit ( ±3 days relative to Baseline)  
The following procedures/assessments will be performed/recorded prior to administration of 
IMP:  
 Vital signs (sitt ing systolic and diastolic BP, pulse rate, and body temperature) should be 
obtained prior to blood sampling  
 Collection of blood and urine samples for the following clinical laboratory tests should be 
obtained prior to dosing:  
 Hematology and biochemistry  
 Urine pregnancy test  
 Bimekizumab plasma concentrations  
 Anti-bimekizumab antibodies  
 Genomic, proteomic, metabolomics, and candidate biomarker  analyses  
 PASI  
 IGA 
 Percentage of BSA  
 DLQI  
 PHQ -9 
 eC-SSRS  
 Patient Symptom Diary (daily)  
 scalp IGA for subjects with scal p involvement at Baseline  
 mNAPSI for subjects with nail involvement at Baseline  
 pp-IGA for subjects with palmoplantar involvement at Baseline  
 EQ-5D-3L 
 SF-36 
 HAQ -DI (only for subjects with PsA)  
 Photographs of skin and nails (participating centers only)  
 Concomitant medication  
 AEs 
 Contact IRT  
After completion of the above -mentioned procedures, administration of bimekizumab or placebo 
will occur.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 55 of 206 8.2.6  Week  12 Visit ( ±3 days relative to Baseline)  
The following procedures/assessments will be performed/recorded pri or to administration of 
IMP:  
 Physical exam including evaluation of signs and symptoms of active TB and risk for 
exposure to TB  
 Body weight  
 Vital signs (sitting systolic and diastolic BP, pulse rate, and body temperature) should be 
obtained prior to blood s ampling  
 Collection of blood and urine samples for the following clinical laboratory tests should be 
obtained prior to dosing:  
 Hematology and biochemistry  
 Urine pregnancy test  
 Bimekizumab plasma concentrations  
 Anti-bimekizumab antibodies  
 Genomic, proteomic, metabolomics, and candidate biomarker  analyses (participating 
subjects only)  
 Record 12 -lead ECG  
 Tuberculosis questionnaire  
 PASI  
 IGA 
 Percentage of BSA  
 DLQI  
 PHQ -9 
 eC-SSRS  
 Patient Symptom Diary (daily)  
 scalp IGA for subjects with scalp inv olvement at Baseline  
 mNAPSI for subjects with nail involvement at Baseline  
 pp-IGA for subjects with palmoplantar involvement at Baseline  
 EQ-5D-3L 
 SF-36 
 PGADA (only for subjects with PsA)  
 HAQ -DI (only for subjects with PsA)  
 Photographs of skin and nails (participating centers only)  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 56 of 206  Concomitant medication  
 AEs 
 Contact IRT  
After completion of the above -mentioned procedures, administration of bimekizumab or placebo 
will occur.  
8.2.7  Week  16 Visit ( ±3 days relative to Baseline)  
The following procedures/assessments w ill be performed/recorded prior to administration of 
IMP:  
 Vital signs (sitting systolic and diastolic BP, pulse rate, and body temperature) should be 
obtained prior to blood sampling  
 Collection of blood and urine samples for the following clinical laborato ry tests should be 
obtained prior to dosing:  
 Hematology and biochemistry  
 Urinalysis  
 Urine pregnancy test  
 Bimekizumab plasma concentrations  
 Anti-bimekizumab antibodies  
 Genomic, proteomic, metabolomics, and candidate biomarker  analyses (participating 
subject s only)  
 PASI  
 IGA 
 Percentage of BSA  
 DLQI  
 PHQ -9 
 eC-SSRS  
 Patient Symptom Diary (daily)  
 scalp IGA for subjects with scalp involvement at Baseline  
 mNAPSI for subjects with nail involvement at Baseline  
 pp-IGA for subjects with palmoplantar involvement at Baseline  
 EQ-5D-3L 
 SF-36 
 PGADA (only for subjects with PsA)  
 HAQ -DI (only for subjects with PsA)  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 57 of 206  WPAI -SHP V2.0  
 Photographs of skin and nails (participating centers only)  
 Concomitant medication  
 AEs 
 Contact IRT  
After completion of the above -mentioned procedure s, the Maintenance Treatment Period will 
begin with administration of bimekizumab, ustekinumab, or placebo.  
8.3 Maintenance Treatment Period  
8.3.1  Week  20 Visit ( ±3 days relative to Baseline)  
The following procedures/assessments will be performed/recorded prior to a dministration of 
IMP:  
 Vital signs (sitting systolic and diastolic BP, pulse rate, and body temperature) should be 
obtained prior to blood sampling  
 Collection of blood and urine samples for the following clinical laboratory tests should be 
obtained prior to  dosing:  
 Hematology and biochemistry  
 Urine pregnancy test  
 PASI  
 IGA 
 Percentage of BSA  
 PHQ -9 
 eC-SSRS  
 Concomitant medication  
 AEs 
 Contact IRT  
After completion of the above -mentioned procedures, administration of bimekizumab or placebo 
will occur.  
8.3.2  Week  24 Visit  (±3 days relative to Baseline)  
The following procedures/assessments will be performed/recorded prior to administration of 
IMP:  
 Physical exam including evaluation of signs and symptoms of active TB and risk for 
exposure to TB  
 Body weight  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 58 of 206  Vital signs (sitti ng systolic and diastolic BP, pulse rate, and body temperature) should be 
obtained prior to blood sampling  
 Collection of blood and urine samples for the following clinical laboratory tests should be 
obtained prior to dosing:  
 Hematology and biochemistry  
 Urinalysis  
 Urine pregnancy test  
 Tuberculosis questionnaire  
 PASI  
 IGA 
 Percentage of BSA  
 PHQ -9 
 eC-SSRS  
 WPAI -SHP V2.0  
 Concomitant medication  
 AEs 
 Contact IRT  
After completion of the above -mentioned procedures, administration of bimekizumab or placebo 
will occu r. 
8.3.3  Week  28 Visit ( ±7 days relative to Baseline)  
The following procedures/assessments will be performed/recorded prior to administration of 
IMP:  
 Vital signs (sitting systolic and diastolic BP, pulse rate, and body temperature) should be 
obtained prior to bl ood sampling  
 Collection of blood and urine samples for the following clinical laboratory tests should be 
obtained prior to dosing:  
 Urine pregnancy test  
 Bimekizumab plasma concentrations  
 Anti-bimekizumab antibodies  
 PASI  
 IGA 
 Percentage of BSA  
 DLQI  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 59 of 206  PHQ -9 
 eC-SSRS  
 scalp IGA for subjects with scalp involvement at Baseline  
 mNAPSI for subjects with nail involvement at Baseline  
 pp-IGA for subjects with palmoplantar involvement at Baseline  
 EQ-5D-3L 
 SF-36 
 Patient Global Assessment of PSO  
 PGADA (only for subjects w ith PsA)  
 HAQ -DI (only for subjects with PsA)  
 Photographs of skin and nails (participating centers only)  
 Concomitant medication  
 AEs 
 Contact IRT  
After completion of the above -mentioned procedures, administration of bimekizumab, 
ustekinumab, or placebo will o ccur.  
8.3.4  Week  32 Visit ( ±7 days relative to Baseline)  
The following procedures/assessments will be performed/recorded prior to administration of 
IMP:  
 Vital signs (sitting systolic and diastolic BP, pulse rate, and body temperature) should be 
obtained prior to  blood sampling  
 Collection of blood and urine samples for the following clinical laboratory tests should be 
obtained prior to dosing:  
 Hematology and biochemistry  
 Urinalysis  
 Urine pregnancy test  
 Record 12 -lead ECG  
 PASI  
 IGA 
 Percentage of BSA  
 PHQ -9 
 eC-SSRS  
 Concomitant medication  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 60 of 206  AEs 
 Contact IRT  
After completion of the above -mentioned procedures, administration of bimekizumab or placebo 
will occur.  
8.3.5  Week  36 Visit ( ±7 days relative to Baseline)  
The following procedures/assessments will be performed/recorded pri or to administration of 
IMP:  
 Physical exam including evaluation of signs and symptoms of active TB and risk for 
exposure to TB  
 Body weight  
 Vital signs (sitting systolic and diastolic BP, pulse rate, and body temperature) should be 
obtained prior to blood s ampling  
 Collection of blood and urine samples for the following clinical laboratory tests should be 
obtained prior to dosing:  
 Urine pregnancy test  
 Tuberculosis questionnaire  
 PASI  
 IGA 
 Percentage of BSA  
 PHQ -9 
 eC-SSRS  
 Concomitant medication  
 AEs 
 Contact IRT  
After completion of the above -mentioned procedures, administration of bimekizumab or placebo 
will occur.  
8.3.6  Week  40 Visit ( ±7 days relative to Baseline)  
The following procedures/assessments will be performed/recorded prior to administration of 
IMP:  
 Vital signs (sitting systolic and diastolic BP, pulse rate, and body temperature) should be 
obtained prior to blood sampling  
 Collection of blood and urine samples for the following clinical laboratory tests should be 
obtained prior to dosing:  
 Hematology and biochemistry  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 61 of 206  Urinalysis  
 Urine pregnancy test  
 Bimekizumab plasma concentrations  
 Anti-bimekizumab antibodies  
 PASI  
 IGA 
 Percentage of BSA  
 DLQI  
 PHQ -9 
 eC-SSRS  
 scalp IGA for subjects with scalp involvement at Baseline  
 mNAPSI for subjects with nail involvement at Baseline  
 pp-IGA for subjects with palmoplantar involvement at Baseline  
 EQ-5D-3L 
 SF-36 
 Patient Global Assessment of psoriasis  
 PGADA (only for subjects with PsA)  
 HAQ -DI (only for subjects with PsA)  
 WPAI -SHP V2.0  
 Photographs of skin and nails (participating c enters only)  
 Concomitant medication  
 AEs 
 Contact IRT  
After completion of the above -mentioned procedures, administration of bimekizumab, 
ustekinumab, or placebo will occur.  
8.3.7  Week  44 Visit ( ±7 days relative to Baseline)  
The following procedures/assessments wil l be performed/recorded prior to administration of 
IMP:  
 Vital signs (sitting systolic and diastolic BP, pulse rate, and body temperature) should be 
obtained prior to blood sampling  
 Collection of blood and urine samples for the following clinical laboratory  tests should be 
obtained prior to dosing:  
 Urine pregnancy test  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 62 of 206  PASI  
 IGA 
 Percentage of BSA  
 PHQ -9 
 eC-SSRS  
 Concomitant medication  
 AEs 
 Contact IRT  
After completion of the above -mentioned procedures, administration of bimekizumab or placebo 
will occur.  
8.3.8  Week  48 Visit ( ±7 days relative to Baseline)  
The following procedures/assessments will be performed/recorded:  
 Informed consent (to be completed for the open -label study, if applicable)  
 Vital signs (sitting systolic and diastolic BP, pulse rate, and body temperatu re) should be 
obtained prior to blood sampling  
 Collection of blood and urine samples for the following clinical laboratory tests should be 
obtained prior to dosing:  
 Hematology and biochemistry  
 Urinalysis  
 Urine pregnancy test  
 IGRA Tuberculosis test  
 PASI  
 IGA 
 Percentage of BSA  
 PHQ -9 
 eC-SSRS  
 Concomitant medication  
 AEs 
 Contact IRT  
After completion of the above -mentioned procedures, administration of bimekizumab or placebo 
will occur.  
8.3.9  Week  52 Visit ( ±7 days relative to Baseline)  
The following procedures/assessments will be performed/recorded:  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 63 of 206  Urine drug screen  
 Physical exam including evaluation of signs and symptoms of active TB and risk for 
exposure to TB  
 Body weight  
 Vital signs (sitting systolic and diastolic BP, pulse rate, and body temperat ure) should be 
obtained prior to blood sampling  
 Collection of blood and urine samples for the following clinical laboratory tests should be 
obtained prior to dosing:  
 Hematology and biochemistry  
 Urinalysis  
 Urine pregnancy test  
 Bimekizumab plasma concentrati ons 
 Anti-bimekizumab antibodies  
 Genomic, proteomic, metabolomics, and candidate biomarker  analyses (participating 
subjects only)  
 Genetic/epigenetic analysis (participating subjects only)  
 Record 12 -lead ECG  
 TB questionnaire  
 PASI  
 IGA 
 Percentage of BSA  
 DLQI  
 PHQ-9 
 eC-SSRS  
 scalp IGA for subjects with scalp involvement at Baseline  
 mNAPSI for subjects with nail involvement at Baseline  
 pp-IGA for subjects with palmoplantar involvement at Baseline  
 EQ-5D-3L 
 SF-36 
 Patient Global Assessment of PSO  
 PASE  
 PGADA (only for subjects with PsA)  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 64 of 206  HAQ -DI (only for subjects with PsA)  
 WPAI -SHP V2.0  
 Photographs of skin and nails (participating centers only)  
 Concomitant medication  
 AEs 
 Contact IRT  
8.4 Premature End of Treatment Visit  
If a subject is withdrawn from the study:  
 The subject wi ll be withdrawn from IMP, will undergo the same assessments as the 
Week  52 visit ( see Section  8.3.9 ), and will enter the SFU Period.  
 The subject  will be encouraged to return for the SFU Visit (20 weeks after the last 
received dose; see Section  8.5). 
8.5 Safety Follow -Up Visit (20 weeks after last dos e, ±7 days)  
All subjects not continuing in the open -label study, including those withdrawn from IMP, will 
have a SFU Visit 20 weeks after their final dose of IMP.  
The following procedures/assessments will be performed/recorded:  
 Physical exam including evaluation of signs and symptoms of active TB and risk for 
exposure to TB  
 Vital signs (sitting systolic and diastolic BP, pulse rate, and body temperature) should be 
obtained prior to blood sampling  
 Collection of blood and urine samples for the following c linical laboratory tests should be 
obtained prior to dosing:  
 Hematology and biochemistry  
 Urinalysis  
 Urine pregnancy test  
 Bimekizumab plasma concentrations  
 Anti-bimekizumab antibodies  
 Tuberculosis questionnaire  
 PASI  
 IGA 
 Percentage of BSA  
 eC-SSRS  
 Concomitant  medication  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 65 of 206  AEs 
 Contact IRT  
8.6 Unscheduled Visit  
At the Investigator’s discretion, an Unscheduled Visit may be completed at any time during the 
study but prior to the SFU Visit, if deemed necessary for the subject’s safety and well -being.  
If an Unscheduled Vi sit is conducted due to safety or efficacy reasons, an eC -SSRS assessment 
will be performed with the subject during the visit. If an Unscheduled Visit is conducted for 
reasons other than safety or efficacy concerns (eg, repeated collection of a laboratory specimen 
due to collection or analysis issues), an eC -SSRS will not be required at these visits.  
At this visit, any assessment may be performed, as needed, depending on the reason for the visit.  
9 ASSESSMENT OF EFFICA CY 
The PASI, BSA, IGA, scalp IGA, mNAPSI,  and pp -IGA should be performed by the 
Investigator, another delegated physician, or an appropriately qualified medical professional 
(based on local requirements) who has had documented training on how to perform these 
assessments correctly. The same asses sor should evaluate the subject at each assessment.  
9.1 Psoriasis Area and Severity Index  
The PASI is the most commonly used and validated assessment for grading the severity of PSO 
in clinical studies (Feldman, 2004). The PASI quantifies the severity and exte nt of the disease 
and weighs these with the percentage of BSA involvement.  
The percent area of involvement (BSA%) is estimated across 4 body areas; head, upper 
extremities, trunk, and lower extremities. Assessors will enter the degree of involvement for a  
given region on a scale of 0 to 6 (0=none; 1=1% to <10% affected, 2=10% to <30% affected, 
3=30% to <50% affected, 4=50% to <70% affected, 5=70% to <90% affected, 6=90% to 100% 
affected) ( Table  9‒1). 
The Investigator assesses the average redness, thickness, and scaliness of lesions in each body 
area (each on a 5 -point scale); 0=none, 1=slight, 2=moderate, 3=marked, and 4=very marked.  
The PASI score ranges from 0 to 72 with a higher score indicating increased disease severity.  
Table  9‒1: Body areas for calculation of percent BSA for PASI  
Body area  Details of area  BSA  Degree of 
involvement of 
body areaa 
Head  Face, back of head  10% 0 to 6  
Upper extremities  Left, right, upper lower, flexor 
surface, extensor surface  20% 0 to 6  
Trunk  Front, back, groin  30% 0 to 6  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 66 of 206 Lower extremities  Left, right, upper lower, flexor 
surface, extensor surface, including 
buttocks  40% 0 to 6  
Total   100%   
BSA=body surface area; PASI=Psoriasis Area and Severity Index  
a Where 0=none;  1=1% to <10% affected; 2=10% to <30% affected; 3=30% to <50% affected; 4=50% to <70% 
affected; 5=70% to <90% affected; 6=90% to 100% affected  
The PASI50, PASI75, PASI90, and PASI100 responses are based on at least 50%, 75%, 90%, 
and 100% improvement in th e PASI score, respectively.  
The total BSA affected by PSO will be entered as a percentage from 0 to 100.  
The PASI will be completed at the visits specified in Table  5‒1. 
9.2 Investigator’s Global Assessment  
A static IGA for PSO will be used to assess disease severity in all subjects during the study. The 
IGA will be completed at the visits specified in Table  5‒1. 
The Investigator will assess the overall severity of PSO using the following 5 -point scale 
presented in Table  9‒2. 
Table  9‒2: Five-point IGA  
Score  Short Descriptor  Detailed Descriptor  
0 Clear  No signs of PSO; post -inflammatory hyperpigmentation may be 
present  
1 Almost clear  No thickening; normal to pink coloration; no to minimal focal scaling  
2 Mild  Just detectable to mild thickening; pink to light red coloration; 
predominately fine scaling  
3 Moderate  Clearly distinguishable to moderate thickening; dull to bri ght red; 
moderate scaling  
4 Severe  Severe thickening with hard edges; bright to deep dark red coloration; 
severe/coarse scaling covering almost all or all lesions  
IGA=Investigator’s Global Assessment; PSO=psoriasis  
9.3 Dermatology Life Quality Index  
The DLQI  is a questionnaire designed for use in adult subjects with PSO. The DLQI is a skin 
disease -specific questionnaire aimed at the evaluation of how symptoms and treatment affect 
subjects’ health related QOL. This instrument asks subjects about symptoms and f eelings, daily 
activities, leisure, work and school, personal relationships and treatment. It has been shown to be 
valid and reproducible in subjects with PSO. The DLQI score ranges from 0 to 30 with higher 
scores indicating lower health related QOL. A 4 -point change in the DLQI score (DLQI 
response) has been reported to be meaningful for the subject (within -subject minimal important 
difference); while a DLQI absolute score of 0 or 1 indicates no or small impact of the disease on 
health related QOL. Subject s will be asked to complete the DLQI as outlined in the Schedule of 
Study Assessments ( Table  5‒1). 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 67 of 206 9.4 Patient Health Questionnaire 9  
The PHQ -9 is a multipurpose instrument for screening, diagnosing, monitoring, and measuring 
the severity of depression (Kroenke et al, 2001). The PHQ -9 scores for depression range from 0 
to 27, with higher scores indicating worse state. A score of 5 -9 is considered to be  minimal 
symptoms of depression. A score of 10 to 14 is considered minor depression, dysthymia, or mild 
major depression. A score of 15 to 19 is considered to indicate moderately severe major 
depression, and a score ≥20 is considered to be severe major dep ression.  
The PHQ -9 will be assessed at the visits specified in Table  5‒1. 
Refer to Section  6.3 for PHQ -9-related withdrawal criteria.  
9.5 Scalp IGA  
A static IGA for scalp PSO will be used to assess disease severity on the scalp.  
All subjects will complete the scalp IGA at Baseline. Only subjects with scalp involvement at 
Baseline will complete the scalp IGA at the other visits specified in Table  5‒1. Subjects with 
scalp involvement at Baseline are defined as those with a scalp IGA score >0 at Baseline.  
Scalp lesions will be assessed in terms of clinical signs of redness, thickness, and scaliness using 
a 5-point scale ( Table  9‒3). 
Table  9‒3: Scalp IGA  
Score  Short Descriptor  Detailed Descriptor  
0 Clear  Scalp has no signs of PSO; post -inflammatory hyperpigmentation may be 
present  
1 Almost clear  Scalp has no thickening; normal to pink coloration; no to minimal focal scaling  
2 Mild  Scalp has just detectable to mild thickening; pink to light red coloration; 
predominately fine scaling  
3 Moderate  Scalp has clearly distinguish able to moderate thickening; dull to bright red, 
moderate scaling  
4 Severe  Scalp has severe thickening with hard edges; bright to deep dark red 
coloration; severe/coarse scaling covering almost all or all lesions  
PSO=psoriasis; scalp IGA=scalp -specific Investigator’s Global Assessment  
9.6 mNAPSI  
Nail PSO will be evaluated using the mNAPSI. All affected nails will be scored (0  to 3) for 
onycholysis/oil drop dyschromia, nail plate crumbling, and pitting and will be scored (0 for “no” 
or 1 for “yes”) for leukonychia, nail bed hyperkeratosis, splinter hemorrhages and red spots in 
the lunula. The score for an individual nail ranges from 0 to 13 with higher scores indicative of 
more severe nail PSO. The total mNAPSI score is the sum of the scores for each ind ividual nail. 
If a nail is unaffected, it will be recorded as such and will not contribute to the total mNAPSI 
score. Subjects with nail PSO at Baseline are defined as those with a mNAPSI score >0 at 
Baseline.  
The mNAPSI will be assessed at the visits spec ified in Table  5‒1. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 68 of 206 9.7 pp-IGA 
A static IGA for palmoplantar PSO will be used to assess palmoplantar disease severity.  
All subjects will complete the pp -IGA at Baseline. Only subjects with palmoplantar involvement 
at Baseline will complete the pp -IGA at the other visits specified in Table  5‒1. Subjects with 
palmoplantar involvement at Baseline are defined as those with a pp -IGA score >0 at Baseline.  
Palmoplantar disease will be assessed in terms of clinical signs of redness, thick ness, and 
scaliness using a 5 -point scale ( Table  9‒4). 
Table  9‒4: pp-IGA 
Score  Short Descriptor  Detailed Descriptor  
0 Clear  Palmoplantar areas have no signs of PSO; post -inflammatory 
hyperpigmentation may be present  
1 Almost clear  Palmoplantar areas have no thickening; normal to pink coloration; no to 
minimal focal scaling  
2 Mild  Palmoplantar areas have just detectable to mild thickening; pink to light red 
coloration; predominately fine scaling  
3 Moderate  Palmoplantar areas have clearly distinguishable to moderate thickening; dull to 
bright red and clearly distingu ishable coloration; moderate scaling  
4 Severe  Palmoplantar areas have severe thickening with hard edges; bright to deep dark 
red coloration; severe/coarse scaling covering almost all or all lesions; 
numerous fissures  
PSO=psoriasis; pp-IGA=palmoplantar -specific Investigator’s Global Assessment  
9.8 Euro Quality of Life 5 -Dimensions, 3 -Level  
The Euro Quality of life 5 -Dimensions 3 -Level (EQ -5D-3L) health questionnaire provides a 
descriptive profile and a single index value for health statu s. The instrument is comprised of a 
5-item health status measure and a VAS. The EQ -5D-3L VAS records the respondent’s self -rated 
health status on a vertical 20cm scale, graduated from 0 to 100 (0=worst imaginable health 
status, 100=best imaginable health s tatus).  
The EQ -5D-3L will be assessed at the visits specified in Table  5‒1. 
9.9 36-Item Short Form Health Survey  
The SF -36 (Version 2, standard recall) is a  36-item generic health related QOL instrument that 
uses a recall period of 4 weeks. Items are grouped into 8 domains as follows: Physical 
Functioning (10 items), Role Physical (4 items), Bodily Pain (2 items), General Health (5 items), 
Vitality (4 items),  Social Functioning (2 items), Role Emotional (3 items), Mental Health (5 
items), and 1 item for perceived stability or change in health (Health Transition) during the last 
year. The concepts represented by these domains contribute to physical, mental, and  social 
aspects of health -related QOL. In addition to domain scores, the PCS and MCS scores are 
calculated from the 8 domains (excluding the Health Transition item). Component scores 
appreciate the impact of each domain on physical and mental health status  (Maruish, 2011). Each 
of the 8 domain scores and the component summary scores range from 0 to 100, with a higher 
score indicating a better health status. The domains and the 2 component summary scores are 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 69 of 206 standardized with a mean of 50 and a standard devi ation (SD) of 10 in the general USA 
population. The minimally important differences (MIDs), in terms of T -score points at a group 
level, for SF -36 domains and component summaries are the following: PCS, 2; MCS, 3; Physical 
Functioning, 3; Role Physical, 3;  Bodily Pain, 3; General Health, 2; Vitality, 2; Social 
Functioning, 3; Role Emotional, 4; and Mental Health, 3.  
The SF -36 will be completed by the subject at the visits specified in Table  5‒1. 
9.10 Patient Global Assessment of psoriasis  
The Patient Global Assessment of PSO is a PSO -specific item in which the patient responds to 
the multiple -choice question, “How severe are your psoriasis -related symptoms righ t now?” 
Possible responses to the question are “no symptoms,” “mild symptoms,” “moderate symptoms”, 
“severe symptoms,” or “very severe symptoms.”  
The Patient Global Assessment of PSO will be performed as part of the patient symptoms diary 
from Screening th rough the Initial Treatment Period.  
During the Maintenance Treatment Period, this assessment will be completed at the visits 
specified in Table  5‒1. 
9.11 Patient Symptom Diary responses  
UCB developed a new patient -reported outcome (PRO) measure that will be used to assess key 
symptoms relevant to patients with moderate to severe chronic plaque PSO. PS0010 used the 
draft PRO measure in selected countries to en able psychometric validation of the PRO. Site staff 
will train the participating subjects on the use of the electronic PRO (ePRO) diary at the 
Screening Visit, following which the device will be dispensed to the subject for home use daily 
until the Week  16 Visit. The ePRO diary will be administered on a daily basis from Screening to 
the Week  16 Visit.  
The ePRO diary will also administer the patient global assessment of PSO as noted above 
appropriate anchor items at the end of every study week. The ePRO diar y software will be 
programmed such that the subjects will be given a window of opportunity to complete the ePRO 
diary. The data collected on the ePRO diary will be uploaded to a central server database and 
will be 21 CFR Part 11 compliant. Appropriate GCP procedures (including subject/site training 
and testing) will be performed at the study sites.  
The Patient Symptom Diary responses for itch, pain, and scaling at Week 16  will be computed 
based on the responder definition as well as the absolute and percent change from Baseline. Each 
of the Patient Symptom Diary response scores included in the statistical testing procedure (itch, 
pain, and scaling) will be characterized in terms of the cumulative percent of subjects 
demonstrating a pre -specified point improvement at Week 16. The threshold for the Patient 
Symptom Diary  response score of itch, pain, and scaling is 2.39, 1.98, and 2.86, respectively. 
The responder analysis will  be limited to the subjects with a Baseline Patient Symptom Diary  
response score at or above the applicable threshold score (i e, at least 2.39, 1.98, and 2.86 for itch, 
pain, and scaling, respectively).  
9.12 PASE questionnaire  
The PASE questionnaire is a self -administered tool to screen for active PsA in patients with PSO 
(Husni et al, 2014). The questionnaire consists of 15 items that are divided into a 7 -item 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 70 of 206 symptoms subscale and an 8 -item functions subscale. Standardized responses are based on 5 
categories r elating to agreement (strongly agree [5], agree [4], no idea [3], disagree [3], and 
strongly disagree [1]). The total maximum score is 75 points (symptom score: 35 points and 
function score: 40 points). Psoriatic Arthritis Screening and Evaluation question naire scores ≥47 
points are indicative of active PsA. Subjects with scores ≥47 should be referred to a 
rheumatologist for evaluation.  
If a subject with a PASE score ≥47 points is referred to a rheumatologist, the referral will be 
recorded in the eCRF. Subj ects with PsA, defined as a past medical history of PsA or PASE ≥47, 
are required to receive the additional PsA assessments (PGADA and HAQ -DI) as noted in 
Section  9.13 and Section  9.14. 
The PASE questionnaire will be completed at the visits specified in Table  5‒1. 
9.13 PGADA for arthritis visual analog scale  
The PGADA for the arthritis VAS will be used to provide an overall evaluation of arthritis 
disease symptoms. Subjects will respond to the question, “Considering all the ways your arthritis 
affects you, please mark a vertical line on the scale below to show how you are feeling today,” 
using a VAS where 0 is “very good, no symptoms” and 100 is “very poor, severe symptoms.”  
All subjects will co mplete the PGADA at Baseline. Subjects with PsA at Baseline (defined as a 
past medical history of PsA or PASE ≥47)  will complete the PGADA at the visits specified in 
Table  5‒1. 
9.14 HAQ -DI score  
The HAQ -DI score contains 20 items divided into 8 domains that measure: dressing and 
grooming, arising, eating, walking, hygiene, reach, grip, and common daily activities. Subjects 
are required to indicate the degree of difficulty they have experienced in each domain in the past 
Week  on a 4 -point scale that ranges from 0 (without difficulty) to 3 (unable to do). Any 
individual score of less than 2 is adjusted to 2 if the activity requires assistance from another 
indivi dual or the use of an assistive device. The highest score in each category is then summed (0 
to 24) and divided by the number of categories scored to give a score that ranges from 0 to 3.  
All subjects will complete the HAQ -DI at Baseline. Subjects with PsA  at Baseline (defined as a 
past medical history of PsA or PASE ≥47) will complete the HAQ -DI at the visits specified in 
Table  5‒1. 
9.15 WPAI -SHP V2.0  
The WP AI-SHP V2.0 is a patient -reported questionnaire that assesses subject’s employment 
status, work absenteeism, work impairment while working (presenteeism), overall work, and 
daily activity impairment attributable to a specific health problem (WPAI:SHP) (Rei lly et al, 
1993). It has been used in several clinical studies of biologic therapy in subjects with plaque PSO 
(Kimball et al, 2012; Vender et al, 2012).  
Five out of 6 items of the WPAI -SHP are regrouped into the 4 dimensions, with scores expressed 
as perc entage, where higher numbers indicate greater impairment and less productivity, ie, worse 
outcomes, as described in the WPAI -SHP scoring rules.  
The WPAI -SHP V2.0 will be assessed at the visits specified in Table  5‒1. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 71 of 206 9.16 Photographs  
At certain clinical sites, representative photographs of the changes in skin and nail appearance 
will be captured. Subjects will have full body (anterior and posterior views) pho tographs taken. 
Only those subjects with nail disease at Baseline will have nail photographs taken. Only those 
subjects with palmoplantar disease at Baseline will have photographs of their palms or soles of 
their feet taken. Only those subjects with scalp disease at Baseline will have scalp photographs 
taken. Photographs will be anonymized.  
Study sites selected for photography will be trained and receive standardized photographic 
equipment by a centralized photographic vendor. Photographs will be electronic ally transferred 
from the site to the vendor.  
At the end of the study, the site will receive an electronic file of all subject photographs for 
archiving.  
The central photography vendor will tabulate and transfer all subject photos to the Sponsor at the 
end of the study.  
10 ASSESSMENT OF PHARMA COKINETIC AND 
PHARMACOGENOMIC VARI ABLE(S)  
10.1 Pharmacokinetic variables  
Blood samples for measurement of PK assessments ( Section  4.3.3 ) will be collected at the time 
points specified in the schedule of study assessments ( Table  5‒1). 
At dosing visits, blood samples will be drawn prior to dosing, and will be drawn at the same time 
of the sampling for clinical laboratory tests. The time and date of collection will be recorded in 
the eCRF.  
Instructions pertaining to sample coll ection, processing, storage, labeling, and shipping are 
provided in the laboratory manual for this study. Detailed information on sample analysis will be 
provided in a bioanalytical report.  
Pharmacokinetic samples from subjects receiving ustekinumab will n ot be analyzed, but stored 
for potential future PK analysis and anti -drug antibody determination.  
10.2 Pharmacogenomic variables  
A separate ICF will be required for those subjects who agree to participate in the genomics, 
genetics, and proteomics substudy, and must be signed prior to collection of any samples for the 
substudy. The substudy will only be conducted where ethically accepted and authorized by the 
regulatory agencies. Refusal to participate in the substudy will not affect a subject’s ability to 
partic ipate in the main study.  
These analyses will enable evaluation of biomarkers relative to disease biology and progression, 
drug treatment, and inflammatory and immune response processes. The nature and format of 
these tentative analyses will be determined a t a later date.  
For individuals consenting to the genomics, genetics, and proteomics substudy, blood samples 
will be drawn for exploratory genetic/epigenetic, genomic, proteomic, metabolomics analysis, 
and for candidate biomarker analyses. Candidate biomarker evaluations may include, but are not 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 72 of 206 limited to, IL -17A/IL -17F pathway signaling and PSO biology (eg, IL -17A, IL -17F, IL -23, IL -6, 
tumor necrosis factor, dendritic cell -specific transmembrane protein, and circulating osteoclast 
precursors).  
Colle ction of these samples will occur at the time points specified in the schedule of study 
assessments ( Table  5‒1). At dosing visits, blood samples will be  drawn prior to dosing, and will 
be drawn at the same time of the sampling for clinical laboratory tests. The time and date of 
collection will be recorded in the eCRF. The samples will be stored at -80°C at the central 
biorepository for up to 20 years.  
Instructions pertaining to sample collection, processing, storage, labeling, and shipping are 
provided in the laboratory manual for this study. Detailed information on sample analysis will be 
provided in a bioanalytical report.  
11 ASSESSMENT OF IMMUNO LOGICAL VAR IABLE(S)  
Blood samples for measurement of antibodies to bimekizumab will be collected at the visits 
specified in Table  5‒1. The threshold for antibody p ositivity will be defined prior to analysis.  
At dosing visits, blood samples will be drawn prior to dosing, and will be drawn at the same time 
of the sampling for clinical laboratory tests. The time and date of collection will be recorded in 
the eCRF.  
Instructions pertaining to sample collection, processing, storage, labeling, and shipping are 
provided in the laboratory manual for this study. The presence of antibodies to bimekizumab will 
be determined using a validated bioanalytical method. Detailed inform ation on sample analysis 
will be provided in a bioanalytical report.  
12 ASSESSMENT OF SAFETY  
12.1 Adverse events  
12.1.1  Definitions  
12.1.1.1  Adverse event  
An AE is any untoward medical occurrence in a patient or clinical investigation subject 
administered a pharmaceutical product  that does not necessarily have a causal relationship with 
this treatment. An AE can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease temporally associated with the use of a 
medicinal (investi gational) product, whether or not related to the medicinal (investigational) 
product.  
In order to ensure complete safety data collection, all AEs occurring during the study (ie,  after 
the signing of the ICF), including any pretreatment and posttreatment pe riods required by the 
protocol, must be reported in the eCRF even if no IMP was taken but specific study procedures 
were conducted. This includes all AEs not present prior to the initial visit and all AEs that 
recurred or worsened after the initial visit.  
Signs or symptoms of the condition/disease for which the IMP is being studied should be 
recorded as AEs only if their nature changes considerably or their frequency or intensity 
increases in a clinically significant manner as compared to the clinical profi le known to the 
Investigator from the subject’s history or the Baseline Period.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 73 of 206 12.1.1.2  Serious adverse event  
Once it is determined that a subject experienced an AE, the seriousness of the AE must be 
determined. An SAE must meet 1 or more of the following criteria : 
 Death  
 Life-threatening  
(Life -threatening does not include a reaction that might have caused death had it occurred in 
a more severe form.)  
 Significant or persistent disability/incapacity  
 Congenital anomaly/birth defect (including that occurring in a fetus ) 
 Important medical event that, based upon appropriate medical judgment, may jeopardize the 
patient or subject and may require medical or surgical intervention to prevent 1 of the other 
outcomes listed in the definition of serious  
(Important medical events  may include, but are not limited to, potential Hy’s Law [see 
Section  12.1.1.1 ], allergic bronchospasm requiring intensive treatment in an emergency  room 
or at home, blood dyscrasias that do not result in inpatient hospitalization, or the 
development of drug dependency or drug abuse.)  
 Initial inpatient hospitalization or prolongation of hospitalization  
(A patient admitted to a hospital, even if he/she  is released on the same day, meets the 
criteria for the initial inpatient hospitalization. An emergency room visit that results in 
admission to the hospital would also qualify for the initial inpatient hospitalization criteria. 
However, emergency room vis its that do not result in admission to the hospital would not 
qualify for this criteria and, instead, should be evaluated for 1 of the other criteria in the 
definition of serious [eg,  life-threatening adverse experience, important medical event].  
Hospitali zations for reasons not associated with the occurrence of an AE [eg,  preplanned 
surgery or elective surgery for a pre -existing condition that has not worsened or manifested 
in an unusual or uncharacteristic manner] do not qualify for reporting. For example , if a 
subject has a condition recorded on his/her medical history and later has a preplanned surgery 
for this condition, it is not appropriate to record the surgery or hospitalization as an SAE, 
since there is no AE upon which to assess the serious criter ia. Please note that, if the 
pre-existing condition has worsened or manifested in an unusual or uncharacteristic manner, 
this would then qualify as an AE and, if necessary, the seriousness of the event would need to 
be determined.)  
Confirmed active TB must  be reported as an SAE. The Investigator is to complete and submit the 
TB Follow -Up Form provided.  
12.1.1.2.1  Anticipated serious adverse events  
The following Anticipated SAEs are anticipated to occur in the population studied in this 
protocol at some frequency that is independent of drug exposure.  
This list does not change the Investigator’s obligation to report all SAEs (including Anticipated 
SAEs) as detailed in Section  12.1.2.3 .
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 74 of 206 Table  12‒1: Anticipated serious adverse events for the population of subjects 
with moderate to severe chronic plaque psoriasis  
MedDRA® system order class  MedDRA preferred term  
Skin and subcutaneous tissue disorders  Any psoriatic condition HLT  
Musculoskeletal and connective tissue disorders  Psoriatic arthropathy  
HLT=high level term; MedDRA=Medical Dictionary for Regulatory Activities; SAE=serious adverse event  
Note: Exception: Listed events will not be regarded as anticipated SAEs if they are life threatening or if they result 
in the death of the study subject.  
12.1.1.1  Adverse events of special interest  
An AE of special interest (AESI) is any AE that a regulatory authority has mandated be reported 
on an expedited basis, regardless of the seriousness, expectedness, or relatedness of the AE to the 
administration of a UCB product/compound.  
Potential Hy’s Law, defined as ≥3xULN ALT or AST with coex isting ≥2xULN total bilirubin in 
the absence of ≥2xULN ALP, with no alternative explanation for the biochemical abnormality, 
must ALWAYS be reported to UCB as an AESI (ie, without waiting for any additional etiologic 
investigations to have been concluded).  Follow -up information should then be reported if an 
alternative etiology is identified during investigation and monitoring of the subject.  
12.1.1.2  Other safety topics of interest  
Pre-specified safety topics of interest for the study are: infections (serious, oppo rtunistic, fungal, 
and TB), neutropenia, hypersensitivity, suicidal ideation and behavior, depression, major 
cardiovascular events, liver function test changes/enzyme elevations, malignancies, and 
inflammatory bowel diseases (with gastroenterology referral , as appropriate).This is based on 
findings from the IMP clinical program to date, potential risks generally associated with biologic 
immunomodulators, or findings from other medicines with a related mechanism of action. There 
are no specific AE reporting requirements for these topics, however special monitoring, 
additional data collection activities, and/or enhanced signal detection activities (within UCB) are 
in place.  
12.1.2  Procedures for reporting and recording adverse events  
The subject will be given the opp ortunity to report AEs spontaneously. A general prompt will 
also be given at each study visit to detect AEs. For example:  
“Did you notice anything unusual about your health (since your last visit)?”  
In addition, the Investigator should review any self -assessment procedures (eg,  diary cards) 
employed in the study.  
12.1.2.1  Description of adverse events  
When recording an AE, the Investigator should use the overall diagnosis or syndrome using 
standard medical terminology, rather than recording individual symptoms or si gns. The eCRF 
and source documents should be consistent. Any discrepancies between the subject’s own words 
on his/her own records (eg,  diary card) and the corresponding medical terminology should be 
clarified in the source documentation.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 75 of 206 When recording the  severity of an AE in the eCRF (ie, mild, moderate, or severe), the 
Investigator may refer to the Common Terminology Criteria for Adverse Events (CTCAE) 
Version 4 (http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm) for 
additional g uidance as needed. Details for completion of the Adverse Event eCRF (including 
judgment of relationship to IMP) are described in the eCRF Completion Guidelines.  
12.1.2.2  Rule for repetition of an adverse event  
An increase in the intensity of an AE should lead to th e repetition of the AE being reported with:  
 The outcome date of the first AE that is not related to the natural course of the disease being 
the same as the start date of the repeated AE, and the outcome of “worsening”  
 The AE verbatim term being the same fo r the first and repeated AE, so that the repeated AE 
can be easily identified as the worsening of the first one  
12.1.2.3  Additional procedures for reporting serious adverse events  
If an SAE is reported, UCB must be informed within 24 hours of receipt of this inform ation by 
the site (see contact information for SAE reporting listed in the Serious Adverse Event Reporting 
section at the front of the protocol). The Investigator must forward to UCB (or its representative) 
a duly completed “Investigator SAE Report Form fo r Development Drug” (SAE report form) 
provided by UCB, even if the data are incomplete, or if it is obvious that more data will be 
needed in order to draw any conclusions. Information recorded on this form will be entered into 
the global safety database.  
An Investigator SAE report form will be provided to the Investigator. The Investigator SAE 
Report form must be completed in English.  
It is important for the Investigator, when completing the SAE report form, to include the 
assessment as to a causal relation ship between the SAE and the IMP administration. This insight 
from the Investigator is very important for UCB to consider in assessing the safety of the IMP 
and in determining whether the SAE requires reporting to the regulatory authorities in an 
expedited  manner.  
Additional information (eg,  autopsy or laboratory reports) received by the Investigator must be 
provided within 24 hours. All documents in the local language must be accompanied by a 
translation in English, or the relevant information included in the same document must be 
summarized in the Investigator SAE report form.  
The Investigator is specifically requested to collect and report to UCB (or its representative) any 
SAEs (even if the Investigator is certain that they are in no way associated with the IMP), up to 
30 days from the end of the study for each subject, and to also inform participating subjects of 
the need to inform the Investigator of any SAE within this period. Serious AEs that the 
Investigator thinks may be associated with the IMP must  be reported to UCB regardless of the 
time between the event and the end of the study.  
Upon receipt of the SAE report form, UCB will perform an assessment of expectedness of the 
reported SAE. The assessment of the expectedness of the SAE is based on the IB . 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 76 of 206 12.1.3  Follow up of adverse events  
An AE should be followed until it has resolved, has a stable sequelae, the Investigator 
determines that it is no longer clinically significant, or the subject is lost to follow up. This 
follow -up requirement applies to AEs, SA Es, and AESIs; further details regarding follow up of 
PDILI events is provided in Section  12.2.1.4 . 
If an AE is ongoing at the end of the study for a subject, follow up should be provided until 
resolution/stable level of sequelae is achieved, or until the Investigator no longer deems that it is 
clinically significant, or until the subject is lost to follow up. If no follow up is provided, the 
Investigator must provide a justification. The follow up will usually be continued for 20 weeks 
after the subject has discontinued his/her IMP.  
Information on SAEs obtained after clinical database lock will be captured through the Patient 
Safety (PS) database without limitation of time.  
12.1.4  Pregnancy  
If an Investigator is notified that a subject has become pregnant after the first intake of any IMP, 
the Investigator must immediately notify UCB’s PS department by providing the completed 
Pregnancy Report and Outcome form (for contact details see Serious Adverse Event reporting 
information at the beginning of this protocol). The subject should be withdraw n from the study 
as soon as pregnancy is known (by positive pregnancy test), and the following should be 
completed:  
 The subject should return for an early discontinuation visit.  
 The subject should immediately stop the intake of the IMP.  
 A SFU Visit should be scheduled 20 weeks after the subject has discontinued her IMP.  
The Investigator must inform the subject of information currently known about potential risks 
and about available treatment alternatives.  
The pregnancy will be documented on the Pregnancy Re port and Outcome form provided to the 
Investigator. The progression of the pregnancy and the eventual birth (if applicable) must be 
followed up using the Pregnancy Report and Outcome form in which the Investigator has to 
report on the health of the mother and of the child. Every reasonable attempt should be made to 
follow the health of the child for 30 days after birth for any significant medical issues. In certain 
circumstances, UCB may request that follow up is continued for a period longer than 30 days. If 
the subject is lost to follow up and/or refuses to give information, written documentation of 
attempts to contact the subject needs to be provided by the Investigator and filed at the site. 
UCB’s PS department is the primary contact for any questions re lated to the data collection for 
the pregnancy, eventual birth, and follow up.  
In cases where the partner of a male subject enrolled in a clinical study becomes pregnant, the 
Investigator or designee is asked to contact the subject to request consent of th e partner via the 
Partner Pregnancy Consent form that has been approved by the responsible IRB/IEC and should 
be available in the Investigator site file. In case of questions about the consent process, the 
Investigator may contact the UCB/contract research  organization (CRO) contract monitor for the 
study. The Investigator will complete the Pregnancy Report and Outcome form and send it to 
UCB’s PS department (for contact details see Serious Adverse Event reporting information at the 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 77 of 206 beginning of this protoc ol) only after the partner has agreed that additional information can be 
captured and has provided the signed Partner Pregnancy Consent form. UCB’s PS department is 
also the primary contact for any questions related to the data collection for the partner p regnancy, 
eventual birth, and follow up.  
A pregnancy becomes a SAE in the following circumstances: miscarriage, elective abortion 
when medically indicated (e.g. when pregnancy is endangering life or health of woman or when 
fetus will be born with severe ab normalities ), unintended pregnancy after hormonal 
contraceptive failure (if the hormonal contraceptive was correctly used), ectopic pregnancy, fetal 
demise, or any congenital anomaly/birth defect of the baby. Those SAEs must be additionally 
reported using the Investigator SAE Report form.  
Should a subject become pregnant while participating in the study, the subject may be offered the 
option to enroll in a separate observational pregnancy follow -up study sponsored by UCB and 
conducted independently from stu dy PS0009. If the study is available locally, the PS0009 PI will 
be provided with the locally approved information about the observational pregnancy follow -up 
study to inform the subject at the time the pregnancy is reported. Participation in this separate  
study will be voluntary and will not impact therapeutic management of the subject nor interfere 
with termination and follow -up procedures as described in study protocol PS0009.  
12.1.5  Suspected transmission of an infectious agent via a medicinal 
product  
For the purposes of reporting, any suspected transmission of an infectious agent via a medicinal 
product should be considered as an SAE; such cases must be reported immediately, recorded in 
the AE module of the eCRF, and followed as any other SAE. Any organism, vi rus, or infectious 
particle (eg, prion protein transmitting transmissible spongiform encephalopathy), pathogenic or 
nonpathogenic, is considered an infectious agent.  
12.1.6  Overdose of investigational medicinal product  
Excessive dosing (beyond that prescribed in the protocol and including overdose) should be 
recorded in the eCRF. Any SAE or nonserious AE associated with excessive dosing must be 
followed as any other SAE or nonserious AE. These events are only considered AEs or SAEs if 
there are associated clinical  signs and symptoms or if the act of taking the excess medicine itself 
is an AE or SAE (eg,  suicide attempt).  
12.1.7  Safety signal detection  
Selected data from this study will be reviewed periodically to detect as early as possible any 
safety concern(s) related t o the IMP so that Investigators, clinical study subjects, regulatory 
authorities, and IRBs/IECs will be informed appropriately and as early as possible.  
In addition, an independent Data Monitoring Committee (DMC) will periodically review and 
monitor safety  data from this study and advise UCB. Details are provided in the DMC Charter.  
Cardiovascular and Neuropsychiatric Adjudication Committees will also periodically review and 
monitor safety data from this study and advise UCB. Details are provided in the Adj udication 
Committee Charters.  
The Study Physician or medically qualified designee/equivalent will conduct an ongoing review 
of SAEs and perform ongoing SAE reconciliations in collaboration with the PS representative.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 78 of 206 As appropriate for the stage of develop ment and accumulated experience with the IMP, 
medically qualified personnel at UCB may identify additional safety measures (eg,  AEs, vital 
signs, laboratory or ECG results) for which data will be periodically reviewed during the course 
of the study.  
12.2 Labora tory measurements  
Clinical laboratory assessments consist of serum chemistry, hematology, urinalysis, and urine 
drug screen. A centralized laboratory will be used to supply all laboratory test supplies and 
analyze all blood and urine samples for hematology , biochemistry, and urinalysis measurements. 
Any unscheduled laboratory testing should also be collected using the central laboratory. Testing 
to rule out hepatitis B, hepatitis C, and HIV (see Exclusion Criterion # 9, Section  6.2) will be 
performed at Screening in addition to those measurements listed in Table  12‒2. 
Specific details regarding the handling and processing of serum chemistry, hematology, and 
urinalysis samples are provided in the study laboratory manuals.  
The following laboratory parameter s will be measured:  
Table  12‒2: Laboratory measurements  
Hematology  Chemistry  Urinalysis dipsticka 
Basophils  Calcium  pH 
Eosinophils  Chloride  Albumin (protein)  
Lymphocytes  Magnesium  Glucose  
Monocytes  Potassium  Blood  
Neutrophils  Sodium  Leukocyte esterase  
Hematocrit  Glucose  Nitrite  
Hemoglobin  BUN  Urine dipstick for pregnancy testingb 
MCH  Creatinine  Urine drug screenc 
MCHC  ALP   
MCV  AST   
Platelet count  ALT   
RBC count  GGT   
WBC count  Total bilirubin   
 Serum pregnancy testingb  
ALP=alkaline phosphatase; ALT=alanine aminotransferase; AST=aspartate aminotransferase; BUN=blood urea 
nitrogen; GGT=gamma glutamyltransferase; MCH=mean corpuscular hemoglobin; MCHC=me an corpuscular 
hemoglobin concentration; MCV=mean corpuscular volume; PEOT=Premature End of Treatment; RBC=red blood 
cell; WBC=white blood cell  
a A urine microscopic examination will be performed if the result for albumin (protein), leukocyte esterase, blood or 
nitrite is abnormal. A urine microscopic examination will include: WBC, RBC, epithelial cells (squamous, 
transitional and renal tubular), hyaline casts, WBC casts, RBC casts, waxy casts, granular casts, calcium oxalate 
crystals, uric acid crystals , triphosphate crystals, yeast, bacteria, amorphous urates, and amorphous phosphates.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 79 of 206 b Pregnancy testing will consist of serum testing at the Screening Visit. The pregnancy test will be urine at all other 
visits.  
c Urine drug screen will be performed at Screening Visit, and Week 52 or PEOT Visit.  
12.2.1  Evaluation of PDILI  
The PDILI IMP discontinuation criteria for this study are provided in Section  6.3.1 , with the 
accompanying required follow -up investigation and monitoring detailed below. All PDILI events 
must be reported as an AE and reported to the study site and sponsor within 24 hours of learning 
of their occurre nce. Any PDILI event that meets the criterion for potential Hy’s Law must be 
reported as an AE of special interest (see Section  12.1.1.1 ), and, if a pplicable, also reported as an 
SAE (see Section  12.1.1.2 ). 
Evaluation of PDILI consists of the diagnostic testing and continued monitoring included in 
Table  12‒3 (specific tests dependent on laboratory results and corresponding symptoms) and 
consultation with a local hepatologist (if applicable; di scussed in Section  12.2.1.1 ). The local 
hepatologist is the expert usually consulted by the treating physician for assessment and 
management of poten tial hepatic disease. This would usually be a hepatologist, but may be a 
gastroenterologist. Additional investigation and monitoring may be required and adapted based 
on the diagnosis after the cause of the liver injury/abnormality is confirmed (details in  
Section  12.2.1.4 ). 
The results of all monitoring, including laboratory testing and other testing, should be made 
available to the study site and sponsor.  
All initial tests resulting in abnormal hepatic laboratory values need to be repeated, but 
appropriate medical action must not be delayed waiting for the repeat result.  
If tests are done locally for more rapid results, a concurrent sample should a lso be sent to the 
central laboratory whenever possible. Medical care decisions are to be made initially using the 
most rapidly available results and a conservative approach must be taken if the results from the 
2 laboratory tests are significantly differe nt. Data from the local and central laboratory are to be 
recorded on the applicable eCRF pages.  
When IMP is discontinued, all concomitant medications and herbal supplements that are not 
medically necessary should also be discontinued. In these cases, the I nvestigator should also 
consider dose reduction for medically necessary concomitant medication and consider changing 
any medically required concomitant medication known to be hepatotoxic to a suitable 
alternative.  
When IMP is stopped due to PDILI (as descr ibed in Section  6.3.1 ), IMP must be permanently 
discontinued unless a subsequent alternative diagnosis fully explains the hepatic findings. If a 
subsequent alternative diagnosis fully explains the hepatic findings, and the requirements 
provided in Section  12.2.1.2.1  are met, rechallenge with IMP m ay be appropriate.  
Table  12‒3 summarizes the approach to investigate PDILI.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 80 of 206 Table  12‒3: Required investigations and follow up for PDILI  
Laboratory value   Immediate  Follow up  
ALT or 
AST  Total 
bilirubin  Symptomsa of 
hepatitis of 
hypersensitivity  Consultation 
requirements  Actions  Testing  Evaluation  
≥3xULN  ≥2xULNb NA Hepatology consultc 
Medical Monitor must 
be notified within 
24 hours (eg,  by 
laboratory alert) and 
subject discussed with 
Medical Monitor 
ASAP.  Immediate, 
permanent IMP 
discontinuation.  
 
 
 Essential: Must have 
repeat liver 
chemistry values 
and additional 
testing completed 
ASAP (see 
Section  12.2.1.3 ); 
recommended to 
occur at the site with 
HCP.  Monitoring of liver 
chemistry values at least 
twice per week until 
values normalize, 
stabilize, or return to 
within baseline values.d ≥3xULN  NA Yes 
≥8xULN  NA NA Need for hepatology 
consult to be 
discussed.(required if 
ALT or  AST 
≥8xULN)  
Medical Monitor must 
be notified within 
24 hours (eg,  by 
laboratory alert) and 
subject discussed with 
Medical Monitor 
ASAP.  Immediate, 
permanent IMP 
discontinuation  
 
 
 
≥5xULN 
(and ≥2x 
baseline) 
and 
<8xULN  <2xULN  No Discussion with 
Medical Monitor 
required.  
Consider need for 
hepatology consult if 
there is no evidence of 
resolution (see Follow Further investigation 
– immediate IMP 
discontinuation not 
required (see 
Section  12.2.1.2 ). 
 
IMP discontinuation Essential: Every 
attempt must be 
made to have repeat 
liver chemistry 
values and 
additional testing 
completed within 
48 hours at the site Monitoring of liver 
chemistry values at least 
twice per week for 2 
weeks.d 
 Immediate IMP 
discontinuation 
required if liver 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 81 of 206 Table  12‒3: Required investigations and follow up for PDILI  
Laboratory value   Immediate  Follow up  
ALT or 
AST  Total 
bilirubin  Symptomsa of 
hepatitis of 
hypersensitivity  Consultation 
requirements  Actions  Testing  Evaluation  
up requirements).c required if any of the 
following occur:  
 Subject cannot 
comply with 
monitoring 
schedule.  
 Liver chemistry 
values continue 
to increase  
 Liver chemistry 
values remain 
≥5xULN  (and 
≥2x baseline) 
after 4 weeks of 
monitoring 
without evidence 
of resolution  with HCP (see 
Section  12.2.1.3 ). chemistry values 
continue to increase. 
After 2 weeks of 
monitoring liver 
chemistry values:  
 ALT or AST remains 
≥5xULN <8xULN, 
IMP should be 
temporarily withheld 
and subject should 
undergo repeat test in 
2 weeks.  
 
Continue IMP if ALT 
or AST values 
<5xULN; continue to 
monitor at least twice 
per week until values 
normalize, stabilize, 
or return to within 
baseline values.  
 
If ALT or AST 
remains ≥5xULN 
after second re -test, 
immediate, 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 82 of 206 Table  12‒3: Required investigations and follow up for PDILI  
Laboratory value   Immediate  Follow up  
ALT or 
AST  Total 
bilirubin  Symptomsa of 
hepatitis of 
hypersensitivity  Consultation 
requirements  Actions  Testing  Evaluation  
permanent IMP 
discontinuation 
required . 
Continue to monitor until 
values normalize, 
stabilize, or return t o 
within baseline values.d 
ALP=alkaline phosphatase; ALT=alanine aminotransferase; ASAP=as soon as possible; AST=aspartate aminotransferase; HCP=healthc are practitioner; 
IMP=investigational medicinal product; NA=not applicable; PDILI=potential drug -induce d liver injury; ULN=upper limit of normal  
a Hepatitis symptoms include fatigue, nausea, vomiting, and right upper quadrant pain or tenderness; hypersensitivity symptoms include eosinophilia (>5%) , 
rash, and fever (without clear alternative cause).  
b If the subject also has ≥2xULN ALP, the possibility of an indication of biliary obstruction should be discussed with the Medi cal Monitor.  
c Details provided in Section  12.2.1.1 . The local hepatologist is the expert usually consulted by the treating physician for assessment and management  of 
potential hepatic disease. This would usually be a hepatologist, but may be a gastroenterologist.  
d Unless an alternative monitoring schedule is agreed by the Investigator and UCB responsible physician. Determination of stabilization is at the discretion of the 
Investigator in consultation with the hepatologist (as applicable) and UCB responsible physician, as needed.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 83 of 206 12.2.1.1  Consultation with Medical Monitor and local hepatologist  
Potentia l drug -induced liver injury events require n otification of the Medical Monitor within 
24 hours (eg, by laboratory alert), and the subject must be discussed with the Medical Monitor as 
soon as possible. If required, the subject must also be discussed with t he local hepatologist. The 
local hepatologist is the expert usually consulted by the treating physician for assessment and 
management of potential hepatic disease. This would usually be a hepatologist, but may be a 
gastroenterologist. If determined necessa ry, this discussion should be followed by a full 
hepatology assessment (see Section  12.2.1.3 ) and SAE report (if applicable).  
12.2.1.2  Immediate action: dete rmination of IMP discontinuation  
All PDILI events require immediate action, testing, and monitoring.  
The immediate action is dependent on the laboratory values and symptoms of hepatitis or 
hypersensitivity and ranges from continuation of IMP (followed by i mmediate investigation) to 
immediate and permanent discontinuation (see Section  6.3.1 and Table  12‒3 for details).  
When IMP is discontinued, all concomitant medications and herbal supplements that are not 
medically necessary should also be discontinued. The Investigator should also consider dose 
reduction for medically necessary concomitant medication and consider changing any medically 
required concomitant medication known to be hepatotoxic to a suitable alternative.  
12.2.1.2.1  IMP restart/rechallenge  
Rechallenge with IMP can occur only if ALL of the following requirements are met:  
 The results of additional testing and monitoring described in Section  12.2.1.3  and 
Section  12.2.1.4  confirm a nondrug -related cause for the abnormal hepatic laboratory 
parameters and any associated symptoms (ie, a subsequent alternative diagnosis fully 
explains the  hepatic findings).  
 The subject has shown clear therapeutic benefit from the IMP.  
 Subject’s ALT or AST elevations do not exceed ≥5xULN.  
 Subject’s total bilirubin is <2xULN.  
 Subject has no signs or symptoms of hypersensitivity or hepatitis.  
 The rechalleng e is approved by the UCB responsible physician, DMC, and a hepatologist. 
The hepatologist must be external to UCB but may be a member of the DMC. It is 
recommended that the hepatologist be a local hepatology expert or the hepatologist treating 
the subject.  
 Subject agrees to the Investigator -recommended monitoring plan.  
12.2.1.3  Testing: identification/exclusion of alternative etiology  
The measurements and additional information required for the assessment of PDILI events when 
there is a reasonable possibility  that t hey may have been caused by the IMP are detailed in 
Table  12‒4 (laboratory measurements) and Table  12‒5 (additional information). Results of the 
laboratory measurements and information collected are to be submitted to the sponsor on the 
corresponding eCRF. If the medical history of the subject indicates a requirement for other 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 84 of 206 assessments not included below, these additional assessments should be completed and 
submitted, as applicable.  
All blood samples should be stored, if possible. If tests are done locally for more rapid results, a 
concurrent  sample must also be sent to the central laboratory.  
The following measurements are to be assessed:  
Table  12‒4: PDILI laboratory measurements  
Virology -related  Hepatitis A IgM antibody  
HBsAg  
Hepatitis E IgM antibody  
HBcAb -IgM 
Hepatitis C RNA  
Cytomegalovirus IgM antibody  
Epstein -Barr viral capsid antigen IgM antibody (if unavailable, obtain 
heterophile antibody or monospot testing)  
Immunology  Anti-nuclear antibody (qualitative and quantitative)  
Anti-smooth muscle antibody (qualitative and quantitative)  
Type 1 anti -liver kidney microsomal antibodies (qualitative and quantitative)  
Hematology  Eosinophil count  
Urinalysis  Urine drug screena 
Chemistry  Amylase  
Sodium, potassium, chloride, glucose, BUN, creatinine  
Total bilirubin, ALP, AST, ALT, GGT, total cholesterol, albumin  
If total bilirubin ≥1.5xULN, obtain fractionated bilirubin to obtain % direct 
bilirubin  
Serum CPK and LDH  to evaluate possible muscle injury causing transaminase 
elevation  
Additional  Prothrombin time/INRb 
Serum pregnancy testc 
PK 
ALP=alkaline phosphatase;  ALT=alanine aminotransferase; AST=aspartate aminotransferase; BUN=blood urea 
nitrogen; CPK=creatine phosphokinase; GGT=gamma glutamyltransferase; HBcAb -IgM=hepatitis B core antibody -
IgM; HBsAg=hepatitis B surface antigen; IgM=immunoglobulin M; INR=international normalized ratio; 
LDH=lactate dehydrogenase; PDILI=potential drug -induced liver i njury; PK=pharmacokinetic; RNA=ribonucleic 
acid; ULN=upper limit of normal  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 85 of 206 Table  12‒4: PDILI laboratory measurements  
a Tests in addition to the specified analytes may be performed based on the Investigator’s medical judgment and 
subject history.  
b Measured only for subjects with ALT >8xULN, eleva tions in total bilirubin, and symptoms of hepatitis or 
hypersensitivity. Hepatitis symptoms include fatigue, nausea, vomiting, and right upper quadrant pain or tenderness; 
hypersensitivity symptoms include eosinophilia (>5%), rash, and fever (without clear  alternative cause).  
c For women of childbearing potential.  
The following additional information is to be collected:  
Table  12‒5: PDILI information to be collected  
New or  updated information  
Concomitant prescription and over -the-counter medications (eg, acetaminophen, herbal remedies, 
vitamins); dosages and dates should be included.  
Pertinent medical history, including the following:  
 History of liver disease (eg, autoimmune hepatitis, nonalcoholic steatohepatitis or other “fatty 
liver disease”)  
 Adverse reactions to drugs  
 Allergies  
 Relevant family history or inheritable disorders (eg, Gilbert’s syndrome, alpha -1 antitrypsin 
deficiency)  
 Recent travel  
Progression of m alignancy involving the liver (Note: Metastatic disease to the liver, by itself, should not 
be used as an explanation for significant AST and/or ALT elevations.)  
The appearance or worsening of clinical symptoms of hepatitis or hypersensitivity (eg, fatigu e, nausea, 
vomiting, right upper quadrant pain or tenderness, decreased appetite, abdominal pain, jaundice, fever, or 
rash)  
Recent clinically significant hypotension or hypoxemia with compromised cardiopulmonary function  
Alcohol and illicit drug use  
Results of liver imaging or liver biopsy, if done  
Results of any specialist or hepatology consult, if done  
Any postmortem/pathology reports  
ALT=alanine aminotransferase; AST=aspartate aminotransferase; PDILI=potential drug -induced liver injury  
12.2.1.4  Follow -up evaluation  
Potential drug -induced liver injury events require follow -up monitoring as described in 
Table  12‒3. Monitoring should continue until liver c hemistry values normalize, stabilize, or 
return to Baseline. Determination of stabilization is at the discretion of the Investigator in 
consultation with the hepatologist (as applicable) and UCB responsible physician, as needed.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 86 of 206 12.3 Other safety measurements  
12.3.1  Assessment and management of TB and TB risk factors  
All subjects will be assessed for tuberculosis (TB) at Screening and at the timepoints specified in 
the Schedule of Assessments ( Table  5‒1) through physical examination for signs and symptoms 
of TB, chest x -ray (Section  12.3.1.2 ), laboratory testing ( Section  12.3.1.1 ), and subject 
questionnaire ( Section  12.3.1.3 ). 
For the purposes of this study, TB definitions are as follows:  
a. Known TB infection:  
 Active TB infection or clinical signs and symptoms suspicious for TB (pulmonary or 
extra -pulmonary).  
 History of active TB infection involving any organ system or findings in other organ 
systems consistent with TB infection, unless adequately treated and proven to be fully 
recovered upon consult with a TB specialist.  
 Any evidence by radiography or other imaging modalities consistent with previously 
active TB infection that is not reported in the subject’s medical history.  
b. High risk of acquiring TB infection:  
 Known close exposure to another person with active TB infecti on within the 3 months 
prior to Screening.  
 Time spent in a healthcare delivery setting or institution where individuals infected with 
TB are housed and where the risk of transmission of infection is high.  
c. Latent TB infection (unless appropriate prophylaxis  is initiated at least 8 weeks prior to IMP 
dosing and continued to completion of prophylaxis):  
 The absence of signs, symptoms, or physical findings suggestive of TB infection with a 
positive IGRA test (or 2 indeterminate IGRA test results) and a chest x -ray (or other 
imaging) without evidence of TB infection. If the result of the IGRA test is 
indeterminate, the particular IGRA test previously performed may be repeated once; if 
positive or indeterminate on retest, the subject may not be randomized to IMP wi thout 
further evaluation by a TB specialist and discussion with the Study Physician, if LTB 
infection is identified. The retest must be done during the protocol -defined Screening 
window.  
Note: If available, respiratory or other specimens must also be smear  and culture negative 
for TB (CDC diagnosis of LTB infection) http://www.cdc.gov/TB/topic 
/testing/default.htm).  
d. NTMB infection is defined as a clinical infection caused by mycobacterial species other than 
those belonging to the Mycobacterium tuberculosis complex.  
e. Tuberculosis test conversion:  
 A positive IGRA result for the current test when previous IGRA test results were 
negative. All subjects with TB test conversion must immediately stop IMP administration 
and be referred to a TB specialist for further e valuation. Confirmed TB  test conversions 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 87 of 206 should be classified as due to LTBI, active  TB infection, or NTMB, and reported to the 
UCB PS function.  
Subject eligibility, retesting requirements, and treatment requirements are depicted in 
Figure  12-1. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 88 of 206 Figure  12-1: Schematic diagram of TB test results and study eligibility  
IGRA TB test
IGRA TB test 
negativeIGRA TB test 
indeterminate IGRA TB test 
positive
Repeat IGRA TB 
testa
IGRA TB test 
negativeIGRA TB test 
indeterminate IGRA TB test 
positiveSubject eligible for 
study
Subject eligible for 
studyEvaluation by TB 
specialist
Latent or active 
TB negativeLatent TB 
positiveActive TB 
positive
Subject eligible for 
study
TB treatment 
initiatedNo TB treatment 
initiated
Subject eligible for 
studybSubject NOT 
eligible for studySubject NOT 
eligible for study
IGRA=interferon-gamma release assay; TB=tuberculosis
a IGRA retest must be done during the protocol-defined Screening window
b Subjects with LTBI may enter the study only after they have completed at least 8 weeks of appropriate 
prophylactic therapy and thereafter, will continue and complete the entire regimen.
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 89 of 206 12.3.1.1  Tuberculosis assessment by IGRA  
During conduct of the study, the TB assessment by IGRA (QuantiFERON TB test is 
recommended) will be performed as described in Table  5‒1 for all subjects. The test results will 
be reported as positive, negative, or indeterminate. Positive and indeterminate TB test results 
must be reported as an adverse event and appropriately updated once the fin al diagnosis is 
known (eg, active TB, latent TB, or false positive TB test). UCB also recommends that a  TB 
specialist be consulted  where TB (latent or active) is suspected or if there are doubts regarding 
test results. If latent or active TB is identified,  subject must undergo appropriate study -specified 
withdrawal procedures. The retest during Screening must be done during the protocol -defined 
Screening window.  
12.3.1.2  Chest x -ray for tuberculosis  
A plain posteroanterior chest x -ray must be performed in the Screen ing Period unless one has 
been performed within 3 months prior to the Screening Visit. The chest x -ray (or, if done, 
Computed Axial Tomography of the Chest) must be clear of signs of TB infection (previous or 
current) before first IMP administration. All c hest imaging (particularly x -rays) should be 
available for review by the Investigator before randomization of the subject. The chest x -ray 
reading should be repeated if the TB test was confirmed positive. If the second read of the 
pretreatment chest x -ray is confirmed to be clear, the subject may be included in the study 
8 weeks after the start of the TB prophylactic treatment. If the pretreatment chest x -ray is not 
available for a re -read, it should be repeated after notification to the radiologist that th is subject 
is IGRA positive, and confirmed to be clear for signs of TB.  
The chest imaging must be negative for any old or recent TB infection as determined by a 
qualified radiologist and/or pulmonary physician. Any new clinically significant findings post 
Baseline on chest x -ray must be documented in the source documents and the eCRF as an AE.  
12.3.1.3  Tuberculosis questionnaire  
The questionnaire “Evaluation of signs and symptoms of tuberculosis” should be used as a 
source document. The questionnaire will be complet ed as described in Table  5‒1. The 
questionnaire will assist with the identification of subjects who may require therapy for TB. A 
subject who answers “Y es” to the question  
 at Screening 
is excluded. A “Yes” response to any of the other questions within the questionnaire at Scree ning 
should trigger further careful assessment to determine if subject has LTB or active TB (see 
Exclusion Criterion # 12, Section  6.2). A “Yes” response to any of the questions during the study 
should trigger further assessments to determine if the subject has either LTB or active TB 
infection.  
12.3.1.4  Tuberculosis management  
LTB infection and active TB identified during study  
During the study, subjects w ho develop evidence of LTB infection or active TB must 
immediately stop further administration of IMP and will be referred to an appropriate TB 
specialist (pulmonologist or infectious disease specialist) for further evaluation. Evidence of 
LTB infection is  defined as subject’s IGRA test converts to positive or indeterminate (and 
confirmed indeterminate on repeat), or the subject’s questionnaire or history and physical 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 90 of 206 indicates that TB infection or exposure may have occurred. Evidence of active TB includes,  in 
addition to the aforementioned tests, signs and symptoms of organ involvement. In either 
situation, the subject should be carefully assessed by a TB specialist for active TB. Subjects 
diagnosed with active TB should be withdrawn from the study and rece ive appropriate TB or 
prophylaxis therapy.  
If a TB specialist excludes an active TB infection the subject can proceed with the IMP no earlier 
than 4 weeks after the start of an appropriate prophylactic therapy.  
Any presumptive diagnosis or diagnosis of a TB infection is a reportable event. Confirmed active 
TB must be reported as an SAE. The Investigator is to complete and submit the TB Follow -Up 
Form provided.  
The subject should be transferred to the care of his/her physician and managed according to the 
best available standard of care. Subjects identified as having converted to active TB during the 
study must be withdrawn and scheduled to return for the PEOT Visit as soon as possible but no 
later than the next scheduled study visit and complete all PEOT Vi sit assessments.  
The subject should be encouraged to complete a SFU Visit (20 weeks after the final dose of 
IMP).  
If infection with NTMB is identified during the study, the same procedure as for active TB 
acquired during the study must be followed.  
12.3.2  Pregnan cy testing  
Pregnancy testing will consist of serum testing at the Screening. The pregnancy test will be urine 
at all other visits.  
The Screening Visit serum pregnancy testing results must be negative and received and reviewed 
prior to randomization. A nega tive urine pregnancy test result should be obtained immediately 
prior to each administration of IMP at the visits specified in Table  5‒1. Pregnancy test s should 
be administered to all female subjects of childbearing potential, regardless of their use of birth 
control.  
12.3.3  Vital signs  
Vital signs will be collected at every visit and will include systolic and diastolic BP, pulse rate, 
and body temperature (oral , axillary, or otic). Subjects should be sitting for 5 minutes before and 
during vital signs assessments.  
Vital signs are to be measured prior to blood sampling, and prior to dosing, where applicable.  
12.3.4  12-lead electrocardiograms  
Twelve -lead standard ECGs wi ll be recorded at the visits specified in Table  5‒1, and read by a 
central ECG reader.  
Full details of ECG recording will be provided in the ECG Manual . 
12.3.5  Physical examination  
A physical examination will be performed at the visits specified in Table  5‒1. The physical 
examination will include general appe arance; ear, nose, and throat; eyes, hair, and skin; 
respiratory; CV; GI; musculoskeletal; hepatic; neurological (including limb reflexes); and mental 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 91 of 206 status. All physical examinations will also include evaluation of signs and symptoms of active 
TB and ris k for exposure to TB. Findings considered clinically significant changes since the 
physical examination at the Screening Visit will be recorded as AEs.  
12.3.6  Height and body weight  
Height will be measured at Baseline only.  
Body weight will be measured at the visits specified in Table  5‒1. 
12.3.7  Assessment of suicidal ideation and behavior  
Suicidal ideation and behavior will be assessed by using the eC -SSRS; the questionnaire will be 
self-administered by the subject and assessed by trained study personnel. This scale will be used 
to assess suicidal ideation and behavior that may occur during the study. The visits at which the 
eC-SSRS assessments will be performed are specified in the schedule of study assessments 
(Table  5‒1). 
The eC -SSRS is a standardized and validated instrumen t developed for the assessment of the 
severity and frequency of suicidal ideation and behavior (Posner et al, 2011; Mundt et al, 2010). 
Subjects respond to standardized clinical questions that are presented in a uniform fashion. The 
eC-SSRS defines 5 subty pes of suicidal ideation and behavior in addition to self -injurious 
behavior with no suicidal intent. The eC -SSRS takes approximately 3 to 10 minutes to complete.  
Refer to Section  6.3 for eC -SSRS -related withdrawal criteria.  
12.4 Other study measurements  
12.4.1  Demographic information  
Demographic information will be collected in all subjects and include age, gender, race and 
ethnicity. Information on demographics will  be collected according to local rules and regulations. 
Demographic information will be recorded in the eCRF.  
12.4.2  Medical history  
A complete medical history will be collected as part of the Screening assessment and include all 
clinically relevant past or coexi sting medical conditions and surgeries. Findings will be recorded 
in the eCRF.  
12.4.3  Psoriasis history  
A detailed history of each subject’s PSO history will be collected and include the date of onset 
and past treatments for PSO.  
12.4.4  Data Monitoring and Adjudication Committees  
The DMC membership includes experienced clinicians and a statistician, all of whom have 
expertise in clinical trials. Cardiovascular and Neuropsychiatric Adjudication Committees will 
also periodically review data from this trial. Both Data Monit oring and Adjudication Committee 
members may not participate in the study as principal or co -Investigators, or as study subject 
care physicians. The duration of membership for the committees will be inclusive of planned 
analyses for PS0009.  Detailed role, scope, responsibilities, and complete procedures, as well as 
the identity of members, are described in the separate committee charters.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 92 of 206 13 STUDY MANAGEMENT AND  ADMINISTRATION  
13.1 Adherence to protocol  
The Investigator should not deviate from the protocol. However , the Investigator should take any 
measure necessary in deviation from or not defined by the protocol in order to protect clinical 
study subjects from any immediate hazard to their health and safety. In this case, this action 
should be taken immediately, w ithout prior notification of the regulatory authority,  IRB/IEC, or 
sponsor.  
After implementation of such measure, the Investigator must notify the CPM of the sponsor 
within 24 hours and follow any local regulatory requirements.  
13.2 Monitoring  
UCB (or designee)  will monitor the study to meet the sponsor’s monitoring SOPs, ICH -GCP 
guideline, and applicable regulatory requirements, and to ensure that study initiation, conduct, 
and closure are adequate. Monitoring of the study may be delegated by UCB to a CRO or a 
contract monitor.  
The Investigator and his/her staff are expected to cooperate with UCB (or designee) and to be 
available during the monitoring visits to answer questions sufficiently and to provide any 
missing information. The Investigator(s)/institution( s) will permit direct access to source 
data/documents for study -related monitoring, audits, IRB/IEC review, and regulatory 
inspection(s).  
The Investigator will allow UCB (or designee) to periodically review all eCRFs and 
corresponding source documents (eg,  hospital and laboratory records for each subject). 
Monitoring visits will provide UCB (or designee) with the opportunity to evaluate the progress 
of the study, verify the accuracy and completeness of eCRFs, ensure that all protocol 
requirements, applicabl e authorities regulations, and Investigator’s obligations are being 
fulfilled, and resolve any inconsistencies in the study records.  
13.2.1  Definition of source data  
All source documents must be accurate, clear, unambiguous, permanent, and capable of being 
audite d. They should be made using some permanent form of recording (ink, typing, printing, 
optical disc). They should not be obscured by correction fluid or have temporary attachments 
(such as removable self -stick notes). Photocopies and/or printouts of eCRFs a re not considered 
acceptable source documents.  
Source documents are original records in which raw data are first recorded. These may include 
hospital/clinic/general practitioner records, charts, diaries, x -rays, laboratory results, printouts, 
pharmacy reco rds, care records, ECG or other printouts, completed scales, or QOL 
questionnaires, for example. Source documents should be kept in a secure, limited access area.  
Source documents that are computer generated and stored electronically must be printed for 
review by the monitor (eg,  ECG reports). Once printed, these copies should be signed and dated 
by the Investigator and become a permanent part of the subject’s source documents. The 
Investigator will facilitate the process for enabling the monitor to compare  the content of the 
printout and the data stored in the computer to ensure all data are consistent.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 93 of 206 Electronic data records, such as Holter monitor records or electroencephalogram records, must 
be saved and stored as instructed by UCB (or designee).  
Patien t-reported outcome measures (eg, DLQI, EQ -5D-3L, SF -36, Patient Global Assessment of 
PSO, and PGADA) and ePRO diary data will be entered electronically by the subject.  
The ePRO diary data will be entered into an electronic diary by the subject. The data co llection 
and database management system will be supplied by a vendor and will be compliant with the 
US Food and Drug Administration Part 11. The data collected on the ePRO diary will be 
uploaded to a central server database and will be sent electronically to UCB (or a designated 
CRO).  
13.2.2  Source data verification  
Source data verification ensures accuracy and credibility of the data obtained. During monitoring 
visits, reported data are reviewed with regard to being accurate, complete, and verifiable from 
source documents (eg,  subject files, recordings from automated instruments, tracings [ECG], 
x-ray films, laboratory notes). All data reported on the eCRF should be supported by source 
documents, unless otherwise specified in Section  13.2.1 . 
13.3 Data handling  
13.3.1  Case Report Form completion  
The Investigator is responsible for prompt reporting of accurate, complete, and legible data in the 
electronic eCRFs and in all required reports.  
Any change or correction to the eCRF after saving must be accompanied by a reason for the 
change.  
Corrections made after the Investigator’s review and approval (by means of a 
password/electronic signature) will be reapproved by the Invest igator.  
The Investigator should maintain a list of personnel authorized to enter data into the electronic 
eCRF.  
Detailed instructions will be provided in the eCRF Completion Guidelines.  
13.3.2  Database entry and reconciliation  
Case Report Forms/external electroni c data will be entered/loaded into a validated electronic 
database using a clinical data management system (CDMS). Computerized data cleaning checks 
will be used in addition to manual review to check for discrepancies and to ensure consistency of 
the data.  This study is performed using Electronic Data Capture: the data are entered into the 
eCRFs once and are subsequently verified.  
An electronic audit trail system will be maintained within the CDMS to track all data changes in 
the database once the data have  been saved initially into the system or electronically loaded. 
Regular backups of the electronic data will be performed.  
13.3.3  Subject Screening and Enrollment log/Subject Identification Code list  
The subject’s screening and enrollment will be recorded in the Subject Screening and Enrollment 
Log. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 94 of 206 The Investigator will keep a Subject Identification Code list. This list remains with the 
Investigator and is used for unambiguous identification of each subject.  
The subject’s consent and enrollment in the study must be recorded in the subject’s medical 
record. These data should identify the study and document the dates of the subject’s 
participation.  
13.4 Termination of the study  
UCB reserves the right to temporarily suspend or prematurely discontinue this study either at a 
single site, multiple sites, or at all sites at any time for reasons including, but not limited to, 
safety or ethical issues, inaccurate or incomplete data recording, noncompliance, or 
unsatisfactory enrollment with respect to quality or quantity.  
If the  study is prematurely terminated or suspended, UCB (or its representative) will inform the 
Investigators/institutions and the regulatory authority(ies) of the termination or suspension and 
the reason(s) for the termination or suspension, in accordance with  applicable regulatory 
requirement(s). The IRB/IEC should also be informed and provided with reason(s) for the 
termination or suspension by the sponsor or by the Investigator/institution, as specified by the 
applicable regulatory requirement(s). In additio n, arrangements will be made for the return of all 
unused IMP and other material in accordance with UCB procedures for the study.  
13.5 Archiving and data retention  
The Investigator will maintain adequate records for the study, including eCRFs, medical records, 
laboratory results, Informed Consent documents, drug dispensing and disposition records, safety 
reports, information regarding participants who discontinued, and other pertinent data.  
All essential documents are to be retained by the Investigator until at least 2 years after the last 
approval of a marketing application in an ICH region and until there are no pending or 
contemplated marketing applications in an ICH region, or at least 2 years have elapsed since the 
formal discontinuation of clinical developm ent of the IMP. These documents should be retained 
for a longer period, however, if required by the applicable regulatory requirement(s) or by an 
agreement with UCB ( Committee for Proprietary Medicinal Products  [CPMP]/ICH/135/95, 2002 
[Section  4.9.5]). The  Investigator will contact UCB for authorization prior to the destruction of 
any study records or in the event of accidental loss or destruction of any study records. The 
Investigator will also notify UCB should he/she relocate or move the study -related fi les to a 
location other than that specified in the sponsor’s trial master file.  
13.6 Audit and inspection  
The Investigator will permit study -related audits mandated by UCB, after reasonable notice, and 
inspections by domestic or foreign regulatory authorities.  
The main purposes of an audit or inspection are to confirm that the rights and well -being of the 
subjects enrolled have been protected, that enrolled subjects (ie,  signing consent and undergoing 
study procedures) are appropriate for the study, and that all  data relevant for the evaluation of the 
IMP have been processed and reported in compliance with the planned arrangements, the 
protocol, investigational site, and IRB/IEC SOPs, ICH GCP, and applicable regulatory 
requirements.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 95 of 206 The Investigator will provide direct access to all study documents, source records, and source 
data. If an inspection by a regulatory authority is announced, the Investigator will immediately 
inform UCB (or designee).  
13.7 Good Clinical Practice  
Noncompliance with the protocol, ICH -GCP, or local regulatory requirements by the 
Investigator, institution, institution staff, or designees of the sponsor will lead to prompt action 
by UCB to secure compliance. Continued noncompliance may result in the termination of the 
site’s involvement in the st udy. 
14 STATISTICS  
A description of statistical methods follows and will be described in more detail in the SAP.  
14.1 Definition of analysis sets  
The Enrolled Set will consist of all subjects who have given informed consent.  
The Randomized Set (RS) will consist of  all randomized subjects.  
The Safety Set (SS) will consist of all subjects that received at least 1 dose of the IMP.  
The Maintenance Set will consist of all subjects who have received at least 1 dose of active IMP 
(bimekizumab or ustekinumab) in the Mainte nance Treatment Period.  
The Full Analysis Set (FAS) will consist of all randomized subjects that received at least 1 dose 
of the IMP and have a valid measurement for each of the co -primary efficacy variables at 
Baseline.  
The Active Medication Set (AMS) wi ll consist of all subjects who have received at least 1 dose 
of active IMP (bimekizumab or ustekinumab). The AMS will be used for summaries of safety 
that include all data from the Initial Treatment Period and/or Maintenance Treatment Period.  
The Per -Proto col Set (PPS) will consist of all subjects in the RS who had no important protocol 
deviations affecting the primary efficacy variable. Important protocol deviations will be 
predefined and subjects with important protocol deviations will be evaluated during  ongoing data 
cleaning meetings prior to unblinding of the data.  
The Pharmacokinetics Per -Protocol Set (PK -PPS) consists of all randomized subjects who 
received at least 1 dose of the IMP and provided at least 1 quantifiable plasma concentration 
post-dose without important protocol deviations that would affect the concentration.  
14.2 General statistical considerations  
Summary statistics will consist of frequency tables for categorical variables. For continuous 
variables, summary statistics will consist of the number of available observations, arithmetic 
mean, SD, median, minimum, and maximum unless stated otherwise.  
The statistical analysis of the co -primary efficacy variables and selected secondary efficacy 
variables will account for multiplicity and control t he familywise Type I error rate at a 2 -sided 
alpha level of 0.05 by using a fixed sequence testing procedure.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 96 of 206 The hypotheses (H 1, H2, H3, H4, H5, H6, H7, H8, H9, H10, H11, H12, H13, H14, H15, H16, and H 17) 
comparing bimekizumab vs. placebo or bimekizumab vs. ustekinumab will be tested at a 2 -sided 
alpha level of 0.05.  
The first 2 hypotheses (H 1 and H  2) test whether bimekizumab is superior to placebo for PASI90 
response and IGA response at Week  16. These are the hypothesis tests corresponding to the co -
primary endpoints. If both are rejected at a 2 -sided alpha level of 0.05, that alpha will be passed 
to the next test in the sequence, allowing the testing procedure to proceed.  
The hypotheses associated with the subsequent tests are for secondary efficacy end points and are 
based on testing for non -inferiority/superiority relative to ustekinumab or for superiority relative 
to placebo. Note that while subjects randomized to ustekinumab may receive either the 45mg or 
90mg dose (according to weight at Baseline), a ll subjects randomized to ustekinumab will be 
analyzed as a single group (and not broken out by dose) since the proposed strategy is consistent 
with the recommended weight -based dosing for ustekinumab. See Figure  14-1 for details on this 
procedure.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 97 of 206 Figure  14-1: Sequence of testing  
 
IGA=Investigator’s Global Assessme nt; PASI=Psoriasis Area Severity Index; PSD=Patient Symptom Diary; 
PSO=psoriasis  
14.3 Planned efficacy analyses  
14.3.1  Analysis of the primary efficacy variable  
The co -primary efficacy variables for this study will be PASI90 response and IGA response at 
Week  16, and the corresponding analyses will be based on the RS. A subject will be classified as 
a PASI90 responder if the PASI score at Week  16 has improved at le ast 90% from Baseline, and 
an IGA responder will be any subject with a score of 0 or 1 (Clear or Almost Clear) with at least 
a 2-category improvement from Baseline in the IGA score. The primary analyses will be based 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 98 of 206 on the stratified Cochran -Mantel -Haensz el (CMH) test where region and prior biologic exposure 
(yes/no) will be used as stratification variables. Region and prior biologic exposure have been 
selected as stratification variables in the analysis because they are stratification variables in the 
randomization and because they may have an impact on efficacy. Pairwise treatment 
comparisons will be made based on the CMH test using the p -value for the general association.  
Nonresponder imputation (NRI) will be used to account for missing data in the prima ry analysis. 
Specifically, any subject who withdraws from IMP prior to Week  16 or who has missing data for 
the co -primary efficacy variables at the Week  16 time point will be considered a nonresponder. 
Based on previous studies of biologics in subjects wit h moderate to severe chronic plaque PSO, 
it is expected that the number of subjects who discontinue prior to Week  16 will be low. For the 
small percentage of subjects for whom primary endpoint data are unavailable at Week  16, this 
lack of data is suggestiv e of an ineffective IMP, thereby supporting the imputation of 
nonresponse. Therefore, NRI is considered an appropriate method for handling missing data 
since achieving the clinical response and making it through 16 weeks of IMP are both critical 
components  of the primary outcome.  
14.3.1.1  Sensitivity analyses  
The primary efficacy analysis described in Section  14.3 will be repeated based on the FAS and 
the PPS.  
As a sensitivity analysis to the primary analysis method, logistic regression based on the RS will 
be used. The odds ratio of the responder rates at Week  16 will be estimated and tested between 
treatment groups using a logistic regression model with factor s of treatment group, region, and 
prior biologic exposure (yes/no). The odds ratio, associated CI, and p -value based on the Wald 
test will be presented. If the logistic regression model is unable to converge, then prior biologic 
exposure may be dropped fro m the model to facilitate convergence. If the model is still unable to 
converge, then region may be removed from the model as well. In addition, if the logistic 
regression model cannot converge due to lack of any placebo responders, then Fisher’s exact tes t 
will be used for inferential comparisons to placebo. As with the primary analysis, missing data 
will be handled using NRI.  
The center -by-treatment interaction will be tested by replacing region with center in the logistic 
regression model described above  and adding a center -by-treatment interaction term. In the 
model, center will be based on the original centers prior to pooling. However, if the model is 
unable to converge due to a low number of subjects at a given center, a pooling (to be described 
in the SAP) will be applied in order to allow the model to converge.  
In order to obtain reasonable estimates of variability for a treatment arm at a given center, a 
minimum of 21 subjects will be considered acceptable for a center to be included in the model 
without pooling. Given the 4:2:1 randomization allocation scheme, this should provide a 
minimum of about 12 subjects in the bimekizumab arm, 6 subjects in the ustekinumab arm, and 
3 subjects in the placebo arm. Centers with fewer than 21 subjects will be eli gible for pooling.  
The following center pooling algorithm will be used for each geographic region:  
 If a center has 21 or more subjects, then no pooling will be done for that center.  
 Centers with fewer than 21 subjects will be ordered from largest to smalle st with pooling 
proceeding in the following manner:  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 99 of 206  Two or more centers will be combined until the cumulative subject total is at least 21.  
 Once a pooled center has at least 21 subjects, the process will continue in an iterative 
fashion for the subsequent centers in the ordered list, where a new pooled center begins 
each time at least 21 subjects has been reached in the previous pool.  
 If this iterative process reaches the end of the ordered list of centers where the final 
pooled center has fewer than 21 sub jects, then the subjects from the centers in that pool 
will be combined with the pooled center formed in the previous iteration.  
This procedure is only to be performed within a geographic region – there will be no pooling of 
centers across regions.  
If the center -by-treatment interaction is not found to be significant (α=0.10), then no further 
analyses will be performed. On the other hand, if the interaction is significant, further analyses 
will be conducted to determine which center or centers may be the so urce of the interaction. This 
will be done by running the logistic regression model (including the interaction term) where each 
center will be systematically removed from the model. The impact of a given center will be 
based on the change in the interactio n p-value when that center is removed. The center or centers 
that appear to be driving the significant interaction effect will then be removed from the model to 
verify that conclusions remain the same with or without the influential center(s).  
Additional s ensitivity analyses to evaluate varying assumptions related to the handling of 
missing data will also be performed and are described in greater detail in Section  14.7. 
14.3.2  Other efficacy analyses  
14.3.2.1  Analysis of the secondary efficacy variables  
14.3.2.1.1  Initial Treatment Period  
The secondary efficacy variables for time points during the initial Treatment Period will be 
analyzed for all subjects in the RS.  
For binary secondary efficacy variables, the stratified CMH test as specified for the primary 
analysis will be implemented to test for superiority. As in the primary analysis, NRI will be used 
to account for missing data. For the assessment of non -inferiority, a non -inferiority margin of 
10% will be used and evaluated based on the confidence interval for the stratified Mantel -
Haenszel risk difference between bimekizumab and ustekinumab. A non -inferiority margin of 
10% has been selected as this is considered to be a cl inically relevant difference that could 
influence the choice of interventions used to treat chronic plaque PSO. Therefore, a difference 
within the 10% non -inferiority margin would suggest a similar impact on efficacy between the 
treatments.  
For continuous change from Baseline efficacy variables, an analysis of covariance (ANCOVA) 
model will be used with fixed effects of treatment, region, and prior biologic exposure and 
Baseline value as a covariate. Missing data for these variables will be imputed using mu ltiple 
imputation (MI) and is further described in Section  14.7. 
Sensitivity analyses for the handling of missing data will be performed for the seco ndary efficacy 
variables during the Initial Treatment Period that are part of the fixed sequence testing 
procedure. These analyses are described in Section  14.7. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 100 of 206 14.3.2.1.2  Maintenance Treatment Period  
Because all placebo subjects will receive bimekizumab treatment starting at Week  16, statistical 
comparisons against placebo after Week  16 will not be performed. However, bimekizumab will 
be compared to ustekinuma b at Week  52 for the RS. The analysis of PASI90 and IGA at 
Week  52 will be based on a stratified CMH test where region and prior biologic exposure will be 
used as stratification variables. Pairwise treatment comparisons will be made based on the p -
value fo r the general association.  
Missing data will be imputed using NRI. All subjects with missing data at Week 52 or who 
discontinue study treatment prior to Week 52 will also be treated as non -responders for this 
secondary efficacy analysis.  
14.3.2.2  Analysis of the ot her efficacy variables  
The other efficacy variables in the Initial Treatment Period will be analyzed for all subjects in the 
RS. For the Maintenance Treatment Period, summaries will primarily be based on the RS. Full 
details will be specified in the SAP.  
Binary (responder) variables will be summarized using frequency tables by treatment group for 
each visit.  
Continuous variables will be summarized using descriptive statistics by treatment group for each 
visit.  
Time to PASI75/90/100 response during the Initi al Treatment Period will be estimated and 
presented using the Kaplan -Meier product -limit method for each treatment. Time to a given 
response will be defined as the length in days from the first dose of IMP until the first date when 
the response is achieved . Subjects who discontinue IMP prior to achieving a response will be 
censored at the date of IMP discontinuation. Subjects who reach the Week  16 Visit without 
achieving the given PASI response will be censored at the date of the Week  16 Visit. The median 
time to response, including the 2 -sided 95% CI, will be calculated for each treatment. Between 
group differences (bimekizumab vs placebo and bimekizumab vs ustekinumab) will be analyzed 
with the log -rank statistic.  
All other efficacy variables during the In itial Treatment Period will be summarized based on 
imputed data (NRI and multiple imputation for binary and continuous variables, respectively, 
unless otherwise stated in the SAP). In some cases, variables may also be summarized based on 
observed case data  (ie, subjects with missing data or who have prematurely discontinued IMP are 
treated as missing). There may be cases where the multiple imputation model fails to converge. 
In such situations, the last observation carried forward (LOCF) approach will inste ad be used to 
impute the missing data. If LOCF is used instead of multiple imputation for this reason, this will 
be clearly specified in the corresponding table summary. Should there be no missing data for a 
study variable, then only observed case data wil l be presented. Note that for LOCF imputation, 
any missing data or data collected following discontinuation of IMP will be imputed with the 
most recent previous value. See Section  14.7 for further details.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 101 of 206 For other efficacy variables during the Maintenance Treatment Period, summaries will include 
the bimekizumab and ustekinumab treatment groups. Details of these summaries will be 
described further in  the SAP, but there will be 2 key approaches for understanding the data in the 
Maintenance Treatment Period:  
1. Summary of data for the RS through Week 52 based on randomized treatment group.  
2. Summary of Maintenance Treatment Period data among responders only . 
14.4 Subgroup analyses  
Subgroup analyses will be performed on the primary and secondary efficacy variables that are 
part of the fixed sequence testing procedure described in Section  14.3. The following variables 
for subgroup analyses will be defined: age, gender, disease duration, region, weight, body mass 
index, prior systemic chemotherapy or phototherapy, prior biologic exp osure, prior systemic 
therapy of any kind, Baseline disease severity, and antibody positivity. These summaries will be 
based on imputed data (NRI or MI) and will include descriptive statistics only. Note that the 
approach for deriving descriptive statistic s using MI is outlined in Section  14.7. 
14.5 Planned safety and other analyses  
14.5.1  Safety analyses  
Safety variables will be analyzed for all subjects in the SS. The AMS will be used for summaries 
of safety that include data from the Initial Treatment Period and/or Maintenance Treatment 
Period.  
Adverse events will be coded according to the Medical Dictionary for Regulatory Activities 
(MedDRA). Adverse events wi ll be summarized descriptively by treatment group, primary 
system organ class, High Level Term (HLT), and preferred term. Additional tables will 
summarize AEs by intensity and relationship to IMP, AEs leading to withdrawal from the study, 
SAEs, and deaths.  Specific safety topics of interest will be summarized and will be described in 
greater detail in the SAP.  
For subjects who switch treatment, AEs will be allocated to the treatment the subject was on the 
day the event occurred. If the event occurs on the d ay of the switch, it will be attributed to the 
initial treatment, unless the event has a HLT of “Injection Site Reactions, in which case it will be 
attributed to the new treatment.  
Laboratory values (including markedly abnormal laboratory values), urinary values, vital signs, 
and extent of exposure will be presented descriptively by treatment group. Definitions for 
markedly abnormal laboratory values will be provided in the SAP.  
14.5.2  Pharmacokinetic analyses  
Pharmacokinetic variables will be analyzed for all subjects in the PK -PPS. Bimekizumab plasma 
concentrations will be summarized for each treatment at each scheduled visit.  
14.5.3  Immunogenicity analyses  
Antibimekizumab antibodies will be assessed using a tiered approach: screening, confirmatory, 
and titer assays will be used. Anti -bimekizumab antibodies (including positivity) will be 
summarized by treatment at each scheduled visit at which samples are collected.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 102 of 206 14.6 Handling of protocol deviations  
Important protocol deviations are deviations from the protocol which po tentially could have a 
meaningful impact on study conduct, or on the primary efficacy, key safety, or PK outcomes for 
an individual subject. The criteria for identifying important protocol deviations will be defined 
within the appropriate protocol -specific  document at study start. Important protocol deviations 
will be reviewed as part of the ongoing data cleaning process and all important deviations will be 
identified and documented prior to unblinding to confirm exclusion from analysis sets.  
14.7 Handling of dr opouts or missing data  
Study variables with multiple components may have rules to account for partial missing data of 1 
or more components. Such rules will be defined in the SAP. The following rules are outlined for 
cases where variables are completely mis sing, including partial missing data where the data 
handling rules conclude that the variable should be treated as completely missing.  
The analysis of the co -primary efficacy variables will use NRI for handling of missing data. That 
is, subjects with missi ng data or who have discontinued IMP prior to Week  16 will be considered 
as nonresponders for the primary analysis.  
The following sensitivity analyses for the co -primary efficacy variables will be performed:  
1. Missing data will be addressed by using MI (Mark ov-Chain Monte Carlo [MCMC] method 
for intermittent missing data, followed by monotone regression for monotone missing data) 
to evaluate the effect of the method for handling missing data on the analysis. The actual 
PASI/IGA scores will be imputed and then  dichotomized to obtain the response status. The 
treatment differences for each imputed data set will subsequently be evaluated using the 
stratified CMH test as used in the primary analysis. The results from each of the imputed data 
sets will be combined f or overall inference using Rubin’s rules, which account for the 
uncertainty associated with the imputed values ( Rubin, 1987 ). This will be done using SAS 
PROC MIANALYZE. This procedure assumes a missing at random (MAR) pattern of 
missingness and correspond s to an estimand of the difference in outcome improvement if all 
subjects tolerated or adhered to treatment (Mallinckrodt et al, 2012). This is an estimand of 
efficacy to evaluate the de jure hypothesis.  
2. Deviations from the MAR pattern assumed above will b e evaluated. A sensitivity analysis 
will be performed in which, as with the above analysis, intermittent missing data will be 
imputed using MI based on the MCMC method. However, the remaining monotone missing 
data will be assumed to follow a missing not at  random pattern. These data will be imputed 
using reference -based imputation in which the imputation model is based on data from the 
placebo group, thereby assuming that monotone missing data follow a trajectory similar to 
the placebo group (Mallinckrodt e t al, 2012). As specified in the previous procedure, actual 
PASI/IGA scores will be imputed and then dichotomized to get the response status. The 
treatment differences for each imputed data set will subsequently be evaluated using the 
stratified CMH test a s used in the primary analysis. The estimand in this procedure is the 
difference in outcome improvement in all randomized subjects at the planned endpoint of the 
study attributable to the initially randomized medication (Mallinckrodt et al, 2012). This is an 
estimand of effectiveness to evaluate the de facto hypothesis.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 103 of 206 3. A final sensitivity analysis will be based on observed data  at Week  16. Subjects with missing 
data or who have prematurely discontinued IMP will be treated as missing. The same 
stratified CMH test as in the primary efficacy analysis will be used.  
Further details on the MI procedures will be provided in the SAP.  
Missing data for binary secondary variables during the Initial Treatment Period will be imputed 
using NRI. Missing data for continu ous secondary variables will be imputed using MI. The MI 
procedure for continuous variables will be similar to sensitivity analysis #1 described above for 
the co -primary efficacy endpoints with the following differences: 1) the imputation model will 
use th e change from Baseline (instead of actual) values by visit and no dichotomization will be 
necessary; and 2) the analysis model will be based on ANCOVA as opposed to the CMH test.  
For the secondary endpoints evaluated at Week  52, all subjects with missing d ata at Week  52 or 
who discontinue treatment prior to Week  52 will be counted as nonresponders. Sensitivity 
analyses #1 and #2 will also be performed for the Week  52 secondary endpoints. A similar 
procedure to what is described above will be followed. Furth er details on this analysis will be 
provided in the SAP.  
For other continuous efficacy variables, MI will be used to impute missing data when possible. If 
the imputation model cannot converge, LOCF will be used. The MI procedure will be similar to 
sensitiv ity analysis #1 described above with the following differences: 1) the imputation model 
will use the change from Baseline (instead of actual) values by visit and no dichotomization will 
be necessary; 2) instead of using the stratified CMH test, the imputed  data sets will be combined 
and simple means and standard errors will be calculated using Rubin’s rules (via SAS PROC 
MIANALYZE). For calculation of other descriptive statistics such as the median, min and max, 
Rubin's rules do not apply. Multiple imputati on estimates will be computed by simply averaging 
the estimates from the multiple repetitions of the imputation algorithm. This is the same 
approach that will be used when summarizing continuous secondary efficacy variables by 
subgroup.  
14.8 Planned interim ana lysis and data monitoring  
After the final Week 52 visit, an interim analysis will be performed and a corresponding interim 
CSR may be written. A final analysis and updated final CSR will be prepared once all data 
(through the SFU visit) have been collected . 
14.9 Determination of sample size  
A total of 560 subjects will be randomly assigned in a 4:2:1 ratio to the following treatment 
groups:  
 Bimekizumab 320mg (320 subjects)  
 Ustekinumab (160 subjects)  
 Placebo (80 subjects)  
The primary efficacy analysis is based on  the comparison of bimekizumab to placebo for the co -
primary efficacy variables of PASI90 response and IGA response at Week  16. However, as 
described in Section  14.3, Week  16 comparisons of bimekizumab against ustekinumab for 
PASI90 response and IGA response will also be part of a fixed sequence testing procedure to 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 104 of 206 control for multiplicity. Therefore, this study has been powered to show statistical su periority to 
ustekinumab based on the co -primary endpoints.  
The assumed responder rates for PASI90 at Week  16 are 75%, 58%, and 2% for bimekizumab, 
ustekinumab, and placebo, respectively. Additionally, the assumed responder rates for IGA are 
85%, 68%, and 5% for bimekizumab, ustekinumab, and placebo, respectively. The assumed 
responder rates for bimekizumab are based on the Phase 2b PS0010 data. The assumptions 
related to the responder rates for ustekinumab are based on those observed in the CLEAR study 
(Thaci et al, 2015). The power to show statistical superiority of bimekizumab relative to placebo 
under these assumptions is >99% for the co -primary endpoints.  
The power to detect a statistically significant difference between bimekizumab and ustekinumab 
at a 2-sided significance level of 0.05 is 95% for PASI90 response and 98% for IGA response. 
Because both co -primary endpoints are highly powered independently, and because PASI and 
IGA response tend to be highly correlated, the overall power for achieving sup eriority on both 
co-primary endpoints is not calculated here. Note that the power for the non -inferiority testing 
between bimekizumab and ustekimumab for both PASI90 and IGA responses is >99% based on 
a 1-sided significance level of 0.025 and a non -inferio rity margin of 10%.  
15 ETHICS AND REGULATOR Y REQUIREMENTS  
15.1 Informed consent  
Subject’s informed consent must be obtained and documented in accordance with local 
regulations, ICH -GCP requirements, and the ethical principles that have their origin in the 
principles of the Declaration of Helsinki.  
Prior to obtaining informed consent, information should be given in a language and at a level of 
complexity understandable to the subject in both oral and written form by the Investigator (or 
designee). Each subje ct will have the opportunity to discuss the study and its alternatives with 
the Investigator.  
Prior to participation in the study, the ICF should be signed and personally dated by the subject 
and by the person who conducted the informed consent discussion (Investigator or designee). 
The subject must receive a copy of the signed and dated ICF. As part of the consent process, 
each subject must consent to direct access to his/her medical records for study -related 
monitoring, auditing, IRB/IEC review, and regul atory inspection.  
If the ICF is amended during the study, the Investigator (or the sponsor, if applicable) must 
follow all applicable regulatory requirements pertaining to the approval of the amended ICF by 
the IRB/IEC and use of the amended form.  
All stud ies conducted at centers in the United States must include the use of a Health Insurance 
Portability and Accountability Act Authorization form.  
The subject may withdraw his/her consent to participate in the study at any time. A subject is 
considered as enr olled in the study when he/she has signed the ICF. A eCRF must not be started, 
nor may any study specific procedure be performed for a given subject, without having obtained 
his/her written consent to participate in the study.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 105 of 206 15.2 Subject identification cards  
Upon signing the Informed Consent and Assent form (as applicable), the subject will be provided 
with a subject identification card in the language of the subject. The Investigator will fill in the 
subject identifying information and medical emergency conta ct information. The Investigator 
will instruct the subject to keep the card with him/her at all times.  
15.3 Institutional Review Boards and Independent Ethics 
Committees  
The study will be conducted under the auspices of an IRB/IEC, as defined in local regulatio ns, 
ICH-GCP, and in accordance with the ethical principles that have their origin in the Declaration 
of Helsinki.  
The Investigator/UCB will ensure that an appropriately constituted IRB/IEC that complies with 
the requirements of the current ICH -GCP version or applicable country -specific regulations will 
be responsible for the initial and continuing review and approval of the clinical study. Prior to 
initiation of the study, the Investigator/UCB will forward copies of the protocol, ICF, IB, 
Investigator’s cur riculum vitae (if applicable), advertisement (if applicable), and all other 
subject -related documents to be used for the study to the IRB/IEC for its review and approval.  
Before initiating a study, the Investigator will have written and dated full approval  from the 
responsible IRB/IEC for the protocol.  
The Investigator will also promptly report to the IRB/IEC all changes in the study, all 
unanticipated problems involving risks to human subjects or others, and any protocol deviations, 
to eliminate immediate hazards to subjects.  
The Investigator will not make any changes in the study or study conduct without IRB/IEC 
approval, except where necessary to eliminate apparent immediate hazards to the subjects. For 
minor changes to a previously approved protocol duri ng the period covered by the original 
approval, it may be possible for the Investigator to obtain an expedited review by the IRB/IEC as 
allowed.  
As part of the IRB/IEC requirements for continuing review of approved studies, the Investigator 
will be respons ible for submitting periodic progress reports to the IRB/IEC (based on IRB/IEC 
requirements), at intervals appropriate to the degree of subject risk involved, but no less than 
once per year. The Investigator should provide a final report to the IRB/IEC fol lowing study 
completion.  
UCB (or its representative) will communicate safety information to the appropriate regulatory 
authorities and all active Investigators in accordance with applicable regulatory requirements. 
The appropriate IRB/IEC will also be info rmed by the Investigator or the sponsor, as specified 
by the applicable regulatory requirements in each concerned country. Where applicable, 
Investigators are to provide the sponsor (or its representative) with evidence of such IRB/IEC 
notification.  
15.4 Subjec t privacy  
UCB staff (or designee) will affirm and uphold the subject’s confidentiality. Throughout this 
study, all data forwarded to UCB (or designee) will be identified only by the subject number 
assigned at Screening.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 106 of 206 The Investigator agrees that represe ntatives of UCB, its designee, representatives of the relevant 
IRB/IEC, or representatives of regulatory authorities will be allowed to review that portion of the 
subject’s primary medical records that directly concerns this study (including, but not limit ed to, 
laboratory test result reports, ECG reports, admission/discharge summaries for hospital 
admissions occurring during a subject’s study participation, and autopsy reports for deaths 
occurring during the study).  
15.5 Protocol amendments  
Protocol changes may  affect the legal and ethical status of the study and may also affect the 
statistical evaluations of sample size and the likelihood of the study fulfilling its primary 
objective.  
Significant changes to the protocol will only be made as an amendment to the protocol and must 
be approved by UCB, the IRB/IEC, and the regulatory authorities (if required), prior to being 
implemented.  
16 FINANCE, INSURANCE, AND PUBLICATION  
Insurance coverage will be handled according to local requirements.  
Finance, insurance, and pub lication rights are addressed in the Investigator and/or CRO 
agreements, as applicable.  
17 REFERENCES  
Augustin M, Glaeske G, Radtke MA, Christophers E, Reich K, Schäfer I. Epidemiology and 
comorbidity of psoriasis in children. Br J Dermatol. 2010;162:633 -6. 
Christophers E, Barker JN, Griffiths CE, Daudén E, Milligan G, Molta C, et al. The risk of 
psoriatic arthritis remains constant following initial diagnosis of psoriasis among patients seen in 
European dermatology clinics. J Eur Acad Dermatol Venereol. 2010 ;24:548 -54. 
Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0. National Institutes of 
Health, National Cancer Institute, Division of Cancer Treatment and Diagnosis. 
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.ht m. Updated 03 Mar 
2016.  
CPMP/ICH/135/95 Note for guidance on Good Clinical Practice (EMEA) Jul 2002.  
Dowlatshahi EA, Wakkee M, Arends LR, Nijsten T. The prevalence and odds of depressive 
symptoms and clinical depression in psoriasis patients: a systematic review and meta -analysis. 
J Invest Dermatol. 2014;134:1542 -51. 
Feldman SR. A quantitative definition of severe psoriasis for use in clinical trials. J Dermatolog 
Treat. 2004;15(1):27 -9. 
Food and Drug Administration. Guidance for Industry. Drug -induced live r injury: premarketing 
clinical evaluation. US Dept of Health and Human Services, Center for Drug Evaluation and 
Research, Center for Biologics Evaluation and Research, 07/2009.  
Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myoca rdial 
infarction in patients with psoriasis. JAMA. 2006;296:1735 -41. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 107 of 206 Gisondi P, Tessari G, Conti A, Piaserico S, Schianchi S, Peserico A, et al. Prevalence of 
metabolic syndrome in patients with psoriasis: a hospital -based case -control study. Br J 
Dermatol . 2007;157:68 -73. 
Gottlieb AB. Psoriasis: Emerging therapeutic strategies. Nat Rev Drug Discov. 2005;4:19 -34. 
Husni ME, Qureshi AA, Keonig AS, Pedersen R, Robertson D. Utility of the PASE 
questionnaire, psoriatic arthritis (PsA) prevalenece and PsA improve ment with anti -TNF 
therapy: results from the PRISTINE trial. J Dermatolog Treat. 2014;25(1):90 -5. 
Icen M, Crowson CS, McEvoy MT, Dann FJ, Gabriel SE, Maradit Kremers H. Trends in 
incidence of adult -onset psoriasis over three decades: a population -based stu dy. J Am Acad 
Dermatol. 2009;60:394 -401. 
Kimball AB, Yu AP, Signorovitch J, Xie, J, Tsaneva M, Gupta SR, et al. The effects of 
adalimumab treatment and psoriasis severity on self -reported work productivity and activity 
impairment for patients with moderate  to severe psoriasis. J Am Acad Dermatol. 2012;66(2):e67 -
e75. 
Kroenke K, Spitzer RL, Williams JB. The PHQ -9: validity of a brief depression severity 
measure. J Gen Intern Med. 2001;16:606 –13. 
Krueger G, Ellis CN. Psoriasis –recent advances in understanding its pathogenesis and treatment. 
J Am Acad Dermatol. 2005;53(1 Suppl 1):S94 -100. 
Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on 
quality of Life. Results of a 1998 National Psoriasis Foundation patient -membership surve y. 
Arch Dermatol. 2001;137:280 -4. 
Kurd SK, Smith N, VanVoorhees A, Troxel AB, Badmaev V, Seykora JT, et al. Oral curcumin 
in the treatment of moderate to severe psoriasis vulgaris: a prospective clinical trial. J Am Acad 
Dermatol. 2008;58:625 -31. 
Kurd SK, Gelfand JM. The prevalence of previously diagnosed and undiagnosed psoriasis in US 
adults: results from NHANES 2003 -2004. J Am Acad Dermatol. 2009;60:218 -24. 
Langley RG, Krueger GG, Griffiths CEM. Psoriasis: epidemiology, clinical features, and quality 
of life. Ann Rheum Dis. 2005;64(Suppl II):ii18 –ii23. 
Mallinckrodt CH, Lin Q, Lipkovich I, Molenberghs G. A structured approach to choosing 
estimands and estimators in longitudinal clinical trials. Pharm Stat. 2012;11:456 -61. 
Maruish, ME (Ed.). User’s manual for the SF -36v2 Health Survey (3rd ed.). Lincoln, RI: 
QualityMetric Incorporated. 2011.  
Mukhtar R, Choi J, Koo JY. Quality of life issues in psoriasis. Dermatol Clin. 2004;22:389 -95. 
Mundt JC, Greist JH, Gelenberg AJ, Katzelnick DJ, Jefferson JW, Modell JG . Feasibility and 
Validation of a Computer -Automated Columbia -Suicide severity Rating Scale Using Interactive 
Voice Response Technology. J Psychiatr Res. 2010;44(16):1224 -8. 
Ortonne JP. Redefining clinical response in psoriasis: targeting the pathological basis of disease. 
J Drugs Dermatol. 2004;3:13 -20. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 108 of 206 Parisi R, Symmons DP, Griffiths CE, Ashcroft DM, Identification and Management of Psoriasis 
and Associated ComorbidiTy (IMPACT) project team. Global epidemiology of psoriasis: A 
systematic review of inciden ce and prevalence. J Invest Dermatol. 2013;133:377 -385. 
Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, et al. The 
Columbia -Suicide Severity Rating Scale: Initial Validity and Internal Consistency Findings From 
Three Multisite Studies Wit h Adolescents and Adults. Am J Psychiatry. 2011;168(12):1266 -77. 
Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United 
States. J Am Acad Dermatol. 2014;70:512 -6. 
Raychaudhuri SP, Gross J. A comparative study of pediatric o nset psoriasis with adult onset 
psoriasis. Pediatric Dermatology. 2000; 17(3):174 -78. 
Reilly MC, Zbrozek AS, Dukes EM. The Validity and Reproducibility of a Work Productivity 
and Activity Impairment Instrument. PharmacoEconomics. 1993:4(5):353 -65. 
Rubin D. B. 1987. Multiple Imputation for Nonresponse in Surveys. New York: John Wiley and 
Sons.  
Thaçi D, Blauvelt A, Reich K, et al. Secukinumab is superior to ustekinumab in clearing skin of 
subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am 
Acad Dermatol 2015; 73:400 -09. 
Valizadeh A, Khosravi A, Zadeh LJ, Parizad EG. Role of IL -25 in Immunity. J Clin Diagn Res. 
2015;9(4):OE01 –OE04.  
Vender R, Lynde C, Ho V, Chau D, Poulin -Costello M. Work Productivity and Healthcare 
Reso urce Utilizatioin Outcomes for Patients on Etanercept for Moderate -to-Severe Plaque 
Psoriasis: Results from a 1 -Year, Multicentre, Open -Lable, Single -Arm Study in a Clinical 
Setting. Appl Health Econ Health Policy. 2012:10(5):343 -53. 
Yeung H, Takeshita J, Mehta NN, Kimmel SE, Ogdie A, Margolis DJ, et al. Psoriasis severity 
and the prevalence of major medical comorbidity: a population -based study. JAMA Dermatol. 
2013;149:1173 -9. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 109 of 206 18 APPENDICES  
18.1 Protocol Amendment 1  
Rationale for the amendment  
The purpose of this amendment is the following:   
 To remove the escape arm to allow for a 1 -year comparison of bimekizumab vs ustekinumab 
that is not confounded by an escape arm at Week 16.  
 To remove the mandatory withdrawal at Week 28 or later  
The other changes in this amend ment are as follows:  
 Clarified the number of subjects to be screened  
 Clarified that the secondary objective of the evaluation of bimekizumab compared to 
ustekinumab to be after 4, 12, 16, and 52 weeks of treatment  
 Added assessment of the Patient Symptom Di ary (daily) to the Screening and Week 16 Visits  
 Clarified that the minimum time between doses should be no less than 21 days and no more 
than 35 days  
 Removed the criterion that excluded subjects exposed to more than 3 biologic response 
modifiers (including  no more than 1 IL -17) 
 Clarified that subjects who experienced primary failure (no response within 12 weeks) to 1or 
more IL -17 biologic response modifiers or more than 1 biologic response modifiers other 
than an IL -17 should be excluded from the study  
 Remo ved the withdrawal criterion that subjects who do not achieve a PASI50 response by 
Week 28 or later be withdrawn from the study  
 Clarified that the same assessor should evaluate the subject at each efficacy assessment.  
 Updated the assessment and management of TB and TB risk factors  
 Updated the sequence testing and the analysis of the secondary efficacy variables and other 
efficacy variables  
 Revised the List of Abbreviations  
 
Modifications and changes  
Global changes  
The following changes were made throughout  the protocol:  
 The study design was changed to remove the escape arm.  
 Mandatory withdrawal at Week 28 or later was removed.  
 Minor editorial revisions were made  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 110 of 206 Specific changes  
Change #1  
List of abbreviations  
The following abbreviations have been deleted:  
ESS Escape Subject Set  
MS Maintenance Set  
WK12ResS  Week 12 Responder Set  
 
Change #2  
Section 1  Summary  
Approximately 800 subjects will be screened in order to have 640 subjects randomized in the 
study. For each subject, the study will last a maximum of  72 weeks and will consist of 4 periods, 
a Screening Period (2 to 4 weeks), a double -blind, placebo - and active comparator -controlled 
Initial Treatment Period (16 weeks), a double -blind, active comparator -controlled Maintenance 
Treatment Period (36 weeks),  and a Safety Follow -Up (SFU) Period (20 weeks after the last dose 
of IMP). After the 36 -week Maintenance Treatment Period, eligible subjects will be allowed to 
enroll in an open -label study.  
During the Treatment Period, eligible subjects will be randomize d 4:3:1 to receive the following 
blinded IMP regimens:  
 Bimekizumab 320mg administered sc Q4W  
 Ustekinumab (45mg or 90mg, depending on subject weight) administered sc at Baseline and 
4 weeks later, followed by ustekinumab sc every 12 weeks  
 Placebo administered sc Q4W  
Approximately 320 subjects will be randomized to bimekizumab 320mg, 240 subjects will be 
randomized to ustekinumab, and approximately 80 subjects will be randomized to placebo. 
Investigational medicinal product (IMP) will be ad ministered in the clinic at Baseline and Q4W 
thereafter, until Week 16 (Initial Treatment Period). Additional nondosing study visits will occur 
at Week 1 and Week 2. At Week 16, subjects will enter the Maintenance Treatment Period and 
will be reallocated b ased on original treatment and response to treatment. The Maintenance 
Treatment Period will include dosing Q4W.  
Subjects who do not achieve a PASI90 response at Week  16 of the Initial Treatment will receive 
bimekizumab 320mg Q4W (ie, escape treatment). At Week  52, all subjects enrolling in the open -
label study will undergo the Week  52 study assessments before receiving their first treatment 
dose in the open -label study. All subjects not enrolling in the open -label study will have the 
Week  52 study assessmen ts and will enter the SFU Period.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 111 of 206 Has been changed to:  
 Approximately 750800 subjects will be screened in order to have 560640 subjects 
randomized in the study. For each subject, the study will last a maximum of 72 weeks and 
will consist of 4 periods, a Screening Period (2 to 4 weeks), a double -blind, placebo - and 
active comparator -controlled Initial Treatment Period (16 weeks), a double -blind, active 
comparator -controlled Maintenance Treatment Period (36 weeks), and a Safety Follow -Up 
(SFU) Period (20 weeks after the last dose of IMP). After the 36 -week Maintenance 
Treatment Period, eligible subjects will be allowed to enroll in an open -label study.  
During the Treatment Period, e Eligible subjects will be randomized 4: 23:1 to receive the 
following blinded IMP regimens:  
 Bimekizumab 320mg administered sc Q4W  
 Ustekinumab (45mg or 90mg, depending on subject weight) administered sc at B aseline and 
4 weeks later, followed by ustekinumab sc every 12 weeks  
 Placebo administered sc Q4W for 16 weeks during the Initial Treatment Period, followed 
by bimekizumab 320mg administered sc Q4W during the Maintenance Treatment 
Period  
Approximately 320 s ubjects will be randomized to bimekizumab 320mg, 160240 subjects will be 
randomized to ustekinumab, and approximately 80 subjects will be randomized to placebo. 
Investigational medicinal product (IMP) will be administered in the clinic at Baseline and Q4W 
thereafter, until Week  16 (Initial Treatment Period). Additional nondosing study visits will occur 
at Week  1 and Week  2. At Week  16, subjects will enter the Maintenance Treatment Period  and 
will be reallocated based on original treatment and response to tr eatment . The Maintenance 
Treatment Period will include Q4W  dosing Q4W  for subjects receiving bimekizumab and 
Q12W dosing for subjects receiving usteinumab . 
Subjects who do not achieve a PASI90 response at Week  16 of the Initial Treatment will 
receive bimek izumab 320mg Q4W (ie, escape treatment).  At Week  52, all subjects enrolling 
in the open -label study will undergo the Week  52 study assessments before receiving their first 
treatment dose in the open -label study. All subjects not enrolling in the open -label  study will 
have the Week  52 study assessments and will enter the SFU Period.  
 
Change #3  
Section 2.1.2  Current treatments for psoriasis  
 Brodalumab has been approved in the US for the treatment of moderate to severe plaque 
psoriasis in adult patients who a re candidates for systemic therapy or phototherapy and 
have failed to respond or have lost response to other systemic therapies. Brodalumab is a 
human monoclonal IgG2 antibody that selectively binds to human IL -17RA and inhibits 
its interactions with cytok ines IL -17A, IL -17F, IL -17C, IL -17A/F heterodimer and IL -25. 
Blocking IL  17RA inhibits IL -17 cytokine -induced responses including the release of 
pro-inflammatory cytokines and chemokines. Brodalumab has a black box warning 
regarding suicidal ideation and behavior.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 112 of 206 Has been changed to:  
 Brodalumab has been approved in the US for the treatment of moderate to severe plaque 
psoriasis in adult patients who are candidates for systemic therapy or phototherapy and 
have failed to respond or have lost response to oth er systemic therapies. In the EU, 
brodalumab is indicated for the treatment of moderate to severe plaque PSO in 
adult patients who are candidates for systemic therapy. Brodalumab is a human 
monoclonal IgG2 antibody that selectively binds to human IL -17RA a nd inhibits its 
interactions with cytokines IL -17A, IL -17F, IL -17C, IL -17A/F heterodimer and IL -25. 
Blocking IL  17RA inhibits IL -17 cytokine -induced responses including the release of 
pro-inflammatory cytokines and chemokines. Brodalumab has a black box w arning 
regarding suicidal ideation and behavior.  
 
Change #4  
Section 2.2.1.1  Completed studies  
Four clinical studies of bimekizumab have been completed: UP0008 in 39 subjects with mild to 
moderate plaque PSO, RA0124 in 30 healthy volunteers, PA0007 in 53 s ubjects with PsA, and 
UP0031 in 12 healthy volunteers. Three studies (RA0123, PS0010, and PS0016) are ongoing in 
subjects with moderate to severe rheumatoid arthritis (RA0123) and in subjects with moderate to 
severe PSO (PS0010 and PS0016).  
Has been change d to:  
Four clinical studies of bimekizumab have been completed: UP0008 in 39 subjects with mild to 
moderate plaque PSO, RA0124 in 30 healthy volunteers, PA0007 in 53 subjects with PsA, and 
UP0031 in 12 healthy volunteers. Three studies (RA0123, PS0010, and  PS0016) are ongoing 
in subjects with moderate to severe rheumatoid arthritis (RA0123) and in subjects with 
moderate to severe PSO (PS0010 and PS0016).  
 
Change #5  
Section 2.2.1.2  Ongoing studies  
Five additional studies of bimekizumab in the treatment of P SO are ongoing.  
Has been changed to:  
Four additional studies of bimekizumab in the treatment of PSO and 1 study in healthy 
volunteers are ongoing. Five additional studies of bimekizumab in the treatment of PSO are 
ongoing.  
 
Change #6  
Section 3.2  Secondary  objectives  
The secondary objectives of the study are to:  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 113 of 206  Evaluate the efficacy of bimekizumab compared to placebo at achieving complete clearance 
(PASI100) after 16 weeks of treatment  
 Evaluate the efficacy of bimekizumab compared to placebo after 4 weeks of treatment  
 Evaluate the efficacy of bimekizumab compared to ustekinumab after 12 weeks, 16 weeks, 
and 52  weeks of treatment  
 Evaluate the change in itch, pain, and scaling of bimekizumab compared to placebo after 
16 weeks of treatment as reported by subje cts using the Patient Symptom Diary  
 Evaluate the change in psoriatic scalp disease of bimekizumab compared to placebo after 
16 weeks of treatment in subjects with scalp PSO at Baseline  
 Assess TEAEs, SAEs, and TEAEs leading to withdrawal adjusted by duratio n of subject 
exposure to study treatment  
Has been changed to:  
The secondary objectives of the study are to:  
 Evaluate the efficacy of bimekizumab compared to placebo at achieving complete clearance 
(PASI100) after 16 weeks of treatment  
 Evaluate the efficacy  of bimekizumab compared to placebo after 4 weeks of treatment  
 Evaluate the efficacy of bimekizumab compared to ustekinumab after 4 weeks,  12 weeks, 16 
weeks, and 52  weeks of treatment  
 Evaluate the change in itch, pain, and scaling of bimekizumab compared to placebo after 
16 weeks of treatment as reported by subjects using the Patient Symptom Diary  
 Evaluate the change in psoriatic scalp disease of bimekizumab compared to placebo after 
16 weeks of treatment in subjects with scalp PSO at Baseline  
 
Change #7  
Section 5.2.2  Initial Treatment Period  
During the 16 -week Initial Treatment Period, approximately 640 subjects will be randomized 
4:3:1 to receive the following blinded IMP regimens:  
 Bimekizumab 320mg administered sc Q4W (320 subjects)  
 Ustekinumab (240 sub jects):  
 For subjects weighing ≤100kg (220lbs), 45mg sc initially and 4 weeks later  
 For subjects weighing >100kg (220lbs), 90mg sc initially and 4 weeks later  
 Placebo administered sc Q4W (80 subjects)  
Investigational medicinal product will be administered i n the clinic by sc injection at the time 
points specified in the schedule of assessments (Table 5 -1). 
Has been changed to:  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 114 of 206 During the 16 -week Initial Treatment Period, approximately 560640 subjects will be randomized 
4:23:1 to receive the following blinded  IMP regimens:  
 Bimekizumab 320mg administered sc Q4W (320 subjects)  
 Ustekinumab ( 160240 subjects):  
 For subjects weighing ≤100kg (220lbs), 45mg sc initially and 4 weeks later  
 For subjects weighing >100kg (220lbs), 90mg sc initially and 4 weeks later  
 Placebo  administered sc Q4W (80 subjects)  
Investigational medicinal product will be administered in the clinic by sc injection at the time 
points specified in the schedule of assessments (Table 5 -1). 
 
Change #8  
Section 5.2.3  Maintenance Treatment Period  
Treatmen t during the Maintenance Treatment Period will be based on initial treatment and 
response to treatment at Week  16, per the following rules:  
 All subjects who do not achieve a PASI90 response at Week  16 will be allocated to the 
escape arm and be treated with  bimekizumab 320mg Q4W.  
 Subjects in the bimekizumab 320mg treatment arm who achieve a PASI90 response at 
Week  16 will continue to receive bimekizumab 320mg Q4W.  
 Subjects in the ustekinumab treatment arm who achieve a PASI90 response at Week  16 will 
continu e on ustekinumab (subjects weighing ≤100kg [220lbs] at Baseline will receive 45mg 
sc every 12 weeks; subjects weighing >100kg [220lbs] at Baseline will receive 90mg sc 
every 12 weeks).  
 Subjects in the placebo arm who achieve a PASI90 response at Week  16 wi ll continue on 
placebo.  
Subjects may receive placebo injections at certain visits in order to blind the IMP (see 
Section  7.2). 
If a subject does not  achieve a PASI50 response at Week  28 or later, the subject will be 
withdrawn from the study after that time point.  
At the end of the Maintenance Treatment Period, all subjects enrolling in the open -label study 
will, after signing a new ICF, undergo the We ek 52 study assessments and then receive their first 
dose of bimekizumab in the open -label study. All subjects not enrolling in the open -label study 
will have the Week  52 study assessments and will enter the SFU Period.  
Has been changed to:  
Treatment durin g the Maintenance Treatment Period will be based on initial treatment  and 
response to treatment at Week  16, per the following rules:  
 All subjects who do not achieve a PASI90 response at Week  16 will be allocated to the 
escape arm and be treated with bimeki zumab 320mg Q4W.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 115 of 206  Subjects in the bimekizumab 320mg treatment arm who achieve a PASI90 response at 
Week  16 will continue to receive bimekizumab 320mg Q4W.  
 Subjects in the ustekinumab treatment arm who achieve a PASI90 response at Week  16 
will continue on ustekinumab (subjects weighing ≤100kg [220lbs] at Baseline will receive 
45mg sc every 12 weeks; subjects weighing >100kg [220lbs] at Baseline will receive 90mg 
sc every 12 weeks).  
 Subjects in the placebo arm will receive bimekizumab 320mg  Q4W who achieve a PASI90 
response at Week  16 will continue on placebo . 
Subjects may receive placebo injections at certain visits in order to blind the IMP (see 
Section  7.2). 
If a subject does not achieve a PASI50 response at Week  28 or later, the subject w ill be 
withdrawn from the study after that time point.  
At the end of the Maintenance Treatment Period, all subjects enrolling in the open -label study 
will, after signing a new ICF, undergo the Week  52 study assessments and then receive their first 
dose of bimekizumab in the open -label study. All subjects not enrolling in the open -label study 
will have the Week  52 study assessments and will enter the SFU Period.  
 
Change #9  
Table 5 -1 Schedule of study assessments  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 116 of 206 Visita/ 
Week  
 
Protocol activity  
Screening  Initial Treatment Period  
(weeks after first dose)  Maintenance Treatment Period  
(weeks after first dose)  
SFUb Baseline 
(first 
dose)  
1 2 4 8 12 16 20 24 28 32 36 40 44 48 52/ 
PEOT  
eC-SSRS  X X X X X X X X X X X X X X X X X X 
Patient Symptom Diary (daily)   X X X X X X             
scalp IGA   X Xn Xn Xn Xn Xn Xn   Xn   Xn   Xn  
n For bimekizumab, the minimum time between doses should be no less than 24 days and no more than 32 days.  
Has been changed to:  
Visita/ 
Week  
 
Protocol activity  
Screening  Initial Treatment Period  
(weeks after first dose)  Maintenance Treatment Period  
(weeks after first dose)  
SFUb Baseline 
(first 
dose)  
1 2 4 8 12 16 20 24 28 32 36 40 44 48 52/ 
PEOT  
eC-SSRS  X X X X X X X X X X X X X X X X X X 
Patient Symptom Diary (daily)   X X X X X X  X           
scalp IGA   X Xn Xn Xn Xn Xn Xn   Xn   Xn   Xn  
n For bimekizumab, the minimum time between doses should be no less than 2 14 days and no more than 3 52 days.  
  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 117 of 206 Change #10  
Figure 5 -1 Schematic diagram  
 
Placebo
Bimekizumab 
320mg Q4W
UstekinumabScreening
N=80
N=320
N=240Initial Treatment Period
Week 16
Co-primary Endpoint: 
PASI90 Response and IGA ResponseBimekizumab 
extension study
to evaluate response 
to treatment and 
long-term safety
SFU Visit
20 Weeks after last 
dose for subjects not 
enrolling in extension 
study
Randomization Escape arm:
             Bimekizumab 320mg Q4WPlacebo
UstekinumabMaintenance Period
52 28<PASI90
<PASI90
<PASI90≥PASI90≥PASI90
<PASI90
Baseline
<PASI50: Mandatory study withdrawal<PASI50
<PASI50
<PASI50
<PASI50: Mandatory 
study withdrawal at 
Week 28 or later<PASI50           Bimekizumab 320mg Q4W ≥PASI90N=640
 
IGA=Investigator’s Global Assessment; PASI=Psoriasis Area Severity Index; Q4W=every 4 weeks; SFU=Safety Follow -Up 
Note: If a subject does not achieve a PASI50 response at Week 28 or later, the subject will be withdrawn from the study at the time point when the PASI50 
response is not achieved.  
Has been changed to:  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 118 of 206  
IGA=Investigator’s Global Assessment; PASI=Psoriasis Area Severity Index; Q4W=every 4 weeks; SFU=Safety Follow -Up 
Note: I f a subject does not achieve a PASI50 response at Week 28 or later, the subject will be withdrawn from the study at the time point when the 
PASI50 response is not achieved.  
 
Placebo
Bimekizumab 
320mg Q4W
UstekinumabScreening
N=80
N=320
N=160Initial Treatment Period
Week 16
Co-primary Endpoint: 
PASI90 Response and IGA ResponseBimekizumab 
extension study
to evaluate response 
to treatment and 
long-term safety
SFU Visit
20 Weeks after last 
dose for subjects not 
enrolling in extension 
study
RandomizationUstekinumabMaintenance Period
52 Baseline           Bimekizumab 320mg Q4WN=560           Bimekizumab 320mg Q4W
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 119 of 206 Change #11  
Section 5.4  Planned number  of subjects and site(s)  
Approximately 860 subjects will be screened in order to have 640 subjects randomized in the 
study. There will be approximately 320 subjects in the bimekizumab 320mg treatment arm, 
240 subjects in the ustekinumab treatment arm and 8 0 subjects in the placebo treatment arm. The 
planned number of study sites is approximately 100. Every eligible subject who signs an ICF will 
be randomized.  
Has been changed to:  
Approximately 750860 subjects will be screened in order to have 560640 subject s randomized in 
the study. There will be approximately 320 subjects in the bimekizumab 320mg treatment arm, 
160240 subjects in the ustekinumab treatment arm and 80 subjects in the placebo treatment arm. 
The planned number of study sites is approximately 10 0. Every eligible subject who signs an ICF 
will be randomized.  
 
Change #12  
Section 5.8.1  Study design  
The following text has been deleted:  
The results of the Phase 2b study PS0010 indicate that approximately 80% of subjects in 
the bimekizumab 320mg Q4W tre atment arm achieved a high level of response (PASI90). 
Subjects who do not achieve a PASI90 response at Week 16 are allocated to escape 
treatment with bimekizumab 320mg Q4W. Allocating subjects who do not achieve a 
PASI90 on placebo or ustekinumab to the b imekizumab 320mg Q4W escape arm provides 
them with the opportunity to potentially achieve a higher level of efficacy. Beyond just 
achieving a higher level of skin clearance, there is evidence that PASI90 is associated with 
higher levels of patient satisfac tion (as measured by DLQI) compared with a lower PASI75 
threshold (Puig et al, 2017).  
If subjects are not responding to escape treatment or if they lose response over time, the 
mandatory withdrawal criterion for subjects who do not achieve a PASI50 respons e at 
Week 28 or later will ensure that subjects do not continue to receive prolonged exposure to 
study treatment that is providing a sub -optimal response, regardless of their initial 
randomized treatment . 
 
Change #13  
Section 6.2  Exclusion criterion #22  
The following criterion has been deleted.  
22. Subject has been exposed to more than 3 biological response modifiers (including no 
more than 1 IL -17). 
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 120 of 206 Change #14  
Section 6.2  Exclusion criterion #23  
23. Subject has experienced one primary failure to an IL -17 biological response modifier (no 
response within 12 weeks).  
Has been changed to:  
23. Subject has experienced one primary failure to an IL -17 biological response modifier  (no 
response within 12 weeks) to 1 or more  IL -17 biologic response modifier (eg, 
broda lumab, ixekizumab, secukinumab) OR more than 1 biologic response modifier 
other than an IL -17. 
 
Change #15  
Section 6.3  Withdrawal criterion #3  
The following criterion has been deleted:  
3. Subject does not achieve a PASI50 response at Week 28 or later.  
 
Change  #16 
Section 7.2  Treatment(s) to be administered  
Maintenance Treatment Period dosing  
Investigational medicinal product treatment during the Maintenance Treatment Period will be 
based on initial treatment and response to treatment at Week  16 as described in  Section  5.2.3 . 
 Subjects who will continue to receive placebo will receive 2 placebo injections sc Q4W.  
 Subjects who are to receive bimekizumab 320mg Q4W will receive 2 bimekizumab 160mg 
injections sc Q4W.  
 Subjects randomized to receive ustekinumab will ha ve received ustekinumab sc at Baseline 
and Week  4, and will continue to receive ustekinumab (based on Week  16 response) sc every 
12 weeks (Weeks 16, 28, and 40). Subjects will receive placebo (2 placebo injections sc) on 
non-ustekinumab treatment weeks (We eks 20, 24, 32, 36, 44, and 48). Because ustekinumab 
dosing is based on weight, on ustekinumab treatment weeks subjects ≤100kg (220lbs) will 
receive 1 ustekinumab 45mg sc injection and 1 placebo injection and subjects >100kg 
(220lbs) will receive 2 ustekin umab 45mg sc injections.  
The dosing scheme is depicted in Table 7 -1.  
Table  7-1: Dosing Scheme  
Week  
Dose Assignment  Baseline 
(first 
dose)  4 8 12 16 20 24 28 32 36 40 44 48 
Bimekizumab 
320mg Q4W  ●● ●● ●● ●● ●● ●● ●● ●● ●● ●● ●● ●● ●● 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 121 of 206 Table  7-1: Dosing Scheme  
Ustekinumab 45mg 
(subjects ≤100kg)  ▲○ ▲○ ○○ ○○ ▲○ ○○ ○○ ▲○ ○○ ○○ ▲○ ○○ ○○ 
Ustekinumab 90mg 
(subjects >100kg)  ▲▲  ▲▲  ○○ ○○ ▲▲  ○○ ○○ ▲▲  ○○ ○○ ▲▲  ○○ ○○ 
Placebo  ○○ ○○ ○○ ○○ ○○ ○○ ○○ ○○ ○○ ○○ ○○ ○○ ○○ 
NR=nonresponder; Q4W=every 4 weeks  
Notes: A bimekizumab 160mg injection is depicted by a black circle (●). A placebo injection is depicted by a white 
circle (○). A  ustekinumab  45mg injection is depicted by a black triangle ( ▲). 
Note: Subjects who enter the bimekizumab 320mg Q4W escape arm will follow the Maintenance dosing scheme  
depicted above for the bimekizumab 320mg Q4W/Q4W group.  
Has been changed to:  
Maintenance Treatment Period dosing  
Investigational medicinal product treatment during the Maintenance Treatment Period will be 
based on initial treatment and response to treatment at Week  16 as described in Section  5.2.3 . 
 Subjects who will continue to receive placebo will receive 2 placebo injections sc Q4W.  
 Subjects who are to receive bimekizumab 320mg Q4W  received bimekizumab or 
placebo in the Initial Treatment Period wi ll receive 2 bimekizumab 160mg injections sc 
Q4W.  
 Subjects randomized to receive ustekinumab will have received ustekinumab sc at Baseline 
and Week  4, and will continue to receive ustekinumab sc every 12 weeks (Weeks 16, 28, and 
40). Subjects will receive placebo (2 placebo injections sc) on non -ustekinumab treatment 
weeks (Weeks 20, 24, 32, 36, 44, and 48). Because ustekinumab dosing is based on weight, 
on ustekinumab treatment weeks subjects ≤100kg (220lbs) will receive 1 ustekinumab 45mg 
sc injection and  1 placebo injection and subjects >100kg (220lbs) will receive 2 ustekinumab 
45mg sc injections.  
The dosing scheme is depicted in Table 7 -1.  
Table  7-1: Dosing Scheme  
Week  
Dose Assignment  Baseline 
(first 
dose)  4 8 12 16 20 24 28 32 36 40 44 48 
Bimekizumab 
320mg Q4W  ●● ●● ●● ●● ●● ●● ●● ●● ●● ●● ●● ●● ●● 
Ustekinumab 45mg 
(subjects ≤100kg)  ▲○ ▲○ ○○ ○○ ▲○ ○○ ○○ ▲○ ○○ ○○ ▲○ ○○ ○○ 
Ustekinumab 90mg 
(subjects >100kg)  ▲▲  ▲▲  ○○ ○○ ▲▲  ○○ ○○ ▲▲  ○○ ○○ ▲▲  ○○ ○○ 
Placebo  ○○ ○○ ○○ ○○ ●● ●● ●● ●● ●● ●● ●● ●● ●● 
NR=nonresponder; Q4W=every 4 weeks  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 122 of 206 Notes: A bimekizumab 160mg injection is depicted by a black circle ( ●). A placebo injection is depicted by a white 
circle (○). A  ustekinumab  45mg injection is depicted by a black triangle ( ▲). 
Note: Subjects who enter  the bimekizumab 320mg Q4W escape arm will follow the Maintenance dosing 
scheme depicted above for the bimekizumab 320mg Q4W/Q4W group.  
 
Change #17  
Table 7 -2 Prohibited psoriasis medications  
Anti-IL-17 therapy  
 3 months  
(bimekizumab is excluded per exclusion 
criteria)  
Has been changed to:  
Anti-IL-17 therapy  
secukinumab  
ixekizumab  
brodalumab  3 months  
(bimekizumab is excluded per exclusion 
criteria)  
 
Change #18  
Section 7.10  Randomization and numbering of subjects  
An IRT will be used for assigning eligible subjects to a treatment regimen based on a 
predetermined production randomization and/or packaging schedule provided by UCB (or 
designee). The randomization schedule will be produced by the IRT vendor. The IRT will 
generate individual assignments for subject kits of IMP, as appropriate, according to the visit 
schedule. Subject treatment assignment will be stratified by region and prior biologic exposure 
(yes/no). The IRT will generate individual assignments for subject kits of IMP, as appropriate, 
according to the visit schedule. Efforts should be made to limit the enrollment of subjects with 
prior biologic exposure to approximately 30% of the total study population.  
Has been changed to:  
An IRT will be used for assigning eligible subjects to a treat ment regimen based on a 
predetermined production randomization and/or packaging schedule provided by UCB (or 
designee). The randomization schedule will be produced by the IRT vendor. The IRT will 
generate individual assignments for subject kits of IMP, as appropriate, according to the visit 
schedule. Subject treatment assignment will be stratified by region and prior biologic exposure 
(yes/no). The IRT will generate individual assignments for subject kits of IMP, as 
appropriate, according to the visit sched ule. Efforts should be made to limit the enrollment of 
subjects with prior biologic exposure to approximately 30% of the total study population.  
 
Change #19  
Section 8.1  Screening Visit (2 to 4 Weeks)  
The following procedures/assessments will be performed a t the Screening Visit:  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 123 of 206  eC-SSRS  
 Concomitant medication  
Has been changed to:  
The following procedures/assessments will be performed at the Screening Visit:  
 eC-SSRS  
 Patient Symptom Diary (daily)  
 Concomitant medication  
 
Change #20  
Section 8.2.2  Week  1 Visit (± 3 days relative to Baseline)  
The bullet for PHQ -9 has been deleted.  
 
Change #21  
Section 8.2.6  Week  12 Visit (±3  days relative to Baseline)  
The bullet for WPAI -SHP V2.0 has been deleted.  
 
Change #22  
Section 8.2.7  Week  16 Visit (±3  days relative to Baseline)  
The following procedures/assessments will be performed/recorded prior to administration of 
IMP:  
 eC-SSRS  
 scalp IGA for subjects with scalp involvement at Baseline  
Has been changed to:  
The following procedures/assessments will be performed/recorded prior to  administration of 
IMP:  
 eC-SSRS  
 Patient Symptom Diary (daily)  
 scalp IGA for subjects with scalp involvement at Baseline  
 
Change #23  
Section 9  Assessment of Efficacy  
The following text has been added:  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 124 of 206 The PASI, IGA, scalp IGA, mNAPSI, and pp -IGA should be p erformed by the Investigator, 
another delegated physician, or an appropriately qualified medical professional (based on local 
requirements) who has had documented training on how to perform these assessments correctly. 
Preferably the same assessor should e valuate the subject at each assessment.  
 
Change #24  
Section 9.1  Psoriasis Area and Severity Index  
The percent area of involvement (BSA%) is estimated across 4 body areas; head, upper 
extremities, trunk, and lower extremities. Assessors will enter the degre e of involvement for a 
given region as a percentage (0 -100%) which will then be mapped into a grade on a scale of 0 -6 
(0=none; 1=1% to <10% affected, 2=10% to <30% affected, 3=30% to <50% affected, 4=50% to 
<70% affected, 5=70% to <90% affected, 6=90% to 1 00% affected) (Table 9 -1). 
The Investigator assesses the average redness, thickness, and scaliness of lesions in each body 
area (each on a 5 point scale); 0=none, 1=slight, 2=moderate, 3=marked, and 4=very marked.  
The PASI score ranges from 0 to 72 with a higher score indicating increased disease severity.  
Table  9-1: Body areas for calculation of percent BSA for PASI  
Body area  Details of area  BSA  Degree of 
involvement of 
body areaa 
Head  Face, back of head  10% 0 to 6 
Upper extremities  Left, right, upper lower, flexor 
surface, extensor surface  20% 0 to 6  
Trunk  Front, back, groin  30% 0 to 6  
Lower extremities  Left, right, upper lower, flexor 
surface, extensor surface, including 
buttocks  40% 0 to 6  
Total   100%   
BSA=body surface area; PASI=Psoriasis Area and Severity Index  
a Where 0=none; 1=1% to <10% affected; 2=10% to <30% affected; 3=30% to <50% affected; 4=50% to <70% 
affected; 5=70% to <90% affecte d; 6=90% to 100% affected  
The PASI50, PASI75, PASI90, and PASI100 responses are based on at least 50%, 75%, 90%, 
and 100% improvement in the PASI score, respectively.  
The total BSA affected by PSO will be derived based on the regional BSA values provided w hen 
assessing the PASI score.  
The PASI will be completed at the visits specified in Table 5 -1. 
Has been changed to:  
The percent area of involvement (BSA%) is estimated across 4 body areas; head, upper 
extremities, trunk, and lower extremities. Assessors wi ll enter the degree of involvement for a 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 125 of 206 given region as a percentage (0 -100%) which will then be mapped into a grade  on a scale of 
0 to 6 (0=none; 1=1% to <10% affected, 2=10% to <30% affected, 3=30% to <50% affected, 
4=50% to <70% affected, 5=70% to <90%  affected, 6=90% to 100% affected) (Table 9 -1). 
The Investigator assesses the average redness, thickness, and scaliness of lesions in each body 
area (each on a 5 point scale); 0=none, 1=slight, 2=moderate, 3=marked, and 4=very marked.  
The PASI score ranges  from 0 to 72 with a higher score indicating increased disease severity.  
Table  9-1: Body areas for calculation of percent BSA for PASI  
Body area  Details of area  BSA  Degree of 
involvement of 
body areaa 
Head  Face,  back of head  10% 0 to 6  
Upper extremities  Left, right, upper lower, flexor 
surface, extensor surface  20% 0 to 6  
Trunk  Front, back, groin  30% 0 to 6  
Lower extremities  Left, right, upper lower, flexor 
surface, extensor surface, including 
buttocks  40% 0 to 6 
Total   100%   
BSA=body surface area; PASI=Psoriasis Area and Severity Index  
a Where 0=none; 1=1% to <10% affected; 2=10% to <30% affected; 3=30% to <50% affected; 4=50% to <70% 
affected; 5=70% to <90% affected; 6=90% to 100% affected  
The PASI50, PASI75, PASI90, and PASI100 responses are based on at least 50%, 75%, 90%, 
and 100% improvement in the PASI score, respectively.  
The total BSA affected by PSO will be entered as a percentage from 0  to 100 derived based 
on the regional BSA values provided when assessing the PASI score . 
The PASI will be completed at the visits specified in Table 5 -1. 
 
Change #25  
Section 9.11  Patient Symptom Diary responses  
UCB developed a new PRO measure that will be u sed to assess key symptoms relevant to 
patients with moderate to severe chronic plaque PSO. PS0010 used the draft PRO measure in 
selected countries to enable psychometric validation of the PRO. Site staff will train the 
participating subjects on the use of  the electronic PRO (ePRO) diary at the BaselineVisit, 
following which the device will be dispensed to the subject for home use until the Week 16 Visit. 
The ePRO diary will be administered on a daily basis from Baseline to the Week 16 Visit.  
Has been chang ed to:  
UCB developed a new PRO measure that will be used to assess key symptoms relevant to 
patients with moderate to severe chronic plaque PSO. PS0010 used the draft PRO measure in 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 126 of 206 selected countries to enable psychometric validation of the PRO. Site staf f will train the 
participating subjects on the use of the electronic PRO (ePRO) diary at the Screening Baseline  
Visit, following which the device will be dispensed to the subject for home use until the Week 16 
Visit. The ePRO diary will be administered on a  daily basis from Screening Baseline  to the 
Week 16 Visit.  
 
Change #26  
Section 12.1.1.4  Other safety topics of interest  
The following paragraph was deleted:  
The following safety topics are prespecified as being of interest for this study, based on 
findings from the IMP clinical program to date, potential risks generally associated with 
biologic immunomodulators, or findings from other medicines belonging to the same class 
of drugs. There are no specific AE reporting requirements for these topics, however spe cial 
monitoring, additional data collection activities, and/or enhanced signal detection activities 
(within UCB), are in place.  
 
Change #27  
Section 12.2  Laboratory measurements  
Clinical laboratory assessments consist of serum chemistry, hematology, and uri nalysis. A 
centralized laboratory will be used to supply all laboratory test supplies and analyze all blood 
and urine samples for hematology, biochemistry, and urinalysis measurements. Any unscheduled 
laboratory testing should also be collected using the c entral laboratory. Testing to rule out 
hepatitis B, hepatitis C, and HIV (see Exclusion Criterion #9 , Section  6.2) will be performed at 
Screening in addition to those measurements listed in Table 12 -2. 
Specific details regarding the handling and processing  of serum chemistry, hematology, and 
urinalysis samples are provided in the study laboratory manuals.  
The following laboratory parameters will be measured:  
Table  12-2: Laboratory measurements  
Hematology  Chemistry  Urinalysis dipsticka 
Basophils  Calcium  pH 
Eosinophils  Chloride  Albumin (protein)  
Lymphocytes  Magnesium  Glucose  
Atypical lymphocytes  Potassium  Blood  
Monocytes  Sodium  Leukocyte esterase  
Neutrophils  Glucose  Nitrite  
Hematocrit  BUN  Urine dipstick for pregnancy testingb 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 127 of 206 Table  12-2: Laboratory measurements  
Hematology  Chemistry  Urinalysis dipsticka 
Hemoglobin  Creatinine   
MCH  ALP   
MCHC  AST   
MCV  ALT   
Platelet count  GGT   
RBC count  Total bilirubin   
WBC count  LDH   
 Serum pregnancy testingc  
ALP=alkaline phosphatase; ALT=alanine aminotransferase; AST=aspartate aminotransferase; BUN=blood urea 
nitrogen; ; GGT=gamma glutamyltransferase; LDH=lactate dehydrogenase; MCH=mean corpuscular hemoglobin; 
MCHC=mean corpuscular hemoglobin concentration; MCV=mean corpuscular volume; RBC=red blood cell; 
WBC=white blood cell  
a A urine microscopic examination will be performed if t he result for albumin (protein), leukocyte esterase, blood or 
nitrite is abnormal. A urine microscopic examination will include: WBC, RBC, epithelial cells (squamous, 
transitional and renal tubular), hyaline casts, WBC casts, RBC casts, waxy casts, granula r casts, calcium oxalate 
crystals, uric acid crystals, triphosphate crystals, yeast, bacteria, amorphous urates, and amorphous phosphates.  
b Pregnancy testing will consist of serum testing at the Screening. The pregnancy test will be urine at all other vis its. 
Has been changed to:  
Clinical laboratory assessments consist of serum chemistry, hematology, urinalysis, and urine 
drug screen. A centralized laboratory will be used to supply all laboratory test supplies and 
analyze all blood and urine samples for hematology, biochemistry, and urinalysis measurements. 
Any unscheduled laboratory testing should also be collected using the central laboratory. Testing 
to rule out hepatitis B, hepatitis C, and HIV (see Exclusion Criterion # 9, Section  6.2) will be 
perform ed at Screening in addition to those measurements listed in Table 12 -2. 
Specific details regarding the handling and processing of serum chemistry, hematology, and 
urinalysis samples are provided in the study laboratory manuals.  
The following laboratory par ameters will be measured:  
Table  12-2: Laboratory measurements  
Hematology  Chemistry  Urinalysis dipsticka 
Basophils  Calcium  pH 
Eosinophils  Chloride  Albumin (protein)  
Lymphocytes  Magnesium  Glucose  
Atypical lymphocytes  Potassium  Blood  
Monocytes  Sodium  Leukocyte esterase  
Neutrophils  Glucose  Nitrite  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 128 of 206 Table  12-2: Laboratory measurements  
Hematology  Chemistry  Urinalysis dipsticka 
Hematocrit  BUN  Urine dipstick for pregnancy testingb 
Hemoglobin  Creatinine  Urine drug screenc 
MCH  ALP   
MCHC  AST   
MCV  ALT   
Platelet count  GGT   
RBC count  Total bilirubin   
WBC count  LDH   
 Serum pregnancy testingc  
ALP=alkaline phosphatase; ALT=alanine aminotransferase; AST=aspartate aminotransferase; BUN=blood urea 
nitrogen; ; GGT=gamma glutamyltransferase; LDH=lactate dehydrogenase; MCH=mean corpuscular hemoglobin; 
MCHC=mean corpuscular hemoglo bin concentration; MCV=mean corpuscular volume; PEOT=Premature End of 
Treatment;  RBC=red blood cell; WBC=white blood cell  
a A urine microscopic examination will be performed if the result for albumin (protein), leukocyte esterase, blood or 
nitrite is abno rmal. A urine microscopic examination will include: WBC, RBC, epithelial cells (squamous, 
transitional and renal tubular), hyaline casts, WBC casts, RBC casts, waxy casts, granular casts, calcium oxalate 
crystals, uric acid crystals, triphosphate crystals,  yeast, bacteria, amorphous urates, and amorphous phosphates.  
b Pregnancy testing will consist of serum testing at the Screening Visit . The pregnancy test will be urine at all other 
visits.  
c Urine drug screen will be performed at Screening Visit and PEOT Visit.  
 
Change #28  
Section 12.3.1  Assessment and management of TB and TB risk factors, Item d  
d. Current or history of NTMB infection despite prior or current therapy.  
Has been changed to:  
d. NTMB infection is defined as a clinical infection caused by mycobacterial species other 
than those belonging to the Mycobacterium tuberculosis complex Current or history of 
NTMB infection despite prior or current therapy . 
 
Change #29  
Section 12.3.1.1  Tuberculosis assessment by IGRA  
During conduct of the study, the T B assessment by IGRA (QuantiFERON TB GOLD is 
recommended) will be performed as described in Table 5 -1 for all subjects. The test results will 
be reported as positive, negative, or indeterminate. Positive TB test results must be reported as an 
adverse event  and appropriately updated once the final diagnosis is known (e.g. active TB, latent 
TB, or false positive TB test). UCB also recommends that a  TB specialist be consulted  where TB 
(latent or active) is suspected or if there are doubts regarding test result s. If latent or active TB is 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 129 of 206 identified, subject must undergo appropriate study -specified withdrawal procedures. The retest 
during Screening must be done during the protocol -defined Screening window.  
Has been changed to:  
During conduct of the study, the TB  assessment by IGRA (QuantiFERON TB GOLD is 
recommended) will be performed as described in Table  5‒1 for all subjects. The test results will 
be reported  as positive, negative, or indeterminate. Positive and indeterminate  TB test results 
must be reported as an adverse event and appropriately updated once the final diagnosis is 
known (eg, active TB, latent TB, or false positive TB test). UCB also recommends  that a  TB 
specialist be consulted  where TB (latent or active) is suspected or if there are doubts regarding 
test results. If latent or active TB is identified, subject must undergo appropriate study -specified 
withdrawal procedures. The retest during Scree ning must be done during the protocol -defined 
Screening window.  
 
Change #30  
Section 14.1  Definition of analysis sets  
The Enrolled Set (ES) will consist of all subjects who have given informed consent.  
The Randomized Set (RS) will consist of all randomized subjects.  
The Safety Set (SS) will consist of all subjects that received at least 1 dose of the IMP.  
The Full Analysis Set (FAS) will consist of all randomized subjects that received at least 1 dose 
of the IMP and have a valid measurement of the co -primary  efficacy variables at Baseline.  
The Escape Subject Set (ESS) will consist of all subjects who receive at least 1 dose of escape 
bimekizumab treatment at Week  16 or later.  
The Week  16 Responder Set (WK16ResS) will consist of all subjects who achieve a PASI 90 
response at Week  16 and receive at least 1 dose of blinded maintenance treatment at Week  16 or 
later.  
The Maintenance Set (MS) will consist of all subjects who have a PASI score at Week  16 to 
evaluate response and who receive at least 1 dose of maintena nce treatment at Week  16 or later. 
Note that the MS combines the ESS and the WK16ResS.  
The Active Medication Set (AMS) will consist of all subjects who have received at least 1 dose 
of active IMP (bimekizumab or ustekinumab). The AMS will be used for summa ries of safety 
that include all data from Baseline (Week  0) to Week  52. 
The Per -Protocol Set (PPS) will consist of all subjects in the RS who had no important protocol 
deviations affecting the primary efficacy variable. Important protocol deviations will b e 
predefined and subjects with important protocol deviations will be evaluated during ongoing data 
cleaning meetings prior to unblinding of the data.  
Has been changed to:  
The Enrolled Set (ES) will consist of all subjects who have given informed consent.  
The Randomized Set (RS) will consist of all randomized subjects.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 130 of 206 The Safety Set (SS) will consist of all subjects that received at least 1 dose of the IMP.  
The Full Analysis Set (FAS) will consist of all randomized subjects that received at least 1 dose 
of the IMP and have a valid measurement of the co -primary efficacy variables at Baseline.  
The Escape Subject Set (ESS) will consist of all subjects who receive at least 1 dose of 
escape bimekizumab treatment at Week  16 or later.  
The Week  16 Responder Set (WK 16ResS) will consist of all subjects who achieve a PASI90 
response at Week  16 and receive at least 1 dose of blinded maintenance treatment at 
Week  16 or later.  
The Maintenance Set (MS) will consist of all subjects who have a PASI score at Week  16 to 
evalua te response and who receive at least 1 dose of maintenance treatment at Week  16 or 
later. Note that the MS combines the ESS and the WK16ResS.  
The Active Medication Set (AMS) will consist of all subjects who have received at least 1 dose 
of active IMP (bime kizumab or ustekinumab). The AMS will be used for summaries of safety 
that include all data from Initial Treatment Period and/or Maintenance Treatment 
Period from Baseline (Week  0) to Week  52. 
The Per -Protocol Set (PPS) will consist of all subjects in the R S who had no important protocol 
deviations affecting the primary efficacy variable. Important protocol deviations will be 
predefined and subjects with important protocol deviations will be evaluated during ongoing data 
cleaning meetings prior to unblinding  of the data.  
 
Change #31  
Section 14.2  General statistical considerations  
The hypotheses (H 1, H2, H3, H4, H5, H6, H7, H8, H9, H10, H11, H12, H13, H14, H15, and H16) 
comparing bimekizumab vs. placebo or bimekizumab vs. ustekinumab will be tested at a 2-sided 
alpha level of 0.05.  
Has been changed to:  
The hypotheses (H 1, H2, H3, H4, H5, H6, H7, H8, H9, H10, H11, H12, H13, H14, H15, and H16, and H 17) 
comparing bimekizumab vs. placebo or bimekizumab vs. ustekinumab will be tested at a 2 -sided 
alpha level of 0.05.  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 131 of 206 Change #32  
Figure 14 -1 Sequence of testing  
 
BL=Baseline; Chg=change; DLQI=Dermatology Life Quality Index; IGA=Investigator’s Global Assessment; 
PASI=Psoriasis Area Severity Index; PSD=Patient Symptom Diary; PSO=psoriasis  
Has been changed to:  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 132 of 206  
BL=Baseline;  Chg=change; DLQI=Dermatology Life Quality Index;  IGA=Investigator’s Global Assessment; 
PASI=Psoriasis Area Severity Index; PSD=Patient Symptom Diary; PSO=psoriasis  
 
Change #33  
Section 14.3.1.1  Sensitivity analyses  
As a sensitivity analysis to t he primary analysis method, logistic regression based on the RS will 
be used. The odds ratio of the responder rates at Week  16 will be estimated and tested between 
treatment groups using a logistic regression model with factors of treatment group, region, and 
prior biologic exposure (yes/no). The odds ratio, associated CI, and p -value based on the Wald 
test will be presented. If the logistic regression model is unable to converge, then prior biologic 
exposure may be dropped from the model to facilitate conv ergence. If the model is still unable to 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 133 of 206 converge, then region may be removed from the model as well. As with the primary analysis, 
missing data will be handled using NRI.  
The center -by-treatment interaction will be tested by replacing region with center i n the logistic 
regression model described above and adding a center -by-treatment interaction term. In the 
model, center will be based on the original centers prior to pooling. However, if the model is 
unable to converge due to a low number of subjects at a  given center, a pooling (to be described 
in the SAP) will be applied in order to allow the model to converge.  
In order to obtain reasonable estimates of variability for a treatment arm at a given center, a 
minimum of 24 subjects will be considered accepta ble for a center to be included in the model 
without pooling. Given the 4:3:1 randomization allocation scheme, this should provide a 
minimum of about 12 subjects in the bimekizumab arm, 9 subjects in the ustekinumab arm, and 
3 subjects in the placebo arm. Centers with fewer than 24 subjects will be eligible for pooling.  
The following center pooling algorithm will be used for each geographic region:  
 If a center has 24 or more subjects, then no pooling will be done for that center.  
 Centers with fewer than 24 subjects will be ordered from largest to smallest with pooling 
proceeding in the following manner:  
 Two or more centers will be combined until the cumulative subject total is at least 24.  
 Once a pooled center has at least 24 subjects, the process will conti nue in an iterative 
fashion for the subsequent centers in the ordered list, where a new pooled center begins 
each time at least 24 subjects has been reached in the previous pool.  
 If this iterative process reaches the end of the ordered list of centers wher e the final 
pooled center has fewer than 24 subjects, then the subjects from the centers in that pool 
will be combined with the pooled center formed in the previous iteration.  
This procedure is only to be performed within a geographic region – there will b e no pooling of 
centers across regions.  
Has been changed to:  
As a sensitivity analysis to the primary analysis method, logistic regression based on the RS will 
be used. The odds ratio of the responder rates at Week  16 will be estimated and tested between 
treatment groups using a logistic regression model with factors of treatment group, region, and 
prior biologic exposure (yes/no). The odds ratio, associated CI, and p -value based on the Wald 
test will be presented. If the logistic regression model is unable  to converge, then prior biologic 
exposure may be dropped from the model to facilitate convergence. If the model is still unable to 
converge, then region may be removed from the model as well. In addition, if the logistic 
regression model cannot converge due to lack of any placebo responders, then Fisher’s 
exact test will be used for inferential comparisons to placebo.  As with the primary analysis, 
missing data will be handled using NRI.  
The center -by-treatment interaction will be tested by replacing regio n with center in the logistic 
regression model described above and adding a center -by-treatment interaction term. In the 
model, center will be based on the original centers prior to pooling. However, if the model is 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 134 of 206 unable to converge due to a low number o f subjects at a given center, a pooling (to be described 
in the SAP) will be applied in order to allow the model to converge.  
In order to obtain reasonable estimates of variability for a treatment arm at a given center, a 
minimum of 2124 subjects will be c onsidered acceptable for a center to be included in the model 
without pooling. Given the 4: 23:1 randomization allocation scheme, this should provide a 
minimum of about 12 subjects in the bimekizumab arm, 69 subjects in the ustekinumab arm, and 
3 subjects i n the placebo arm. Centers with fewer than 2124 subjects will be eligible for pooling.  
The following center pooling algorithm will be used for each geographic region:  
 If a center has 2124 or more subjects, then no pooling will be done for that center.  
 Cent ers with fewer than 2124 subjects will be ordered from largest to smallest with pooling 
proceeding in the following manner:  
 Two or more centers will be combined until the cumulative subject total is at least 2124. 
 Once a pooled center has at least 2124 subjects, the process will continue in an iterative 
fashion for the subsequent centers in the ordered list, where a new pooled center begins 
each time at least 2124 subjects has been reached in the previous pool.  
 If this iterative process reaches the end of t he ordered list of centers where the final 
pooled center has fewer than 2124 subjects, then the subjects from the centers in that pool 
will be combined with the pooled center formed in the previous iteration.  
This procedure is only to be performed within a  geographic region – there will be no pooling of 
centers across regions.  
 
Change #34  
Section 14.3.2.1.2  Maintenance Treatment Period  
Because it is anticipated that most placebo subjects will escape to bimekizumab treatment at 
Week  16, statistical compariso ns against placebo after Week  16 will not be performed. However, 
bimekizumab will be compared to ustekinumab at Week  52 for the RS. The analysis of PASI90 
and IGA at Week  52 will be based on a stratified CMH test where region and prior biologic 
exposure wi ll be used as stratification variables. Pairwise treatment comparisons will be made 
based on the p -value for the general association.  
Missing data will be imputed using NRI. Subjects who do not achieve a PASI90 response at 
Week 16 and are therefore eligibl e for escape will be treated as PASI90 and IGA nonresponders 
at Week 52. All other subjects with missing data at Week 52 or who discontinue study treatment 
prior to Week 52 will also be treated as non -responders for this secondary efficacy analysis. 
Furthe rmore, since subjects who do not achieve a PASI50 response at Week 28 or beyond are to 
be removed from the study, all such subjects will also be treated as non -responders at Week 52, 
whether or not they were actually removed from the study.  
Has been change d to:  
Because it is anticipated that most all placebo subjects will escape to receive  bimekizumab 
treatment starting  at Week  16, statistical comparisons against placebo after Week  16 will not be 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 135 of 206 performed. However, bimekizumab will be compared to ustekinumab at Week  52 for the RS. 
The analysis of PASI90 and IGA at Week  52 will be based on a stratified CMH test where reg ion 
and prior biologic exposure will be used as stratification variables. Pairwise treatment 
comparisons will be made based on the p -value for the general association.  
Missing data will be imputed using NRI. Subjects who do not achieve a PASI90 response at  
Week 16 and are therefore eligible for escape will be treated as PASI90 and IGA 
nonresponders at Week 52. All other subjects with missing data at Week 52 or who 
discontinue study treatment prior to Week 52 will also  be treated as non -responders for this 
secondary efficacy analysis. Furthermore, since subjects who do not achieve a PASI50 
response at Week 28 or beyond are to be removed from the study, all such subjects will also 
be treated as non -responders at Week 52, whether or not they were actually remov ed from 
the study.  
 
Change #35  
Section 14.3.2.2  Analysis of the other efficacy variables  
The other efficacy variables in the Initial Treatment Period will be analyzed for all subjects in the 
RS. For the Maintenance Period, summaries will primarily be based  on the MS (or split between 
the ESS and Wk16ResS as appropriate).  
Binary (responder) variables will be summarized using frequency tables by treatment group for 
each visit.  
Continuous variables will be summarized using descriptive statistics by treatment group for each 
visit.  
… 
For other efficacy variables during the Maintenance Treatment Period, summaries will include 
the bimekizumab and ustekinumab treatment groups. Placebo will not be included in these 
summaries as few placebo subjects are expected to c ontinue on placebo during the Maintenance 
Treatment Period. Details of these summaries will be described further in the SAP, but there will 
be 3 key approaches for understanding the data in the Maintenance Treatment Period:  
1. Summary of data for the RS th rough Week 52 based on randomized treatment group. 
Subjects who escape at Week 16 will be treated as non -responders during Maintenance (for 
responder variables) or have their Week 16 values carried forward (for continuous variables).  
2.  Summary of Mainten ance Treatment Period data among responders only (ie, WK16ResS).  
3. Summary of Maintenance Treatment Period data for subjects who escape at Week 16 (ie, 
ESS) by treatment group at randomization.  
Has been changed to:  
The other efficacy variables in the Init ial Treatment Period will be analyzed for all subjects in the 
RS. For the Maintenance Treatment Period, summaries will primarily  be based on the MS (or 
split between the ESS RS and Wk16ResS as appropriate) . Full details will be specified in 
the SAP.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 136 of 206 Binary  (responder) variables will be summarized using frequency tables by treatment group for 
each visit.  
Continuous variables will be summarized using descriptive statistics by treatment group for each 
visit.  
… 
For other efficacy variables during the Maintenanc e Treatment Period, summaries will include 
the bimekizumab and ustekinumab treatment groups. Placebo will not be included in these 
summaries as few placebo subjects are expected to continue on placebo during the 
Maintenance Treatment Period.  Details of the se summaries will be described further in the 
SAP, but there will be 32 key approaches for understanding the data in the Maintenance 
Treatment Period:  
1. Summary of data for the RS through Week 52 based on randomized treatment group. Subjects 
who escape at  Week 16 will be treated as non -responders during Maintenance (for 
responder variables) or have their Week 16 values carried forward (for continuous 
variables).  
2.  Summary of Maintenance Treatment Period data among responders only (ie, WK16ResS).  
3. Summary of Maintenance Treatment Period data for subjects who escape at Week 16 
(ie, ESS) by treatment group at randomization.  
 
Change #36  
Section 14.5.1  Safety analyses  
Safety variables will be analyzed for all subjects in the SS. The AMS will be used for  summaries 
of safety that include all data from Baseline (Week  0) to Week  52. 
Adverse events will be coded according to the Medical Dictionary for Regulatory Activities 
(MedDRA). Adverse events will be summarized descriptively by treatment group, primary 
system organ class, High Level Term (HLT), and preferred term. Additional tables will 
summarize AEs by intensity and relationship to IMP, AEs leading to withdrawal from the study, 
SAEs, and deaths. Adverse Events of Special Monitoring will be summarized and  will be 
described in greater detail in the SAP.  
Has been changed to:  
Safety variables will be analyzed for all subjects in the SS. The AMS will be used for summaries 
of safety that include data from Baseline (Week  0) to Week  52the Initial Treatment Period  
and/or Maintenance Treatment Period . 
Adverse events will be coded according to the Medical Dictionary for Regulatory Activities 
(MedDRA). Adverse events will be summarized descriptively by treatment group, primary 
system organ class, High Level Term (HLT) , and preferred term. Additional tables will 
summarize AEs by intensity and relationship to IMP, AEs leading to withdrawal from the study, 
SAEs, and deaths. Adverse Events of Special Monitoring Specific safety topics of interest  will 
be summarized and will be described in greater detail in the SAP.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 137 of 206 Change #37  
Section 14.7  Handling of dropouts or missing data  
For the secondary endpoints evaluated at Week  52, subjects who meet the criterion for escape at 
Week  16 (ie, do not achieve a PASI90 response) will be imputed as nonresponders for PASI90 
and IGA at Week  52. All other subjects with missing data at Week  52 or who discontinue 
randomized treatment prior to Week  52 will also be counted as nonresponders. Furthermore, 
since subjects who do not achieve a PASI50 response at Week 28 or beyond are to be removed 
from the study, all such subjects will also be treated as non -responders at Week 52, whether or 
not they were actually removed from the study.  
Sensitivity analyses #1 and #2 will also be performed for the Wee k 52 secondary endpoints. A 
similar procedure to what is described above will be followed with the exception that subjects 
who meet the criterion for escape at Week  16 (ie, do not achieve a PASI90 response) and those 
who meet the criterion for mandatory wi thdrawal (ie, do not achieve a PASI50 response at Week 
28 or later) will be considered nonresponders at Week  52 and will be handled outside of the MI 
procedure. Further details on this analysis will be provided in the SAP.  
Has been changed to:  
For the seco ndary endpoints evaluated at Week  52, all subjects who meet the criterion for 
escape at Week  16 (ie, do not achieve a PASI90 response) will be imputed as nonresponders 
for PASI90 and IGA at Week  52. All other subjects  with missing data at Week  52 or who 
discontinue randomized treatment prior to Week  52 will also be counted as nonresponders. 
Furthermore, since subjects who do not achieve a PASI50 response at Week 28 or beyond 
are to be removed from the study, all such subjects will also be treated as non -responders 
at Week 52, whether or not they were actually removed from the study.  
Sensitivity analyses #1 and #2 will also be performed for the Week  52 secondary endpoints. A 
similar procedure to what is described above will be followed with the exception that  subjects 
who meet the criterion for escape at Week  16 (ie, do not achieve a PASI90 response) and 
those who meet the criterion for mandatory withdrawal (ie, do not achieve a PASI50 
response at Week 28 or later) will be considered nonresponders at Week  52 and will be 
handled outside of the MI procedure . Further details on this analysis will be provided in the 
SAP.  
 
Change #38  
Section 14.9  Determination of sample size  
A total of 640 subjects will be randomly assigned in a 4:3:1 ratio to the following treatmen t 
groups:  
 Bimekizumab 320mg (320 subjects)  
 Ustekinumab (240 subjects)  
 Placebo (80 subjects)  
Has been changed to:  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 138 of 206 A total of 560640 subjects will be randomly assigned in a 4: 23:1 ratio to the following treatment 
groups:  
 Bimekizumab 320mg (320 subjects)  
 Ustekinumab ( 160240 subjects)  
 Placebo (80 subjects)  
 
Change #39  
Section 14.9  Determination of sample size  
The power to detect a statistically significant difference between bimekizumab and ustekinumab 
at a 2 -sided significance level of 0.05 is 98% for PASI 90 response and >99% for IGA response. 
Because both co -primary endpoints are highly powered independently, and because PASI and 
IGA response tend to be highly correlated, the overall power for achieving superiority on both 
co-primary endpoints is not calcu lated here as it is similar to the lower of the individual tests. 
Note that the power for the non -inferiority testing between bimekizumab and ustekimumab for 
both PASI90 and IGA responses is >99% based on a 1 -sided significance level of 0.025 and a 
non-inferiority margin of 10%.  
Has been changed to:  
The power to detect a statistically significant difference between bimekizumab and ustekinumab 
at a 2 -sided significance level of 0.05 is 9 58% for PASI90 response and >989% for IGA 
response. Because both co -prim ary endpoints are highly powered independently, and because 
PASI and IGA response tend to be highly correlated, the overall power for achieving superiority 
on both co -primary endpoints is not calculated here as it is similar to the lower of the individual 
tests. Note that the power for the non -inferiority testing between bimekizumab and ustekimumab 
for both PASI90 and IGA responses is >99% based on a 1 -sided significance level of 0.025 and a 
non-inferiority margin of 10%.  
18.2 Protocol Amendment 2  
Rationale for the amendment  
The purpose of this amendment was the following:  
 Correct the information regarding the number of ongoing studies  
 Add a new other efficacy variable (absolute and percent change from Baseline in the product 
of IGA and BSA [IGAxBSA])  
 Correct the  Exclusion Criterion cross -reference in Section 5.1 Study description  
 Clarify the dosing window  
 Add percentage of BSA as an assessment at all visits  
 Correct all text throughout the protocol to clarify that PGADA and HAQ -DI will be 
performed on all subjects  at Baseline  
 Remove the pp -IGA assessment at Week 1 and Week 2  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 139 of 206  Add a PGADA assessment at Week 4  
 Remove the IGRA Tuberculosis test at Week 44  
 Clarify that the Maintenance Treatment Period will begin with the administration of 
bimekizumab, ustekinumab, or pl acebo at Week 16  
 Remove the 30% enrollment limit for subjects with prior biologic exposure  
 Delete the erroneous statements that at Week 16 subjects will be reallocated to a new 
treatment group based on the PASI response  
 Correct discrepancies between Sect ion 8 Study procedures by visit and Table 5 -1 Schedule of 
study assessments  
 Clarify in footnote c of Table 12 -2 Laboratory measurements the visits in which the urine 
drug screen will be performed  
 Revised text throughout document to consistently use the term Maintenance Treatment 
Period  
 Revise the section regarding the determination of sample size  
In addition, minor spelling, editorial, and formatting changes were made, and the List of 
abbreviations was updated.  
Specific changes  
Change #1  
Section 2.2.1.2  Ongoing studies  
Four additional studies of bimekizumab in the treatment of PSO and 1 study in healthy 
volunteers are ongoing. Five additional studies of bimekizumab in the treatment of PSO are 
ongoing.  
 
Has been changed to:  
Four additional studies of bime kizumab in the treatment of PSO and 1 study in healthy 
volunteers are ongoing. Five additional studies of bimekizumab in the treatment of PSO are 
ongoing.  
 
Change #2  
Section 4.3.1 Other efficacy variable(s)  
The following was added to the bulleted list of o ther efficacy variables:  
 Absolute and percent change from Baseline in the product of IGA and BSA (IGAxBSA)  
 
Change #3  
Section 5.1 Study description  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 140 of 206 PS0009 is a randomized, double -blind, placebo - and active comparator -controlled study to 
evaluate the efficacy and safety of bimekizumab administered sc to subjects with PSO. To be 
eligible to participate in this study, subjects must be adults with a diagnosis of moderate to 
severe plaque PSO (PASI ≥12 and BSA ≥10% and IGA score ≥3 [on a 5 -point scale]) wh o are a 
candidate for ustekinumab, or for systemic PSO therapy and/or phototherapy and/or 
photochemotherapy. Subjects may have been previously exposed to a biologic therapy (see 
Exclusion Criteria # 22 and # 23). 
 
Has been changed to:  
PS0009 is a randomized,  double -blind, placebo - and active comparator -controlled study to 
evaluate the efficacy and safety of bimekizumab administered sc to subjects with PSO. To be 
eligible to participate in this study, subjects must be adults with a diagnosis of moderate to 
severe plaque PSO (PASI ≥12 and BSA ≥10% and IGA score ≥3 [on a 5 -point scale]) who are a 
candidate for ustekinumab, or for systemic PSO therapy and/or phototherapy and/or 
photochemotherapy. Subjects may have been previously exposed to a biologic therapy (see  
Exclusion Criteri ona #22 and  #23). 
 
Change #4  
Table 5 -1 Schedule of study assessments  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page  141 of 206 Table  5-1: Schedule of study assessments  
Visita / 
Week  
 
Protocol activity  
Screening  Initial Treatment Period  
(weeks after first dose)  Maintenance Treatment Period  
(weeks after first dose)  
SFUb Baseline 
(first 
dose)  
1 2 4 8 12 16 20 24 28 32 36 40 44 48 52/ 
PEOT  
Informed consentc X               Xd   
Inclusion/exclusion  X X                 
Urine drug screen  X                X  
Demographic data  X                  
Psoriasis history  X                  
Significant past medical history and 
concomitant diseases  X Xe                 
Physical examf, g X       X  X   X    X X 
Height   X                 
Body weight   X      X  X   X    X  
Vital signsh X X X X X X X X X X X X X X X X X X 
Hematology and biochemistry  X X X X X X X X  X  X  X  X X X 
Urinalysis  X X      X  X  X  X  X X X 
ECG  X       X     X     X  
Pregnancy testingi X X   X X X X X X X X X X X X X X 
Hepatitis B and C testingk X                  
HIV testingk X                  
Chest x -rayl X                  
IGRA Tuberculosis test  X              X X   
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page  142 of 206 Table  5-1: Schedule of study assessments  
Visita / 
Week  
 
Protocol activity  
Screening  Initial Treatment Period  
(weeks after first dose)  Maintenance Treatment Period  
(weeks after first dose)  
SFUb Baseline 
(first 
dose)  
1 2 4 8 12 16 20 24 28 32 36 40 44 48 52/ 
PEOT  
Tuberculosis questionnaire  X X      X  X   X   X X X 
Blood sample for bimekizumab 
plasma concentrationsm  X X X X X X X   X   X   X X 
Blood sample for anti - 
bimekizumab antibodies m  X   X X X X   X   X   X X 
For participating centers: Blood 
sample for immunophenotypingc,m  X X   X X X         X  
Blood sample genomic, proteomic, 
metabolomics, and candidate 
biomarker analysesc,m  X X   X X X         X  
Blood sample genetic/epigenetic 
analysisc,m  X               X  
PASI  X X X X X X X X X X X X X X X X X X 
IGA X X X X X X X X X X X X X X X X X X 
DLQI   X X X X X X X   X   X   X  
PHQ -9 X X   X X X X X X X X X X X X X  
eC-SSRS  X X X X X X X X X X X X X X X X X X 
Patient Symptom Diary (daily)  X X X X X X X  X           
scalp IGA   X Xn Xn Xn Xn Xn Xn   Xn   Xn   Xn  
mNAPSI   X   Xo Xo Xo Xo   Xo   Xo   Xo  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page  143 of 206 Table  5-1: Schedule of study assessments  
Visita / 
Week  
 
Protocol activity  
Screening  Initial Treatment Period  
(weeks after first dose)  Maintenance Treatment Period  
(weeks after first dose)  
SFUb Baseline 
(first 
dose)  
1 2 4 8 12 16 20 24 28 32 36 40 44 48 52/ 
PEOT  
pp-IGA  X Xp Xp Xp Xp Xp Xp   Xp   Xp   Xp  
EQ-5D-3L  X   X X X X   X   X   X  
SF-36  X   X X X X   X   X   X  
Patient Global Assessment of 
psoriasisq           X   X   X  
PASE   X               X  
PGADAr  X      X X   X   X   X  
HAQ -DIr  X   X X X X   X   X   X  
WPAI -SHP V2.0   X      X  X    X   X  
Photographs of skin and nails 
(subset of sites)   X X X X X X X  X   X    X  
Concomitant medication  X X X X X X X X X X X X X X X X X X 
Adverse  events  X X X X X X X X X X X X X X X X X X 
IRTs,t X X X X X X X X X X X X X X X X X X 
Bimekizumab, ustekinumab, or 
placebo administrations,t  X   X X X Xu X X X X X X X X   
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page  144 of 206 Table  5-1: Schedule of study assessments  
Visita / 
Week  
 
Protocol activity  
Screening  Initial Treatment Period  
(weeks after first dose)  Maintenance Treatment Period  
(weeks after first dose)  
SFUb Baseline 
(first 
dose)  
1 2 4 8 12 16 20 24 28 32 36 40 44 48 52/ 
PEOT  
DLQI=Dermatology Life Quality Index; ECG=electrocardiogram; eC -SSRS=electronic Columbia Suicide Severity Rating Scale; eCRF=electronic Case Report 
Form; EQ -5D-3L=Euro -Quality of Life 5 -Dimensions 3 -level; HAQ -DI=Health Assessment Questionnaire -Disability I ndex; HIV=human immunodeficiency 
virus; ICF=Informed Consent Form; IGA=Investigator’s Global Assessment; IGRA=interferon -gamma release assay; IMP=investigational medicinal product; 
IRT=interactive response technology; PASE= Psoriatic Arthritis Screening an d Evaluation; PASE=Psoriatic Arthritis Screening and Evaluation;  
PASI=Psoriasis Area Severity Index; PEOT=Premature End of Treatment; PGADA=Patient’s Global Assessment of Disease Activity; P HQ-9=Patient Health 
Questionnaire 9; SF -36=Short Form 36 -item Health Survey; SFU=Safety Follow -Up; scalp IGA=scalp -specific Investigator’s Global Assessment; 
TB=tuberculosis; WPAI -SHP=Work Productivity and Activity Impairment Questionnaire -specific health problem  
a Visit windows of +/ - 3 days from the first dose at all visits except SFU. SFU Visit window is -3 and +7 days from last dose.  
b The SFU Visit will occur 20 weeks after the last dose.  
c A separate ICF will be required for subjects who decide to participate in the genomics, genetics, and proteomics substudy. The ICF must be signed prior to 
collecting any samples for the substudy. Samples for immunophenotyping will be analyzed immediately. All PD samples and genom ic, proteomic, and 
metabolomics samples will be stored at -80°C at the central biorepository for up  to 20 years.  
d A separate ICF is required to be completed for the open -label study.  
e Ensure no significant changes in medical history.  
f Includes evaluation of signs and symptoms of active TB and risk for exposure to TB.  
g The physical examination will i nclude examination of the following systems: eyes, hair, and skin; respiratory; CV; and GI.  
h Vital signs (blood pressures, pulse rate, and temperature) are to be measured prior to blood sampling, and prior to dosing, w here applicable.  
i Pregnancy testing will consist of serum testing at the Screening. The pregnancy test will be urine at all other visits.  
j Subjects who have evidence of or test positive for hepatitis B by any of the following criteria: 1) positive for hepatitis B surface antigen (HBsAg+); 2 ) positive 
for anti -hepatitis B core antibody (HBcAb+) are excluded. A positive test for HCV is defined as: 1) positive for hepatitis C antibody (anti-HCV Ab), and 2) 
positive via a confirmatory test for HCV (for example, HCV polymerase chain reaction) are  also excluded. Subjects will also be tested for anti -hepatitis  B 
surface antibody.  
k The HIV test results will not be recorded in the eCRF.  
l Screening chest x -ray must occur within 3 months prior to Screening Visit.  
m All blood samples taken prior to dos ing, except at Visit 2 (at which no dose administration occurs).  
n The scalp IGA will only be assessed for those subjects with scalp involvement (scalp IGA score >0) at Baseline.  
o The mNAPSI will be assessed only in subjects with nail involvement (mNAPSI score >0) at Baseline.  
p The pp -IGA will only be assessed in subjects with palmoplantar involvement (pp -IGA score >0) at Baseline.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page  145 of 206 q The Patient Global Assessment of psoriasis will be performed as part of the patient symptoms diary on a weekly basis from b aseline through the initial 
treatment period with a +3 day completion window. During the maintenance period this assessment will be completed at each cli nic visit specified with a 
±3 day completion window.  
r The PGADA and HAQ -DI are assessed only for subjects with PsA at Baseline (defined as a past medical history of PsA or PASE ≥47).  
s IMP administration is based on randomization.  
t For bimekizumab, the minimum time between doses should be no less than 21 days and no more than 35 days.  
u At Week 16 su bjects will be re -allocated based on original treatment and response to treatment and will receive their first Maintenance Treatment Period dos e. 
 
Has been changed to:  
Table  5-1: Schedule of study assessments  
Visita/ 
Week  
 
Protocol activity  
Screening  Initial Treatment Period  
(weeks after first dose)  Maintenance Treatment Period  
(weeks after first dose)  
SFUb Baseline 
(first 
dose)  
1 2 4 8 12 16 20 24 28 32 36 40 44 48 52/ 
PEOT  
Informed consentc X               Xd   
Inclusion/exclusion  X X                 
Urine drug screen  X                X  
Demographic data  X                  
Psoriasis history  X                  
Significant past medical history and 
concomitant diseases  X Xe                 
Physical examf,g X       X  X   X    X X 
Height   X                 
Body weight   X      X  X   X    X  
Vital signsh X X X X X X X X X X X X X X X X X X 
Hematology and biochemistry  X X X X X X X X  X  X  X  X X X 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page  146 of 206 Table  5-1: Schedule of study assessments  
Visita/ 
Week  
 
Protocol activity  
Screening  Initial Treatment Period  
(weeks after first dose)  Maintenance Treatment Period  
(weeks after first dose)  
SFUb Baseline 
(first 
dose)  
1 2 4 8 12 16 20 24 28 32 36 40 44 48 52/ 
PEOT  
Urinalysis  X X      X  X  X  X  X X X 
ECG  X       X     X     X  
Pregnancy testingi X X   X X X X X X X X X X X X X X 
Hepatitis B and C testingj X                  
HIV testingk X                  
Chest x -rayl X                  
IGRA Tuberculosis test  X              X X   
Tuberculosis questionnaire  X X      X  X   X   X X X 
Blood sample for bimekizumab 
plasma concentrationsm  X X X X X X X   X   X   X X 
Blood sample for anti - 
bimekizumab antibodiesm  X   X X X X   X   X   X X 
For participating centers: Blood 
sample for immunophenotypingc,m  X X   X X X         X  
Blood sample genomic, proteomic, 
metabolomics, and candidate 
biomarker analysesc,m  X X   X X X         X  
Blood sample genetic/epigenetic 
analysisc,m  X               X  
PASI  X X X X X X X X X X X X X X X X X X 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page  147 of 206 Table  5-1: Schedule of study assessments  
Visita/ 
Week  
 
Protocol activity  
Screening  Initial Treatment Period  
(weeks after first dose)  Maintenance Treatment Period  
(weeks after first dose)  
SFUb Baseline 
(first 
dose)  
1 2 4 8 12 16 20 24 28 32 36 40 44 48 52/ 
PEOT  
IGA X X X X X X X X X X X X X X X X X X 
Percentage of BSA  X X X X X X X X X X X X X X X X X X 
DLQI   X X X X X X X   X   X   X  
PHQ -9 X X   X X X X X X X X X X X X X  
eC-SSRS  X X X X X X X X X X X X X X X X X X 
Patient Symptom Diary (daily)  X X X X X X X  X           
scalp IGA   X Xn Xn Xn Xn Xn Xn   Xn   Xn   Xn  
mNAPSI   X   Xo Xo Xo Xo   Xo   Xo   Xo  
pp-IGA  X Xp Xn Xp Xp Xp Xp   Xp   Xp   Xp  
EQ-5D-3L  X   X X X X   X   X   X  
SF-36  X   X X X X   X   X   X  
Patient Global Assessment of 
psoriasisq           X   X   X  
PASE   X               X  
PGADAr  X    X  X X   X   X   X  
HAQ -DIr  X   X X X X   X   X   X  
WPAI -SHP V2.0   X      X  X    X   X  
Photographs of skin and nails 
(subset of sites)   X X X X X X X  X   X    X  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page  148 of 206 Table  5-1: Schedule of study assessments  
Visita/ 
Week  
 
Protocol activity  
Screening  Initial Treatment Period  
(weeks after first dose)  Maintenance Treatment Period  
(weeks after first dose)  
SFUb Baseline 
(first 
dose)  
1 2 4 8 12 16 20 24 28 32 36 40 44 48 52/ 
PEOT  
Concomitant medication  X X X X X X X X X X X X X X X X X X 
Adverse events  X X X X X X X X X X X X X X X X X X 
IRTs,t X X X X X X X X X X X X X X X X X X 
Bimekizumab, ustekinumab, or 
placebo administrations,t  X   X X X Xu X X X X X X X X   
BSA=body surface area ; CV=cardiovascular; DLQI=Dermatology Life Quality Index; ECG=electrocardiogram; eC -SSRS=electronic Columbia Suicide 
Severity Rating Scale; eCRF=electronic Case Report Form; EQ -5D-3L=Euro -Quality of Life 5 -Dimensions 3 -level; GI=gastrointestinal;  HAQ -DI=He alth 
Assessment Questionnaire -Disability Index; HCV=hepatitis C virus;  HIV=human immunodeficiency virus; ICF=Informed Consent Form; 
IGA=Investigator’s Global Assessment; IGRA=interferon -gamma release assay; IMP=investigational medicinal product; IRT=intera ctive response 
technology; mNAPSI=Modified Nail Psoriasis Severity Index Score;   PASE= Psoriatic Arthritis Screening and Evaluation;  PASE=Psoriatic Arthritis 
Screening and Evaluation;  PASI=Psoriasis Area Severity Index; PD=pharmacodynamics;  PEOT=Premature End of Treatment; PGADA=Patient’s Global 
Assessment of Disease Activity; PHQ -9=Patient Health Questionnaire 9; pp-IGA=palmoplantar Investigator’s Global Assessment; PsA=psoriatic 
arthritis;  SF-36=Short Form 36 -item Health Survey; SFU=Safety Follow -Up; scal p IGA=scalp -specific Investigator’s Global Assessment; TB=tuberculosis; 
WPAI -SHP=Work Productivity and Activity Impairment Questionnaire -specific health problem  
a Visit windows of +/ - 3 days from the first dose at all visits except SFU. SFU Visit window i s -3 and +7 days from last dose.  
b The SFU Visit will occur 20 weeks after the last dose for subjects who do not enroll in the open -label study . 
c A separate ICF will be required for subjects who decide to participate in the genomics, genetics, and proteom ics substudy. The ICF must be signed prior to 
collecting any samples for the substudy. Samples for immunophenotyping will be analyzed immediately. All PD samples and genom ic, proteomic, and 
metabolomics samples will be stored at -80°C at the central biorep ository for up to 20 years.  
d A separate ICF is required to be completed for the open -label study.  
e Ensure no significant changes in medical history.  
f Includes evaluation of signs and symptoms of active TB and risk for exposure to TB.  
g The physical examination will include examination of the following systems: eyes, hair, and skin; respiratory; CV; and GI.  
h Vital signs sitting systolic and diastolic  blood pressure, pulse rate, and body temperature) are to be measured prior to blood sampling, and pri or to dosing, 
where applicable.  
i Pregnancy testing will consist of serum testing at the Screening. The pregnancy test will be urine at all other visits.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page  149 of 206 j Subjects who have evidence of or test positive for hepatitis B by any of the following criteria: 1) positive for hepatitis B surface antigen (HBsAg+); 2) positive 
for anti -hepatitis B core antibody (HBcAb+) are excluded. A positive test for HCV is defined as: 1) positive for hepatitis C antibody (anti-HCV Ab), and 2) 
positive via a confirmatory test for HCV (for example, HCV polymerase chain reaction) are also excluded. Subjects will also be tested for anti -hepatitis  B 
surface antibody.  
k The HIV test results will not be recorded in the eCRF.  
l Screening chest x -ray must occur within 3 months prior to Scr eening Visit.  
m All blood samples taken prior to dosing, except at Visit 1 and  Visit 2 (at which no dose administration occurs).  
n The scalp IGA will only be assessed for those subjects with scalp involvement (scalp IGA score >0) at Baseline.  
o The mNAPSI will be assessed only in subjects with nail involvement (mNAPSI score >0) at Baseline.  
p The pp -IGA will only be assessed in subjects with palmoplantar involvement (pp -IGA score >0) at Baseline.  
q The Patient Global Assessment of psoriasis will be performe d as part of the patient symptoms diary on a weekly basis from baseline through the initial 
treatment period with a +3 day completion window. During the mMaintenance Treatment  pPeriod  this assessment will be completed at each clinic visit 
specified with a  ±3 day completion window.  
r The PGADA and HAQ -DI are assessed for all subjects at Baseline. At all subsequent visits, the PGADA and HAQ -DI are assessed  only for subjects with 
PsA at Baseline (defined as a past medical history of PsA or PASE ≥47).  
s IMP administration is based on randomization.  
t The dosing window is ±7 days relative to the scheduled dosing visit For bimekizumab, the minimum time between doses should be no less than 21 days 
and no more than 35 days . 
u At Week 16 subjects will be re -allocated based on original treatment and response to treatment and will receive their first Maintenance Treatment 
Period dose.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 150 of 206 Change #5  
Figure 5 -1 Schematic diagram  
 
Placebo
Bimekizumab 
320mg Q4W
UstekinumabScreening
N=80
N=320
N=160Initial Treatment Period
Week 16
Co-primary Endpoint: 
PASI90 Response and IGA ResponseBimekizumab 
extension study
to evaluate response 
to treatment and 
long-term safety
SFU Visit
20 Weeks after last 
dose for subjects not 
enrolling in extension 
study
RandomizationUstekinumabMaintenance Period
52 Baseline           Bimekizumab 320mg Q4WN=560           Bimekizumab 320mg Q4W
 
 
Has been changed to:  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 151 of 206 
Placebo
Bimekizumab 
320mg Q4W
UstekinumabScreening
N=80
N=320
N=160Initial Treatment Period
Week 16
Co-primary Endpoint: 
PASI90 Response and IGA ResponseBimekizumab 
extension study
to evaluate response 
to treatment and 
long-term safety
SFU Visit
20 Weeks after last 
dose for subjects not 
enrolling in extension 
study
RandomizationUstekinumabMaintenance Treatment Period
52 Baseline           Bimekizumab 320mg Q4WN=560           Bimekizumab 320mg Q4W
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 152 of 206 Change #6  
Section 6.2  Exclusion criterion #27  
27. Subject has presence of severe depression, indicated by a sc ore ≥15 using the screening 
PHQ -9. Medication used to treat depression should be stable for 4 weeks prior to baseline.  
 
Has been changed to:  
27. Subject has presence of severe depression, indicated by a score ≥of 15 to 19  using the 
screening PHQ -9. Medication used to treat depression should be stable for 4 weeks prior to 
baseline.  
 
Change #7  
Section 6.3 Withdrawal criterion #2  
2. Moderately severe depression as indicated by a PHQ -9 score ≥15 if this represents an 
increase of 3 points compared to last  visit.  
 
Has been changed to:  
2. Moderately severe depression as indicated by a PHQ -9 score ≥of15 to 19  if this represents an 
increase of 3 points compared to last visit.  
 
Change #8  
Section 7.8.1 Permitted concomitant treatments (medications and therapies)  
The following was deleted:  
The following concomitant medications are permitted during the study.  
 
Change #9  
Section 7.10 Randomization and numbering of subjects  
An IRT will be used for assigning eligible subjects to a treatment regimen based on a 
predetermin ed production randomization and/or packaging schedule provided by UCB (or 
designee). The randomization schedule will be produced by the IRT vendor. The IRT will 
generate individual assignments for subject kits of IMP, as appropriate, according to the visit  
schedule. Subject treatment assignment will be stratified by region and prior biologic exposure 
(yes/no). Efforts should be made to limit the enrollment of subjects with prior biologic exposure 
to approximately 30% of the total study population.  
At Screen ing, each subject will be assigned a 5 -digit number that serves as the subject identifier 
throughout the study. The subject number will be required in all communication between the 
Investigator or designee and the IRT regarding a particular subject.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 153 of 206 At the  Baseline Visit, a subject will be randomized into the study. The Investigator or designee 
will use the IRT for randomization. The IRT will automatically inform the Investigator or 
designee of the subject’s identification number. The IRT will allocate kit numbers to the subject 
based on the subject number during the course of the study. The kits are blinded.  
At Week 16, subjects may be reallocated to a new treatment group based on their PASI response.  
Subject numbers and kit numbers will be tracked via the IRT. 
 
Has been changed to:  
An IRT will be used for assigning eligible subjects to a treatment regimen based on a 
predetermined production randomization and/or packaging schedule provided by UCB (or 
designee). The randomization schedule will be produced by the IRT vendor. The IRT will 
generate individual assignments for subject kits of IMP, as appropriate, according to the visit 
schedule. Subject treatment assignment will be stratified by region and prior biologic exposure 
(yes/no). Efforts should be made to  limit the enrollment of subjects with prior biologic 
exposure to approximately 30% of the total study population.  
At Screening, each subject will be assigned a 5 -digit number that serves as the subject identifier 
throughout the study. The subject number will be required in all communication between the 
Investigator or designee and the IRT regarding a particular subject.  
At the Baseline Visit, a subject will be randomized into the study. The Investigator or designee 
will use the IRT for randomization. The IRT will automatically inform the Investigator or 
designee of the subject’s identification number. The IRT will allocate kit numbers to the subject 
based on the subject number during the course of the study. The kits are blinded.  
At Week 16, subjects may b e reallocated to a new treatment group based on their PASI 
response.  
Subject numbers and kit numbers will be tracked via the IRT.  
 
Change #10  
Section 8 STUDY PROCEDURES BY VISIT  
Table 5 -1 (Schedule of study assessments) provides a general overview of study assessments. A 
list of procedures to be completed at each visit is described below.  
 Visit windows of ±3 days on either side of the scheduled dosing are permitted; however, the 
Investigat or should try to keep the subjects on the original dosing schedule. The window of 
±3 days is relative to Baseline and applicable for all subsequent visits. Changes to the dosing 
schedule outside of the 3 -day window must be discussed with the Medical Monito r. 
 The minimum of time between doses should be no less than 21 days and no more than 35 
days.  
 For the SFU Visit (20 weeks after the last dose), the visit should occur no more than 3 days 
prior to the scheduled visit date and within 7 days after the schedul ed visit date ( -3 days/+7 
days).  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 154 of 206 Has been changed to:  
Table 5 -1 (Schedule of study assessments) provides a general overview of study assessments. A 
list of procedures to be completed at each visit is described below.  
 Visit windows of ±3 days on either side  of the scheduled dosing are permitted; however, the 
Investigator should try to keep the subjects on the original dosing schedule. The window of 
±3 days is relative to Baseline and applicable for all subsequent visits. Changes to the dosing 
schedule outsid e of the 3 -day window must be discussed with the Medical Monitor.  
 The dosing window is ±7 days relative to the scheduled dosing visit The minimum of 
time between doses should be no less than 21 days and no more than 35 days . 
 For the SFU Visit (20 weeks afte r the last dose), the visit should occur no more than 3 days 
prior to the scheduled visit date and within 7 days after the scheduled visit date ( -3 days/+7 
days).  
 
Change #11  
Section 8.1 Screening Visit (2 to 4 Weeks), Section 8.2.1 Baseline Visit, Section  
8.2.2 Week 1 Visit (±3 days relative to Baseline), Section 8.2.3 Week 2 Visit (±3 
days relative to Baseline), Section 8.2.4 Week 4 Visit (±3 days relative to 
Baseline), Section 8.2.5 Week 8 Visit (±3 days relative to Baseline), Section 8.2.6 
Week 12 Visit  (±3 days relative to Baseline), Section 8.2.7 Week  16 Visit (±3  days 
relative to Baseline), Section 8.3.1 Week  20 Visit (±3  days relative to Baseline), 
Section 8.3.2 Week  24 Visit (±3  days relative to Baseline), Section 8.3.3 Week  28 
Visit (±3  days relati ve to Baseline), Section 8.3.4 Week  32 Visit (±3  days relative to 
Baseline), Section 8.3.5 Week  36 Visit (±3  days relative to Baseline), Section 8.3.6 
Week  40 Visit (±3  days relative to Baseline), Section 8.3.7 Week  44 Visit (±3  days 
relative to Baseline),  Section 8.3.8 Week  48 Visit (±3  days relative to Baseline), 
Section 8.3.9 Week  52 Visit (±3  days relative to Baseline),  and Section 8.5 Safety 
Follow -Up Visit (20 weeks after last dose, -3 days/+7 days)  
The following was added to the bulleted lists:  
 Percentage of BSA  
 
Change #12  
Section 8.2.1 Baseline Visit  
The following items in the bulleted list:  
 Collection of blood and urine samples for the following clinical laboratory tests should be 
obtained prior to dosing:  
 Genomic, proteomic, metabolomics, and  candidate biomarker  analyses  
 Genetic/epigenetic analysis  
 PGADA (only for subjects with PsA)  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 155 of 206  HAQ -DI (only for subjects with PsA)  
 
Have been changed to:  
 Collection of blood and urine samples for the following clinical laboratory tests should be 
obtained prior to dosing:  
 Genomic, proteomic, metabolomics, and candidate biomarker  analyses (participating 
subjects only)  
 Genetic/epigenetic analysis (participating subjects only)  
 PGADA  (only for subjects with PsA)  
 HAQ -DI (only for subjects with PsA)  
 
Change #13  
Section 8.2.2 Week 1 Visit (±3 days relative to Baseline)  
The following was deleted from the bulleted list:  
 pp-IGA 
 
Change #14  
Section 8.2.3 Week 2 Visit (±3 days relative to Baseline)  
The following was added to the bulleted list:  
 DLQI  
 
Change #15  
Section 8.2.3 Week 2 Visit (±3 days relative to Baseline)  
The following was deleted from the bulleted list:  
 pp-IGA 
 
Change #16  
Section 8.2.4 Week 4 Visit (±3 days relative to Baseline)  
The following was added to the bulleted list:  
 PGADA (only for subjects with PsA ) 
 
Change #17  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 156 of 206 Section 8.2.6 Week 4 Visit (±3 days relative to Baseline) and Section 8.2.7 Week 16 
Visit (±3 days relative to Baseline)  
 Collection of blood and urine samples for the following clinical laboratory tests should be 
obtained prior to dosing:  
 Genomic, proteomic, metabolomics, and candidate biomarker  analyses  
 
Has been changed to:  
 Collection of blood and urine samples for the following clinical laboratory tests should be 
obtained prior to dosing:  
 Genomic, proteomic, metabolomics, and candidate biomarker  analyses (participating 
subjects only)  
 
Change #18  
Section 8.2.7 Week 16 Visit (±3 days relative to Baseline)  
After completion of the above -mentioned procedures, administration of bimekizumab, 
ustekinumab, or placebo will occur.  
 
Has been changed  to: 
After completion of the above -mentioned procedures, the Maintenance Treatment Period will 
begin with  administration of bimekizumab, ustekinumab, or placebo  will occur . 
 
Change #19  
Section 8.2.7 Week 16 Visit ( ±3 days relative to Baseline) and Section 8.3.7 Week 
44 Visit ( ±3 days relative to Baseline)  
The following was deleted from the bulleted lists:  
 IGRA Tuberculosis test  
 
Change #20  
Section 8.3.5 Week 36 Visit (±3 days relative to Baseline)  
The following was deleted from the bulleted list:  
 Bimekizuma b plasma concentrations  
 Anti-bimekizumab antibodies  
 
Change #21  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 157 of 206 Section 8.3.9 Week 52 Visit (±3 days relative to Baseline)  
 Collection of blood and urine samples for the following clinical laboratory tests should be 
obtained prior to dosing:  
 Genomic, proteomic, metabolomics, and candidate biomarker  analyses  
 Immunophenotyping (participating centers only)  
 Genetic/epigenetic analysis  
 
Has been changed to:  
 Collection of blood and urine samples for the following clinical laboratory tests should b e 
obtained prior to dosing:  
 Genomic, proteomic, metabolomics, and candidate biomarker  analyses (participating 
subjects only)  
 Immunophenotyping (participating centers only)  
 Genetic/epigenetic analysis (participating subjects only)  
 
Change #22  
Section 9 Assessment of efficacy  
The PASI, IGA, scalp IGA, mNAPSI, and pp -IGA should be performed by the Investigator, 
another delegated physician, or an appropriately qualified medical professional (based on local 
requirements) who has had documented training on ho w to perform these assessments correctly. 
Preferably the same assessor should evaluate the subject at each assessment.  
 
Has been changed to:  
The PASI, BSA,  IGA, scalp IGA, mNAPSI, and pp -IGA should be performed by the 
Investigator, another delegated physic ian, or an appropriately qualified medical professional 
(based on local requirements) who has had documented training on how to perform these 
assessments correctly. Preferably the same assessor should evaluate the subject at each 
assessment.  
 
Change #23  
Section 9.4 Patient Health Questionnaire 9  
A score of 15 to 19 is considered to indicate moderately severe major depression, and a score 
>20 is considered to be severe major depression.  
 
Has been changed to:  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 158 of 206 A score of 15 to 19 is considered to indicate mode rately severe major depression, and a score 
>≥20 is considered to be severe major depression.  
 
Change #24  
Section 9.10 Patient Global Assessment of psoriasis  
During the maintenance period, this assessment will be completed within a ±3 -day completion 
window  at the visits specified in  Table 5 -1. 
 
Has been changed to:  
During the mMaintenance Treatment pPeriod , this assessment will be completed within a ±3 -
day completion window at the visits specified in Table 5 -1. 
 
Change #25  
Section 9.14 HAQ -DI score  
Subjects  with PsA at Baseline (defined as a past medical history of PsA or PASE ≥47) will 
complete the HAQ -DI at the visits specified in  Table 5 -1. 
 
Has been changed to:  
All subjects will complete the HAQ -DI at Baseline. Subjects with PsA at Baseline (defined as 
a past medical history of PsA or PASE ≥47) will complete the HAQ -DI at the visits specified in 
Table 5 -1. 
 
Change #26  
Section 9.16 Photographs  
At certain clinical sites, representative photographs of the changes in skin and nail appearance 
will be captured.  Subjects will have full body (anterior and posterior views, below neck) and nail 
photographs taken. Photographs will be anonymized.  
 
Has been changed to:  
At certain clinical sites, representative photographs of the changes in skin and nail appearance 
will be captured. Subjects will have full body (anterior and posterior views , below neck ) and nail 
photographs taken. Photographs will be anonymized.  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 159 of 206 Change #27  
Table 12 -2 Laboratory measurements, footnote c  
c Urine drug screen will be performed at Screening Visit and PEOT Visit  
 
Has been changed to:  
c Urine drug screen will be performed at Screening Visit , and Week 52 or  PEOT Visit  
 
Change #28  
Section 14.9 Determination of sample size  
The power to detect a sta tistically significant difference between bimekizumab and ustekinumab 
at a 2 -sided significance level of 0.05 is 95% for PASI90 response and 98% for IGA response. 
Because both co -primary endpoints are highly powered independently, and because PASI and 
IGA response tend to be highly correlated, the overall power for achieving superiority on both 
co-primary endpoints is not calculated here as it is similar to the lower of the individual tests. 
Note that the power for the non -inferiority testing between bimeki zumab and ustekimumab for 
both PASI90 and IGA responses is >99% based on a 1 -sided significance level of 0.025 and a 
non-inferiority margin of 10%.  
 
Has been changed to:  
The power to detect a statistically significant difference between bimekizumab and ustekinumab 
at a 2 -sided significance level of 0.05 is 95% for PASI90 response and 98% for IGA response. 
Because both co -primary endpoints are highly powered independently, and because PASI and 
IGA response tend to be highly correlated, the overall power f or achieving superiority on both 
co-primary endpoints is not calculated here  as it is similar to the lower of the individual tests . 
Note that the power for the non -inferiority testing between bimekizumab and ustekimumab for 
both PASI90 and IGA responses is  >99% based on a 1 -sided significance level of 0.025 and a 
non-inferiority margin of 10%.  
 
Change #29  
Section 17 REFERENCES  
The following references were deleted from the list:  
Dauden E, Griffiths CE, Ortonne JP, Kragballe K, Molta CT, Robertson D, et al. Improvements 
in patient -reported outcomes in moderate -to-severe psoriasis patients receiving continuous or 
paused etanercept treatment over 54 weeks: the CRYSTEL study. J Eur Acad Dermatol Venereol. 
2009;23(12):1374 -82. 
Langley RG, Feldman SR, Han C, Schen kel B, Szapary P, Hsu MC, et al. Ustekinumab 
significantly improves symptoms of anxiety, depression, and skin -related quality of life in 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 160 of 206 patients with moderate -to-severe psoriasis: Results from a randomized, doubleblind, 
placebo -controlled phase III trial.  J Am Acad Dermatol. 2010;63(3):457 -65. 
Puig L, Thom H, Mollon P, Tian H, Ramakrishna GS. Clear or almost clear skin improves the 
quality of life in patients with moderate -to-severe psoriasis: a systematic review and meta -
analysis. J Eur Acad Dermatol Vene reol. 2017;31(2):213 -220. 
Snaith RP, Zigmond AS. The hospital anxiety and depression scale, with the irritability -
depression -anxiety scale and the Leeds situational anxiety scale manual. NFER -Nelson. 1994.  
Sozu T, Sugimoto T, Hamasaki T. Sample size determ ination in clinical trials with multiple 
co-primary binary endpoints. Statistics in Medicine. 2010;29:2169 -79. 
Sozu T, Sugimoto T, Hamasaki T. Sample size determination in clinical trials with multiple 
co-primary endpoints including mixed continuous and bi nary variables. Biometrical Journal. 
2012;5:716 -29. 
18.3 Protocol Amendment 3  
Rationale for the amendment  
The purpose of this amendment was the following:   
 Update name and contact information for Sponsor study physician  
 Extend the duration of the Screening Per iod, and therefore the overall study duration, by 
1 week  
 Update list of current treatment for PSO to reflect changes in labeling and approved countries  
 Update list of completed and ongoing bimekizumab studies to reflect completion of study 
UP0042  
 Clarify c alculation of PASI responder rates  
 Remove references to PD assessments as they will not be conducted in this study  
 Update Schedule of study assessments to include a hematology and biochemistry sample at 
Week 20, to modify the visits at which the TB questio nnaire, body weight, physical 
examination, and ECG are assessed, and to modify the visits at which photographs are taken  
 Clarify that all visits from first dose to Week 24 would have a ±3 day visit window, while all 
visits from Week 28 to end of study woul d have a ±7 day window  
 Clarify the dosing window  
 Modify exclusion criterion to clarify exclusion of subjects who have participated in other 
studies of bimekizumab, other medications (systemic or topical), or devices  
 Modify exclusion criteria pertaining to history of malignancy, systemic disease, and major 
depression  
 Add new withdrawal criteria for nonresponders and for subjects with newly diagnosed IBD  
 Clarify withdrawal criteria for subjects with depression or suicidal ideation or behavior  
 Clarify that for  subjects receiving ustekinumab, dosing is based on weight at Baseline  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 161 of 206  Update prohibited concomitant medications to include tildrakizumab and risankizumab  
 Corrected discrepancies between Section 8 Study procedures by visit and Table 5 -1 Schedule 
of study assessments  
 Revise PASE questionnaire scoring  
 Remove immunophenotyping assessments  
 Clarify photography requirements  
 Clarify definition of abortion  
 Updated laboratory measurements to be performed  
 Provide additional details for requirements for IMP rechallenge in the event of PDILI  
 Defined a Maintenance Set as an analysis population  
 Update the definition of the FAS Set  
 Clarify regions for analyses  
 Update the sequence testing  
In addition, minor spelling, editorial, and formatting changes were made, and the List of 
abbreviations was updated.  
 
Change #1  
Study Contact Information  
Sponsor Study Physician  
Name:  , MD  
Address:  UCB Biosciences, 8010 Arco Corporation Drive, Raleigh, NC 27617  
Phone:   
Fax:  
Sponsor Study Physician  
Name:  , MD, PhD  
Address:  UCB Biosciences, 8010 Arco Corporation Drive, Raleigh, NC 27617  
Phone:   
Fax:  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 162 of 206 Change #2  
Section 1  Summary, second and third paragraphs  
The study population consists of adult subjects (≥18 years of age) with a diagnosis of moderate 
to severe chronic plaque PSO (Baseline Psoriasis Area and Severity Index [PASI] ≥12 and body 
surface area [BSA] affected by PSO ≥10% and Investigator’s Global Assessment [IGA] score ≥3 
[on a 5 -point scale]) who are a candidate for ustekinumab, or for systemic PSO therapy and/or 
phototherapy and/or photochemotherapy.  
Approximately 750 subjects will be screened in order to have 560 subjects randomized in the 
study. For each subject, the study will last a maximum of 72 weeks and will consist of 4 periods, 
a Screening Period (2 to 4 weeks), a double -blind, placebo - and active comparator -controlled 
Initial Treatment Period (16 weeks), a double -blind, active comparator -controlled  Maintenance 
Treatment Period (36 weeks), and a Safety Follow -Up (SFU) Period (20 weeks after the last dose 
of investigational medicinal product (IMP).  
Has been changed to:  
The study population consists of adult subjects (≥18 years of age) with a diagnos is of moderate 
to severe chronic plaque PSO (Baseline Psoriasis Area and Severity Index [PASI] ≥12 and body 
surface area [BSA] affected by PSO ≥10% and Investigator’s Global Assessment [IGA] score ≥3 
[on a 5 -point scale]) who are a candidate for ustekinuma b, or for systemic PSO therapy and/or 
phototherapy and/or photochemotherapy . 
Approximately 750 subjects will be screened in order to have 560 subjects randomized in the 
study. For each subject, the study will last a maximum of 72 73 weeks and will consist of 4 
periods, a Screening Period (2 to 4 5 weeks), a double -blind, placebo - and active comparator -
controlled Initial Treatment Period (16 weeks), a double -blind, active comparator -controlled 
Maintenance Treatment Period (36 weeks), and a Safety Follow -Up (SFU) Period (20 weeks 
after the last final  dose of investigational medicinal product (IMP).  
 
Change #3  
Section 1  Summary, second to last paragraph  
Pharmacokinetic, PD, genomic, genetic, proteomic, and immunological variables will be 
evaluated to assess their relationship to treatment response.  
Has been changed to:  
Pharmacokinetic, PD, genomic, genetic, proteomic, and immunological variables will be 
evaluated to assess their relationship to treatment response.  
 
Change #4  
Section  2.1.2 Current treatments for psoriasis, first paragraph  
Therapy for patients with PSO varies according to the severity of disease. Limited or mild 
disease is often treated with topical therapies such as corticosteroids and vitamin D analogs. 
Patients with more severe disease are o ften treated with photochemotherapy, methotrexate, 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 163 of 206 cyclosporine, the oral phosphodiesterase 4 (PDE4) inhibitor apremilast, or biologic agents, such 
as tumor necrosis factor (TNF) antagonists, interleukin (IL) 12/23 inhibitors, IL -23p19 inhibitors 
and IL -17A inhibitors. The effectiveness of TNF inhibitors in the treatment of PSO has been 
demonstrated in many Phase 3 clinical studies and has led to the approval of multiple TNF 
inhibitors for use in patients with moderate to severe PSO. Interleukin inhibitors approved for 
this indication include the IL -12/23 antagonist ustekinumab, the IL -23p19 antagonist 
guselkumab (in the US only), the IL -17A inhibitors secukinumab and ixekizumab, and the 
IL-17 receptor antagonist brodalumab.  
Has been changed to:  
Therapy for patients with PSO varies according to the severity of disease. Limited or mild 
disease is often treated with topical therapies such as corticosteroids and vitamin D analogs. 
Patients with more severe disease are often treated with photochemothe rapy  phototherapy , 
methotrexate, cyclosporine, the oral phosphodiesterase 4 (PDE4) inhibitor apremilast, or biologic 
agents, such as tumor necrosis factor (TNF) antagonists, interleukin (IL) 12/23 inhibitors, IL -
23p19 inhibitors and IL -17A inhibitors. The effectiveness of TNF inhibitors in the treatment of 
PSO has been demonstrated in many Phase 3 clinical studies and has led to the approval of 
multiple TNF inhibitors for use in patients with moderate to severe PSO. Interleukin inhibitors 
approved for this indication include the IL -12/23 antagonist ustekinumab, the IL -23p19 
antagonist guselkumab (in the US only) , the IL -17A inhibitors secukinumab and ixekizumab, 
and the IL -17 receptor antagonist brodalumab.  
 
Change #5  
Section  2.1.2 Current treatments for ps oriasis, third bullet  
 Chemophototherapy is a frequent option for moderate to severe patients, but the 
inconvenience of multiple treatment visits and varying efficacy limits its use in the market.  
Has been changed to:  
 Chemophototherapy  Phototherapy is a fr equent option for moderate to severe patients, but 
the inconvenience of multiple treatment visits and varying efficacy limits its use in the 
market.  
 
Change #6  
Section 2.1.2 Current treatments for psoriasis, last bullet, second and fourth sub -bullets  
 Ustek inumab has been approved in the US and the EU for the treatment of adult patients 
with moderate to severe plaque PSO who are candidates for phototherapy or systemic 
therapy. Ustekinumab is a human immunoglobulin (Ig) G1κ monoclonal antibody that 
binds with  specificity to the p40 protein subunit used by both the IL -12 and IL -23 
cytokines, naturally occurring cytokines that are involved in inflammatory and immune 
responses, such as natural killer cell activation and CD4+ T -cell differentiation and 
activation.   
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 164 of 206  Guselkumab has been approved in the US for the treatment of adult patients with 
moderate to severe plaque PSO who are candidates for systemic therapy or phototherapy. 
It is a human monoclonal IgG1λ antibody that selectively binds to the p19 subunit of 
interleukin 23 (IL -23) and inhibits its interaction with the IL -23 receptor. IL -23 is a 
naturally occurring cytokine that is involved in normal inflammatory and immune 
responses. Guselkumab inhibits the release of proinflammatory cytokines and 
chemokines.  
Has been changed to:  
 Ustekinumab has been approved in the US and the EU for the treatment of adult patients 
with moderate to severe plaque PSO who are candidates for phototherapy or systemic 
therapy. Ustekinumab is a human immunoglobulin (Ig) G1κ monoclonal  antibody that 
binds with specificity to the p40 protein subunit used by both the IL -12 and IL -23 
cytokines, naturally occurring cytokines that are involved in inflammatory and immune 
responses, such as natural killer cell activation and CD4+ T -cell differ entiation and 
activation.  
 Guselkumab has been approved in the US and the EU for the treatment of adult patients 
with moderate to severe plaque PSO who are candidates for systemic therapy or 
phototherapy. It is a human monoclonal IgG1λ antibody that select ively binds to the p19 
subunit of interleukin 23 (IL -23) and inhibits its interaction with the IL -23 receptor. 
IL-23 is a naturally occurring cytokine that is involved in normal inflammatory and 
immune responses. Guselkumab inhibits the release of proinfla mmatory cytokines and 
chemokines.  
 
Change #7  
Section  2.2.1.1 Completed studies  
Four clinical studies of bimekizumab have been completed: UP0008 in 39 subjects with mild to 
moderate plaque PSO, RA0124 in 30 healthy volunteers, PA0007 in 53 subjects with PsA , and 
UP0031 in 12 healthy volunteers.  
Hs been changed to:  
Four  Five clinical studies of bimekizumab have been completed: UP0008 in 39 subjects with 
mild to moderate plaque PSO, RA0124 in 30 healthy volunteers, PA0007 in 53 subjects with 
PsA, and UP0031 in 12 healthy volunteers , and UP0042 in 48 healthy volunteers .  
And the following paragraph has been added:  
UP0042 was a randomized double -blind, placebo -controlled, single -dose, parallel -group 
study to evaluate the safety, tolerability, and pharma cokinetics of bimekizumab 
administered as subcutaneous injection to Japanese and Caucasian healthy subjects. This 
study demonstrated that the PK profiles following single administration of 80mg, 160mg, 
and 320mg with sc injection were dose proportional wit h a linear elimination in both 
Japanese and Caucasian subjects and that the PK profiles of Japanese and Caucasian 
subjects were considered to be generally similar. A single dose of bimekizumab (80mg, 
160mg, or 320mg) administered as sc injection was genera lly safe and well tolerated in 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 165 of 206 healthy Japanese and Caucasian subjects and no major differences in safety findings were 
observed between Japanese and Caucasian subjects.  
 
Change #8  
Section  2.2.1.1 Ongoing studies  
Four additional studies of bimekizumab in t he treatment of PSO and 1 study in healthy 
volunteers are ongoing.  
 PS0010 is a Phase 2b, double -blind, placebo -controlled, dose ranging study to evaluate the 
safety, efficacy, PK, and pharmacodynamics (PD) of bimekizumab in adult subjects with 
moderate to  severe chronic plaque PSO.  
 PS0011 is a long -term extension study for subjects who completed PS0010 to assess the 
long-term safety, tolerability, and efficacy of bimekizumab.  
 PS0016 is a Phase 2a, subject -blind, Investigator -blind study to evaluate the tim e course of 
PD response, safety, and PK of bimekizumab in adult subjects with moderate to severe 
chronic plaque PSO.  
 PS0018 is a long -term extension study for eligible subjects from PS0016 to assess the safety, 
tolerability, and efficacy of bimekizumab.  
 UP0042 is a Phase 1 study designed to evaluate the safety, tolerability, and PK of 
bimekizumab administered as an sc injection of 80mg, 160mg, or 320mg to Japanese and 
Caucasian healthy subjects.  
Has been changed to:  
Four additional studies of bimekizumab i n the treatment of PSO and 1 study in healthy 
volunteers  are ongoing.  
 PS0010 is a Phase 2b, double -blind, placebo -controlled, dose ranging study to evaluate the 
safety, efficacy, PK, and pharmacodynamics (PD) of bimekizumab in adult subjects with 
moderate  to severe chronic plaque PSO.  
 PS0011 is a long -term extension study for subjects who completed PS0010 to assess the 
long-term safety, tolerability, and efficacy of bimekizumab.  
 PS0016 is a Phase 2a, subject -blind, Investigator -blind study to evaluate the time course of 
PD response, safety, and PK of bimekizumab in adult subjects with moderate to severe 
chronic plaque PSO.  
 PS0018 is a long -term extension study for eligible subjects from PS0016 to assess the safety, 
tolerability, and efficacy of bimekizumab.  
 UP0042 is a Phase 1 study designed to evaluate the safety, tolerability, and PK of 
bimekizumab administered as an sc injection of 80mg, 160mg, or 320mg to Japanese 
and Caucasian healthy subjects.  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 166 of 206 Change #9  
Section 3.3  Other objectives, 12th bullet  
 Assess  the PK and PD of bimekizumab  
Has been changed to:  
 Assess the PK and PD  of bimekizumab  
 
Change #10  
Section 4.3 Other variables  
The following text has been added:  
The other variables are listed below and will be evaluated according to the planned 
assessments Table 5 -1. 
 
 
Change #11  
Section 4.3.1 Other efficacy variables, last sentence in third paragraph  
Note that PASI responder rates will always be calculated relative to the Baseline (first dose) 
Visit.  
Has been changed to:  
Note that  Unless otherwise stated PASI responder rates will  always  be calculated relative to the 
Baseline Visit (first dose).  
 
Change #12  
Section 4.4 Pharmacokinetic and pharmacodynamic variable(s)  
Section 4.4.1.1 Pharmacokinetic and pharmacodynamic variables  
The P K variable is the plasma concentration of bimekizumab.  
For subjects enrolled in participating centers, immunophenotyping by flow cytometry on whole 
blood will be performed.  
Has been changed to:  
Section 4.3.3  Pharmacokinetic and pharmacodynamic  variable (s) 
Section 4.4.1.1 Pharmacokinetic and pharmacodynamic variables  
The PK variable is the plasma concentration of bimekizumab.  
For subjects enrolled in participating centers, immunophenotyping by flow cytometry on 
whole blood will be performed.  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 167 of 206 Change #13  
Section 4.5 Pharmacogenomic variables  
Section 4.6 Immunological variable  
Have been changed to:  
Section 4.3.4  Pharmacogenomic variables  
Section 4.3.5  Immunological variable  
 
Change #14  
Section 5.1 Study description  
PS0009 is a randomized, double -blind, placebo - and active comparator -controlled study to 
evaluate the efficacy and safety of bimekizumab administered sc to subjects with PSO. To be 
eligible to participate in this study, subjects must be adults with a diagnosis of moderate to 
severe plaque PSO (PASI ≥12 and BSA ≥10% and IGA score ≥3 [on a 5 -point scale]) who are a 
candidate for ustekinumab, or for systemic PSO therapy and/or phototherapy and/or 
photochemotherapy. Subjects may have been previously exposed to a biologic therapy (see 
Exclusion Crit erion #23).  
Has been changed to:  
PS0009 is a randomized, double -blind, placebo - and active comparator -controlled study to 
evaluate the efficacy and safety of bimekizumab administered sc to subjects with PSO. To be 
eligible to participate in this study, su bjects must be adults with a diagnosis of moderate to 
severe plaque PSO (PASI ≥12 and BSA ≥10% and IGA score ≥3 [on a 5 -point scale]) who are a 
candidate for ustekinumab, or for systemic PSO therapy and/or phototherapy  and/or 
photochemotherapy . Subjects ma y have been previously exposed to a biologic therapy (see 
Exclusion Criterion #23).  
 
Change #15  
Section 5.2  Study periods  
This study will include 4 periods, a Screening Period (2 to 4 weeks), an Initial Treatment Period 
(16 weeks), a Maintenance Treatment Period (36 weeks), and a SFU Period (20 weeks after the 
last dose of IMP). After completion of the Maintenance Treatment Period, eligible subjects will 
be allowed to enroll in an open -label study. Subjects enrolling into the open -label study will not 
have the PS0009 SFU Visit.  
Has been changed to:  
This study will include 4 periods, a Screening Period (2 to 4 5 weeks), an Initial Treatment 
Period (16 weeks), a Maintenance Treatment Period (36 weeks), and a SFU Period (20 weeks 
after the last final  dose of I MP). After completion of the Maintenance Treatment Period, eligible 
subjects will be allowed to enroll in an open -label study. Subjects enrolling into the open -label 
study will not have the PS0009 SFU Visit.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 168 of 206  
Change #16  
Section 5.2.1 Screening Period  
The S creening Period will last 2 weeks, but can be extended up to a total of 4 weeks.  
Has been changed to:  
The Screening Period will last 2 weeks, but can be extended up to a total of 4 5 weeks  in cases 
where a laboratory assessment needs to be repeated or to allow washout of prohibited 
medications . 
 
Change #17  
Section 5.2.2  Initial Treatment Period  
 Ustekinumab (160 subjects):  
 For subjects weighing ≤100kg (220lbs), 45mg sc initially and 4 weeks later  
 For subjects weighing >100kg (220lbs), 90mg sc initially and 4 weeks later  
Has been changed to:  
 Ustekinumab (160 subjects):  
 For subjects weighing ≤100kg (220lbs) at Baseline , 45mg sc initially and 4 weeks later  
 For subjects weighing >100kg (220lbs) at Baseline , 90mg sc initially and 4 weeks later  
 
Change #18  
Section 5.3 Study duration per subject  
For each subject, the study will last a maximum of up to 72 weeks, as follows:  
 Screening Period: 2 to 4 weeks  
Has been changed to:  
For each subject, the study will last a maximum of up to 72 73 weeks, as follows:  
 Screening Period: 2 to 4 5 weeks  
 
Change #19  
Section 5.5 Anticipated regions and countries  
 The regions planned for study conduct are Europe, Canada, and the US, with possible 
extension to other regions and countries.   
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 169 of 206 Has been changed to:  
The regions pla nned for study conduct are North America, Western  Europe, Canada, and the 
US Central/Eastern Europe, and Asia/Australia , with possible extension to other regions and 
countries.  
 
Change #20  
Section  5.6 Schedule of study assessments  
The schedule of study as sessments is presented in Table 5 -1. 
Has been changed to:  
The schedule of study assessments is presented in Table 5 -1. At each visit, all study 
assessments should be performed prior to administration of IMP.  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 170 of 206 Table  5--1 Schedule of study assessments  
Visita/ 
Week  
 
Protocol activity  
Screening  Initial Treatment Period  
(weeks after first dose)  Maintenance Treatment Peri  
(weeks after first dose)  
SFUbb Baseline 
(first 
dose)  
1 2 4 8 12 16 20 24 28 32 36 40 44 48 52/ 
PEOT  
Informed consentc X               Xd   
Inclusion/exclusion  X X                 
Urine drug screen  X                X  
Demographic data  X                  
Psoriasis history  X                  
Significant past medical history and 
concomitant diseases  X Xe                 
Physical examf, g X       X  X   X    X X 
Height   X                 
Body weight   X      X  X   X    X  
Vital signsh X X X X X X X X X X X X X X X X X X 
Hematology and biochemistry  X X X X X X X X  X  X  X  X X X 
Urinalysis  X X      X  X  X  X  X X X 
ECG  X       X     X     X  
Pregnancy testingi X X   X X X X X X X X X X X X X X 
Hepatitis B and C testingj X                  
HIV testingk X                  
Chest x -rayl X                  
IGRA Tuberculosis test  X               X   
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 171 of 206 Table  5--1 Schedule of study assessments  
Visita/ 
Week  
 
Protocol activity  
Screening  Initial Treatment Period  
(weeks after first dose)  Maintenance Treatment Peri  
(weeks after first dose)  
SFUbb Baseline 
(first 
dose)  
1 2 4 8 12 16 20 24 28 32 36 40 44 48 52/ 
PEOT  
Tuberculosis questionnaire  X X      X  X   X   X X X 
Blood sample for bimekizumab 
plasma concentrationsm  X X X X X X X   X   X   X X 
Blood sample for anti - 
bimekizumab antibodiesm  X   X X X X   X   X   X X 
For participating centers: Blood 
sample for immunophenotypingc,m  X X   X X X         X  
Blood sample genomic, proteomic, 
metabolomics, and candidate 
biomarker analysesc,m  X X   X X X         X  
Blood sample genetic/epigenetic 
analysisc,m  X               X  
PASI  X X X X X X X X X X X X X X X X X X 
IGA X X X X X X X X X X X X X X X X X X 
Percentage of BSA  X X X X X X X X X X X X X X X X X X 
DLQI   X X X X X X X   X   X   X  
PHQ -9 X X   X X X X X X X X X X X X X  
eC-SSRS  X X X X X X X X X X X X X X X X X X 
Patient Symptom Diary (daily)  X X X X X X X  X           
scalp IGA   X Xn Xn Xn Xn Xn Xn   Xn   Xn   Xn  
mNAPSI   X   Xo Xo Xo Xo   Xo   Xo   Xo  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 172 of 206 Table  5--1 Schedule of study assessments  
Visita/ 
Week  
 
Protocol activity  
Screening  Initial Treatment Period  
(weeks after first dose)  Maintenance Treatment Peri  
(weeks after first dose)  
SFUbb Baseline 
(first 
dose)  
1 2 4 8 12 16 20 24 28 32 36 40 44 48 52/ 
PEOT  
pp-IGA  X   Xp Xp Xp Xp   Xp   Xp   Xp  
EQ-5D-3L  X   X X X X   X   X   X  
SF-36  X   X X X X   X   X   X  
Patient Global Assessment of 
psoriasisq           X   X   X  
PASE   X               X  
PGADAr  X    X  X X   X   X   X  
HAQ -DIr  X   X X X X   X   X   X  
WPAI -SHP V2.0   X      X  X    X   X  
Photographs of skin and nails 
(subset of sites)   X X X X X X X  X   X    X  
Concomitant medication  X X X X X X X X X X X X X X X X X X 
Adverse events  X X X X X X X X X X X X X X X X X X 
IRTs,t X X X X X X X X X X X X X X X X X X 
Bimekizumab, ustekinumab, or 
placebo administrations,t  X   X X X X X X X X X X X X   
BSA=body surface area; CV=cardiovascular; DLQI=Dermatology Life Quality Index; ECG=electrocardiogram; eC -SSRS=electronic Columbia Suicide 
Severity Rating Scale; eCRF=electronic Case Report Form; EQ -5D-3L=Euro -Quality of Life 5 -Dimensions 3 -level; GI=gastro intestinal; HAQ -DI=Health 
Assessment Questionnaire -Disability Index; HCV=hepatitis C virus; HIV=human immunodeficiency virus; ICF=Informed Consent Form; IGA=Investigator’s 
Global Assessment; IGRA=interferon -gamma release assay; IMP=investigational medicina l product; IRT=interactive response technology; 
mNAPSI=Modified Nail Psoriasis Severity Index Score; PASE=Psoriatic Arthritis Screening and Evaluation;  PASI=Psoriasis Area Severity Index; 
PD=pharmacodynamics; PEOT=Premature End of Treatment; PGADA=Patient’ s Global Assessment of Disease Activity; PHQ -9=Patient Health 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 173 of 206 Table  5--1 Schedule of study assessments  
Visita/ 
Week  
 
Protocol activity  
Screening  Initial Treatment Period  
(weeks after first dose)  Maintenance Treatment Peri  
(weeks after first dose)  
SFUbb Baseline 
(first 
dose)  
1 2 4 8 12 16 20 24 28 32 36 40 44 48 52/ 
PEOT  
Questionnaire 9; pp -IGA=palmoplantar Investigator’s Global Assessment; PsA=psoriatic arthritis; SF -36=Short Form 36 -item Health Survey; SFU=Safety 
Follow -Up; scalp IGA=scalp -specific Investigato r’s Global Assessment; TB=tuberculosis; WPAI -SHP=Work Productivity and Activity Impairment 
Questionnaire -specific health problem  
a Visit windows of +/ - 3 days from the first dose at all visits except SFU. SFU Visit window is -3 and +7 days from last dose.  
b The SFU Visit will occur 20 weeks after the last dose for subjects who do not enroll in the open -label study.  
c A separate ICF will be required for subjects who decide to participate in the genomics, genetics, and proteomics substudy. Th e ICF must be sig ned prior to 
collecting any samples for the substudy. Samples for immunophenotyping will be analyzed immediately. All PD samples and genom ic, proteomic, and 
metabolomics samples will be stored at -80°C at the central biorepository for up to 20 years.  
d A separate ICF is required to be completed for the open -label study.  
e Ensure no significant changes in medical history.  
f Includes evaluation of signs and symptoms of active TB and risk for exposure to TB.  
g The physical examination will include examination of the following systems: eyes, hair, and skin; respiratory; CV; and GI.  
h Vital signs (sitting systolic and diastolic blood pressure, pulse rate, and body temperature) are to be measured prior to blo od sampling, and prior to dosing, 
where applicable.  
i Pregnancy testing will consist of serum testing at the Screening. The pregnancy test will be urine at all other visits.  
j Subjects who have evidence of or test positive for hepatitis B by any of the following criteria: 1) positive for hepatitis B surface ant igen (HBsAg+); 2) positive 
for anti -hepatitis B core antibody (HBcAb+) are excluded. A positive test for HCV is defined as: 1) positive for hepatitis C antibody (anti-HCV Ab), and 2) 
positive via a confirmatory test for HCV (for example, HCV polymerase cha in reaction) are also excluded. Subjects will also be tested for anti -hepatitis  B 
surface antibody.  
k The HIV test results will not be recorded in the eCRF.  
l Screening chest x -ray must occur within 3 months prior to Screening Visit.  
m All blood samples ta ken prior to dosing.  
n The scalp IGA will only be assessed for those subjects with scalp involvement (scalp IGA score >0) at Baseline.  
o The mNAPSI will be assessed only in subjects with nail involvement (mNAPSI score >0) at Baseline.  
p The pp -IGA will onl y be assessed in subjects with palmoplantar involvement (pp -IGA score >0) at Baseline.  
q The Patient Global Assessment of psoriasis will be performed as part of the patient symptoms diary on a weekly basis from bas eline through the initial 
treatment period  with a +3 day completion window. During the Maintenance Treatment Period this assessment will be completed at each clinic vis it specified 
with a ±3 day completion window.  
r The PGADA and HAQ -DI are assessed for all subjects at Baseline. At all subsequent visits, the PGADA and HAQ -DI are assessed only for subjects with PsA 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 174 of 206 Table  5--1 Schedule of study assessments  
Visita/ 
Week  
 
Protocol activity  
Screening  Initial Treatment Period  
(weeks after first dose)  Maintenance Treatment Peri  
(weeks after first dose)  
SFUbb Baseline 
(first 
dose)  
1 2 4 8 12 16 20 24 28 32 36 40 44 48 52/ 
PEOT  
at Baseline (defined as a past medical history of PsA or PASE ≥47).  
s IMP administration is based on randomization.  
t The dosing window is ±7 days relative to the scheduled dosing visit.  
 
 
Has been changed to:  
Table  5-1: Schedule of study assessments  
Visita/ 
Week  
 
Protocol activity  
Screening  Initial Treatment Period  
(weeks after first dose)  Maintenance Treatment Peri  
(weeks after first dose)  
SFUcb Baseline 
(first 
dose)  
1 2 4 8 12 16 20 24 28 32 36 40 44 48 52/ 
PEOT  
Informed consentc X               Xd   
Inclusion/exclusion  X X                 
Urine drug screen  X                X  
Demographic data  X                  
Psoriasis history  X                  
Significant past medical history and 
concomitant diseases  X Xe                 
Physical examf, g X X     X X  X   X    X X 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 175 of 206 Table  5-1: Schedule of study assessments  
Visita/ 
Week  
 
Protocol activity  
Screening  Initial Treatment Period  
(weeks after first dose)  Maintenance Treatment Peri  
(weeks after first dose)  
SFUcb Baseline 
(first 
dose)  
1 2 4 8 12 16 20 24 28 32 36 40 44 48 52/ 
PEOT  
Height   X                 
Body weight   X     X X  X   X    X  
Vital signsh X X X X X X X X X X X X X X X X X X 
Hematology and biochemistry  X X X X X X X X X X  X  X  X X X 
Urinalysis  X X      X  X  X  X  X X X 
ECG  X      X X     X     X  
Pregnancy testingi X X   X X X X X X X X X X X X X X 
Hepatitis B and C testingj X                  
HIV testingk X                  
Chest x -rayl X                  
IGRA Tuberculosis test  X               X   
Tuberculosis questionnaire  X X     X X  X   X   X X X 
Blood sample for bimekizumab 
plasma concentrationsm  X X X X X X X   X   X   X X 
Blood sample for anti - 
bimekizumab antibodiesm  X   X X X X   X   X   X X 
For participating centers: Blood 
sample for 
immunophenotypingc,m  X X   X X X         X  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 176 of 206 Table  5-1: Schedule of study assessments  
Visita/ 
Week  
 
Protocol activity  
Screening  Initial Treatment Period  
(weeks after first dose)  Maintenance Treatment Peri  
(weeks after first dose)  
SFUcb Baseline 
(first 
dose)  
1 2 4 8 12 16 20 24 28 32 36 40 44 48 52/ 
PEOT  
Blood sample genomic, proteomic, 
metabolomics, and candidate 
biomarker analysesc,m  X X   X X X         X  
Blood sample genetic/epigenetic 
analysisc,m  X               X  
PASI  X X X X X X X X X X X X X X X X X X 
IGA X X X X X X X X X X X X X X X X X X 
Percentage of BSA  X X X X X X X X X X X X X X X X X X 
DLQI   X X X X X X X   X   X   X  
PHQ -9 X X   X X X X X X X X X X X X X  
eC-SSRS  X X X X X X X X X X X X X X X X X X 
Patient Symptom Diary (daily)  X X X X X X X  X           
scalp IGA   X Xn Xn Xn Xn Xn Xn   Xn   Xn   Xn  
mNAPSI   X   Xo Xo Xo Xo   Xo   Xo   Xo  
pp-IGA  X   Xp Xp Xp Xp   Xp   Xp   Xp  
EQ-5D-3L  X   X X X X   X   X   X  
SF-36  X   X X X X   X   X   X  
Patient Global Assessment of 
psoriasisq           X   X   X  
PASE   X               X  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 177 of 206 Table  5-1: Schedule of study assessments  
Visita/ 
Week  
 
Protocol activity  
Screening  Initial Treatment Period  
(weeks after first dose)  Maintenance Treatment Peri  
(weeks after first dose)  
SFUcb Baseline 
(first 
dose)  
1 2 4 8 12 16 20 24 28 32 36 40 44 48 52/ 
PEOT  
PGADAr  X    X  X X   X   X   X  
HAQ -DIr  X   X X X X   X   X   X  
WPAI -SHP V2.0   X      X  X    X   X  
Photographs of skin and nails 
(subset of sites)   X X X X X X X  X X  X X   X  
Concomitant medication  X X X X X X X X X X X X X X X X X X 
Adverse events  X X X X X X X X X X X X X X X X X X 
IRTs,t X X X X X X X X X X X X X X X X X X 
Bimekizumab, ustekinumab, or 
placebo administrations,t  X   X X X X X X X X X X X X   
BSA=body surface area; CV=cardiovascular; DLQI=Dermatology Life Quality Index; ECG=electrocardiogram; eC -SSRS=electronic Columbia Suicide 
Severity Rating Scale; eCRF=electronic Case Report Form; EQ -5D-3L=Euro -Quality of Life 5 -Dimensions 3 -level; GI=gastro intestinal; HAQ -DI=Health 
Assessment Questionnaire -Disability Index; HCV=hepatitis C virus; HIV=human immunodeficiency virus; ICF=Informed Consent Form; IGA=Investigator’s 
Global Assessment; IGRA=interferon -gamma release assay; IMP=investigational medicina l product; IRT=interactive response technology; 
mNAPSI=Modified Nail Psoriasis Severity Index Score; PASE=Psoriatic Arthritis Screening and Evaluation;  PASI=Psoriasis Area Severity Index; 
PD=pharmacodynamics; PEOT=Premature End of Treatment; PGADA=Patient’ s Global Assessment of Disease Activity; PHQ -9=Patient Health 
Questionnaire 9; pp -IGA=palmoplantar Investigator’s Global Assessment; PsA=psoriatic arthritis; SF -36=Short Form 36 -item Health Survey; SFU=Safety 
Follow -Up; scalp IGA=scalp -specific Investigato r’s Global Assessment; TB=tuberculosis; WPAI -SHP=Work Productivity and Activity Impairment 
Questionnaire -specific health problem  
a Visit windows of +/- 3 ±3 days from the first dose to the Week 24 visit. Visit windows of ±7 days from the Week 28 visit to t he Week 52 visit. The  SFU 
Visit window is ±7 days -3 and +7 days  from last final  dose.  
b The SFU Visit will occur 20 weeks after the last final  dose for subjects who do not enroll in the open -label study.  
c A separate ICF will be required for subjects who decide to participate in the genomics, genetics, and proteomics substudy. The ICF must be signed 
prior to collecting any samples for the substudy. Samples for immunophenotyping will be analyzed immediately.  All PD samples and  genomic, 
proteomic, and metabo lomics samples will be stored at -80°C at the central biorepository for up to 20 years.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 178 of 206 Table  5-1: Schedule of study assessments  
Visita/ 
Week  
 
Protocol activity  
Screening  Initial Treatment Period  
(weeks after first dose)  Maintenance Treatment Peri  
(weeks after first dose)  
SFUcb Baseline 
(first 
dose)  
1 2 4 8 12 16 20 24 28 32 36 40 44 48 52/ 
PEOT  
d A separate ICF is required to be completed for the open -label study.  
e Ensure no significant changes in medical history.  
f Includes evaluation of signs and symptoms o f active TB and risk for exposure to TB.  
g The physical examination will include examination of the following systems: eyes, hair, and skin; respiratory; CV; and GI  be performed as per 
Section  12.3.5 . 
h Vital signs (sitting systolic and diastolic blood pre ssure, pulse rate, and body temperature) are to be measured prior to blood sampling, and prior to dosing, 
where applicable.  
i Pregnancy testing will consist of serum testing at the Screening. The pregnancy test will be urine at all other visits.  
j Subjects  who have evidence of or test positive for hepatitis B by any of the following criteria: 1) positive for hepatitis B surface a ntigen (HBsAg+); 2) positive 
for anti -hepatitis B core antibody (HBcAb+) are excluded. A positive test for HCV is defined as: 1) p ositive for hepatitis C antibody (anti -HCV Ab), and 2) 
positive via a confirmatory test for HCV (for example, HCV polymerase chain reaction) are also excluded. Subjects will also b e tested for anti -hepatitis  B 
surface antibody.  
k The HIV test results will not be recorded in the eCRF.  
l Screening chest x -ray must occur within 3 months prior to Screening Visit.  
m All blood samples taken prior to dosing except at Visit 1 and Visit 2 (at which no dose administration occurs) . 
n The scalp IGA will only be assesse d for those subjects with scalp involvement (scalp IGA score >0) at Baseline.  
o The mNAPSI will be assessed only in subjects with nail involvement (mNAPSI score >0) at Baseline.  
p The pp -IGA will only be assessed in subjects with palmoplantar involvement ( pp-IGA score >0) at Baseline.  
q The Patient Global Assessment of psoriasis will be performed as part of the patient symptoms diary on a weekly basis from bas eline through the initial 
treatment period with a +3 day completion window . During the Maintenance Treatment Period this assessment will be completed at each clinic visit 
specified with a ±3 day completion window  the specified clinic visits . 
r The PGADA and HAQ -DI are assessed for all subjects at Baseline. At all subsequent visits, the PGADA and HAQ -DI are assessed only for subjects with PsA 
at Baseline (defined as a past medical history of PsA or PASE ≥47).  
s IMP administration is based on randomization.  
t The dosing window is ±7 ±3 days relative to the scheduled dosing visit  through Week 24. The dosing  window is ±7 days from Week 28 through the end of 
the study . 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 179 of 206 Change #21  
Section 5.7 Schematic diagram  
The following footnote was added after Figure 5 -1 Schematic diagram:  
Note: At Week 24 and all following visits, subjects on continuous treatment with the same 
IMP for at least 12 weeks with a persistent IGA score ≥3 over at least a 4 -week period 
are defined as nonresponders and should discontinue IMP.  
 
Change #22  
Section 6.1  Inclusion criteria  
To be eligible to participate in this study, all of the following criteria must be met at Screening 
and be reconfirmed at the Baseline Visit:  
6. Subject is a candidate for systemic PSO therapy and/or phototherapy and/or 
photochemotherapy.  
Have been changed to:  
To be eligible to participate in this study, all of the following criteria must be met at Screening 
and be reconfirmed  at the Baseline Visit:  
6. Subject is a candidate for systemic PSO therapy and/or phototherapy  and/or 
photochemotherapy . 
 
Change #23  
Section 6.2  Exclusion criteria  
3. Subject previously participated in another study of a medication (systemic) under 
investigation within the 12 weeks or at least 5 half -lives prior to the Screening Visit, 
whichever is greater, or is currently participating  in another study of a medication (systemic) 
under investigation.  
4. Subject previously participated in another study of a topical medication under investigation 
within the 4 weeks prior to the Screening Visit, or is currently participating in another stud y 
of a topical medication under investigation.  
5. Subject previously participated in another study of a medical device under investigation 
within the 4  weeks prior to the Screening Visit, or is currently participating in another study 
of a medical device u nder investigation.  
14. Subject has any active malignancy or history of malignancy within 5 years prior to the 
Screening Visit EXCEPT treated and considered cured cutaneous squamous or basal cell 
carcinoma, or in situ cervical cancer, or ductal carcinoma i n situ of the breast.  
17. Subject has any systemic disease (eg, renal failure, heart failure, hypertension, liver disease, 
diabetes) considered by the Investigator to be uncontrolled, unstable, or likely to progress to 
a clinically significant degree durin g the course of the study.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 180 of 206 27. Subject has presence of severe depression, indicated by a score of 15 to 19 using the 
screening PHQ -9. Medication used to treat depression should be stable for 4 weeks prior to 
Baseline.  
Have been changed to:  
3a. Subject prev iously participated in another study of a medication (systemic) under 
investigation within the 12 weeks or at least 5 half -lives prior to the Screening Visit, 
whichever is greater, or  is currently participating in another study of a medication 
(systemic) u nder investigation. Subject must be washed out of the medication for 12 
weeks or at least 5 half -lives prior to the Baseline Visit, whichever is greater.  
4a. Subject previously participated in another study of a topical medication under 
investigation withi n the 4 weeks prior to the Screening Visit , or is currently participating 
in another study of a topical medication under investigation. Subject must be washed out of 
the medication for 4 weeks prior to the Baseline Visit.  
5a. Subject previously participate d in another study of a medical device under investigation 
within the 4  weeks prior to the Screening Visit, or  is currently, or was within the 4 weeks 
prior to the Baseline  Visit, participating in another study of a medical device under 
investigation.  
14a. Subject has any active malignancy or history of malignancy within 5 years prior to the 
Screening Visit EXCEPT treated and considered cured cutaneous squamous or basal cell 
carcinoma, or in situ cervical cancer, or ductal carcinoma in situ of the breast.  
17a. Subject has any systemic disease (eg, renal failure, heart failure, hypertension, liver 
disease, diabetes  ie, cardiovascular, neurological, renal, liver, metabolic, 
gastrointestinal, hematological, immunological, etc.)  considered by the Investigator to  be 
uncontrolled, unstable, or likely to progress to a clinically significant degree during the 
course of the study.  
27a. Subject has presence of moderately severe major depression or  severe  major  
depression, indicated by a score of 15 to 19 ≥15  using the screening PHQ -9. Medication used 
to treat depression should be stable for 4-8 weeks prior to Baseline.  
 
Change #24  
Section 6.2  Exclusion criteria  
The following text has been added:  
30. Subject is taking or has taken prohibited psoriasis medications without  meeting the 
mandatory washout period relative to the Baseline Visit ( Table 7 -2). 
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 181 of 206 Change #25  
Section 6.3 Withdrawal criteria  
The following withdrawal criteria have been added, modified, and/or renumbered:  
8. At Week 24 and all following visits, subjects on continuous treatment for at least 
12 weeks with a persistent IGA score ≥3 over at least a 4 -week period are defined as 
nonresponders and should discontinue study product.  
9. There is confirmation of a pregnancy during the study, as evidenced by a positi ve pregnancy 
test (see Section  12.1.4  for more information regarding pregnancies).  
10. A subject considered as having either a suspected new LTB infection or who develops active 
TB or NTMB infection during the study (including but not limited to, conversio n 
demonstrated by IGRA or other diagnostic means) must be immediately discontinued from 
IMP and a PEOT Visit must be scheduled as soon as possible, but not later than the next 
regular visit.  
The subject must be permanently withdrawn if further examinations  result in a diagnosis of 
active TB, or if the subject is diagnosed with latent TB infection (LTBI) with no initiation of 
prophylactic treatment, prematurely discontinues prophylactic treatment, or, in the opinion of 
the Investigator or Sponsor, is noncomp liant with prophylactic TB therapy.  
Confirmed active TB is an SAE and must be captured on an SAE Report Form and provided 
to the Sponsor in accordance with SAE reporting requirements. As with all SAEs, periodic 
follow -up reports should be completed as per protocol requirements until such time as the TB 
infection resolves.  
Additional information on TB policies is provided in Section  12.3.1 . 
11. Subjects with newly diagnosed inflammatory bowel disease (IBD) or with IBD flares 
during the study must:  
 Be referre d, as appropriate, to a health care professional treating IBD, such as a 
gastroenterologist  
 Discontinue IMP and be followed -up until resolution of active IBD symptoms  
If IBD flares increase in severity or frequency during the study, the Investigator should  
use clinical judgement in deciding whether the subject should continue in the study and 
contact the Medical Monitor and UCB study physician to confirm the subject’s 
suitability for continued participation in the study.  
12. Subjects must be referred immedi ately to a mental health care professional and may be 
withdrawn from the study based upon the Investigator’s judgment of benefit/risk  for either 
of the following:  
 Active suicidal ideation as indicated by a positive response (“Yes”) to Question s 4 or 5 or t o 
the suicidal behavior questions of the “Since Last Visit” version of the eC -SSRS.  
 Moderately severe major  depression as indicated by a PHQ -9 score of 15 to 19 if this 
represents an increase of 3 points compared to last visit.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 182 of 206 13. Subjects must be referre d immediately to a mental healthcare professional and must be 
withdrawn in case of:  
 Active suicidal ideation as indicated by a positive response (“Yes”) to Question 5 of the 
“Since Last Visit” version of the eC -SSRS  
 Any suicidal behavior since last visit.  
 Severe  major  depression as indicated by a PHQ -9 score ≥20.  
The mental health consultation will be documented  must be recorded in source 
documentation.  
 
Change #26  
Section 7.2 Treatment(s) to be administered  
Double -blind Initial Treatment Period dosing  
 Subjects randomized to receive ustekinumab will receive ustekinumab sc at Baseline and 
Week  4, followed by placebo (2 placebo injections sc) at Week  8 and Week  12. Because 
ustekinumab dosing is based on weight, on ustekinumab treatment weeks subjects ≤100k g 
(220lbs) will receive 1 ustekinumab 45mg sc injection and 1 placebo injection and subjects 
>100kg (220lbs) will receive 2 ustekinumab 45mg sc injections.  
Maintenance Treatment Period dosing  
 Subjects randomized to receive ustekinumab will have received us tekinumab sc at Baseline 
and Week  4, and will continue to receive ustekinumab sc every 12 weeks (Weeks 16, 28, and 
40). Subjects will receive placebo (2 placebo injections sc) on non -ustekinumab treatment 
weeks (Weeks 20, 24, 32, 36, 44, and 48). Because u stekinumab dosing is based on weight, 
on ustekinumab treatment weeks subjects ≤100kg (220lbs) will receive 1 ustekinumab 45mg 
sc injection and 1 placebo injection and subjects >100kg (220lbs) will receive 2 ustekinumab 
45mg sc injections.  
Has been changed to: 
Double -blind Initial Treatment Period dosing  
 Subjects randomized to receive ustekinumab will receive ustekinumab sc at Baseline and 
Week  4, followed by placebo (2 placebo injections sc) at Week  8 and Week  12. Because 
ustekinumab dosing is based on weig ht, on ustekinumab treatment weeks subjects ≤100kg 
(220lbs) at Baseline will receive 1 ustekinumab 45mg sc injection and 1 placebo injection 
and subjects >100kg (220lbs) at Baseline will receive 2 ustekinumab 45mg sc injections.  
Maintenance Treatment Perio d dosing  
 Subjects randomized to receive ustekinumab will have received ustekinumab sc at Baseline 
and Week  4, and will continue to receive ustekinumab sc every 12 weeks (Weeks 16, 28, and 
40). Subjects will receive placebo (2 placebo injections sc) on non -ustekinumab treatment 
weeks (Weeks 20, 24, 32, 36, 44, and 48). Because ustekinumab dosing is based on weight, 
on ustekinumab treatment weeks subjects ≤100kg (220lbs) at Baseline will receive 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 183 of 206 1 ustekinumab 45mg sc injection and 1 placebo injection and subj ects >100kg (220lbs) at 
Baseline will receive 2 ustekinumab 45mg sc injections.  
 
Change #27  
Section 7.2 Treatment(s) to be administered  
Table 7 -1: Dosing scheme  
Week  
Dose Assignment  Baseline 
(first 
dose)  4 8 12 16 20 24 28 32 36 40 44 48 
Bimekizumab 
320mg Q4W  ●● ●● ●● ●● ●● ●● ●● ●● ●● ●● ●● ●● ●● 
Ustekinumab 45mg 
(subjects ≤100kg)  ▲○ ▲○ ○○ ○○ ▲○ ○○ ○○ ▲○ ○○ ○○ ▲○ ○○ ○○ 
Ustekinumab 90mg 
(subjects >100kg)  ▲▲  ▲▲  ○○ ○○ ▲▲  ○○ ○○ ▲▲  ○○ ○○ ▲▲  ○○ ○○ 
Placebo  ○○ ○○ ○○ ○○ ●● ●● ●● ●● ●● ●● ●● ●● ●● 
Q4W=every 4 weeks  
Has been changed to:  
Table 7 -1: Dosing scheme  
Week  
Dose Assignment  Baseline 
(first 
dose)  4 8 12 16 20 24 28 32 36 40 44 48 
Bimekizumab 
320mg Q4W  ●● ●● ●● ●● ●● ●● ●● ●● ●● ●● ●● ●● ●● 
Ustekinumab 45mg 
(subjects ≤100kg)  ▲○ ▲○ ○○ ○○ ▲○ ○○ ○○ ▲○ ○○ ○○ ▲○ ○○ ○○ 
Ustekinumab 90mg 
(subjects >100kg)  ▲▲  ▲▲  ○○ ○○ ▲▲  ○○ ○○ ▲▲  ○○ ○○ ▲▲  ○○ ○○ 
Placebo / 
bimekizumab 
320mg Q4W  ○○ ○○ ○○ ○○ ●● ●● ●● ●● ●● ●● ●● ●● ●● 
Q4W=every 4 weeks  
Change #28  
Section  7.6 Drug Accountability  
Blinded study staff may be delegated the responsibility to receive, inventory, and destroy the 
used kits. The packaging identifies each kit by a unique number that does not correlate to the 
contents and therefore, does not unblind study site staff. Unblinded study staff will be 
responsible for preparation (breaking tamper proof sticker on kit, etc) of the clinical study 
material, including recording the administration information on source documents.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 184 of 206 Has been changed to:  
Unblinded study staff will be delegated the responsibility to receive, inventory and destroy 
the used kits. The packaging identifies each kit by a unique number, but due to the 
commercial packaging of the comparator, the unblinded study staff will be responsible in 
order to maintain the blind.  Blinded study staff may be delegated the responsibility to receive, 
inventory, and destroy the used kits. The packaging identifies each kit by a unique number that 
does not correlate to the contents and therefore, does not unblind study site staff. Unblinded 
study staff will be responsible for preparation (breaking tamper proof sticker on kit, etc) of the 
clinical study material, including recording the administration information on source documents.  
 
Change #29  
Section 7.8.2  Prohibited concomitant treatments (medications and therapies)  
Table  7-2: Prohibited psoriasis medications  
Drug  Washout period relative to Baseline Visit  
Topicals except for those permitted ( Section  7.8.1.1 ) 2 weeks  
Systemic retinoids  3 months  
Systemic treatment (nonbiological):  
systemic immunosuppressant agents (eg, 
methotrexate, cyclosporine, azathioprine, thioguanine)  
fumaric acid esters specifically used for the treatment 
of PSO  
systemic corticosteroids  
phototherapy or photochemotherapy  1 month  
Anti-TNFs:  
adalimumab (including biosimi lar) 
etanercept (including biosimilar)  
infliximab (including biosimilar), golimumab, 
certolizumab pegol   
Any exposure to adalimumab  
1 month for etanercept  
3 months for infliximab (including biosimilar), 
golimumab, certolizumab pegol  
Other biologics and other systemic therapies, eg:   
apremilast, tofacitinib  2 weeks for apremilast and tofacitinib  
alefacept, efalizumab, guselkumab  3 months for alefacept, efalizumab, and guselkumab  
ustekinumab, briakinumab  6 months for ustekinumab and briakinumab  
rituxim ab 12 months for rituximab  
Anti-IL-17 therapy:  
brodalumab  
ixekizumab  
secukinumab  3 months  
(bimekizumab is excluded per exclusion criteria)  
Any other antipsoriatic agent (systemic) under 
investigation (or approved after the protocol is approved)  3 months or 5 half -lives, whichever is greater  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 185 of 206 Table  7-2: Prohibited psoriasis medications  
Drug  Washout period relative to Baseline Visit  
Any other antipsoriatic agent (topical) under investigation  1 month  
IL-17=interleukin 17; PSO=psoriasis; TNF=tumor necrosis factor  
Has been changed to:  
Table  7-2: Prohibited psoriasis medications  
Drug  Washout period relative to Baseline Visit  
Topicals except for those permitted ( Section  7.8.1.1 ) 2 weeks  
Systemic retinoids  3 months  
Systemic treatment (nonbiological):  
systemic immunosuppressant agents (eg, 
methotrexate, cyclosporine, azathioprine, thioguanine ) 
fumaric acid esters specifically used for the treatment 
of PSO  
systemic corticosteroids  
phototherapy or photochemotherapy  1 month  
Anti-TNFs:  
adalimumab (including biosimilar)  
etanercept (including biosimilar)  
infliximab (including biosimilar), golimumab, 
certolizumab pegol   
Any exposure to adalimumab  
1 month for etanercept  
3 months for infliximab (including biosimilar), 
golimumab, certolizumab pegol  
Other biologics and other systemic therapies, eg:   
apremilast, tofacitinib  2 weeks for apremilast and tofacitinib  
alefacept, efalizumab, guselkumab  3 months for alefacept, efalizumab, and guselkumab  
tildrakizumab, risankizumab  5 months for tildrakizumab and risankizumab  
ustekinumab, briakinumab  6 months for ustekinumab and briakinumab  
rituximab  12 months for rituximab  
Anti-IL-17 therapy:  
brodalumab  
ixekizumab  
secukinumab  3 months  
(bimekizumab is excluded per exclusion criteria)  
Any other antipsoriatic agent (systemic) under 
investigation (or approved after the protocol is approved)  3 months or 5 half -lives, whichever is greater  
Any other antipsoriatic agent (topical) under investigation  1 month  
IL-17=interleukin 17; PSO=psoriasis; TNF=tumor necrosis factor  
Change #30  
Section  7.10 Randomization and numbering of subjects, first paragraph  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 186 of 206 An IRT will be used for assigning eligible subjects to a treatment regimen based on a 
predetermined production randomization and/or packaging schedule provided by UCB (or 
designee). The randomization schedule will be produced by the IRT vendor. T he IRT will 
generate individual assignments for subject kits of IMP, as appropriate, according to the visit 
schedule. Subject treatment assignment will be stratified by region and prior biologic exposure 
(yes/no). The IRT will generate individual assignmen ts for subject kits of IMP, as appropriate, 
according to the visit schedule.  
Has been changed to:  
An IRT will be used for assigning eligible subjects to a treatment regimen based on a 
predetermined production randomization and/or packaging schedule provid ed by UCB (or 
designee). The randomization schedule will be produced by the IRT vendor. The IRT will 
generate individual assignments for subject kits of IMP, as appropriate, according to the visit 
schedule. Subject treatment assignment will be stratified b y region (North America, Western 
Europe, Central/Eastern Europe, and Asia/Australia)  and prior biologic exposure (yes/no). 
The IRT will generate individual assignments for subject kits of IMP, as appropriate, according 
to the visit schedule.  
 
Change #31  
Section 8 STUDY PROCEDURES BY VISIT, first bullet  
 Visit windows of ±3 days on either side of the scheduled dosing are permitted; however, the 
Investigator should try to keep the subjects on the original dosing schedule. The window of 
±3 days is relative to B aseline and applicable for all subsequent visits. Changes to the dosing 
schedule outside of the 3 -day window must be discussed with the Medical Monitor.  
 The dosing window is ±7 days relative to the scheduled dosing visit.  
 For the SFU Visit (20 weeks after the last dose), the visit window  should occur no more than 
3 days prior to the scheduled visit date and within 7 days after the scheduled visit date 
(-3 days/+7 days).  
Has been changed to:  
 From the Week1 visit to the Week 24 visit,  Visit  visit windows of ± 3 days on either side of 
the scheduled dosing are permitted; however, the Investigator should try to keep the subjects 
on the original dosing schedule. The window of ±3 days is relative to Baseline and 
applicable for all subsequent visits. From the Week 28  visit to the Week 52 visit, visit 
windows are ±7  days.  Changes to the dosing schedule outside of the visit window must be 
discussed with the Medical Monitor.  
 The dosing window is ±3 days relative to the scheduled dosing visit through Week 24. 
The dosing window is ±7 days relative to the scheduled dosing visit  from Week 28 through 
the end of the study.  
 For the SFU Visit (20 weeks after the last final  dose), the visit window should occur no 
more than 3 days prior to the scheduled visit date and within 7 day s after  is ±7  days 
relative to the scheduled visit date (-3 days/+7 days) . 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 187 of 206 Change #32  
Section 8.1 Screening Visit (2 to 4 weeks)  
Has been changed to:  
Section 8.1 Screening Visit (2 to 4 5 weeks)  
 
Change #33  
Sections 8.2.1 Baseline Visit  
The following has been added from the bulleted list:  
 Physical exam including evaluation of signs and symptoms of active TB and risk for 
exposure to TB  
 
Change #34  
Sections 8.2.1 Baseline Visit, 8.2.2 Week 1 Visit (±3 days relative to Baseline), 8.2.5 Week 8 
Visit (±3 days r elative to Baseline), 8.2.6 Week 12 Visit (±3 days relative to Baseline), 8.3.9 
Week 52 ( ±3 ±7 days),  
The following has been deleted from the bulleted list:  
 Immunophenotyping (participating centers only)  
 
Change #35  
Section 8.2.6 Week 12 Visit (±3 days rel ative to Baseline)  
The following have been added to the bulleted list:  
 Physical exam including evaluation of signs and symptoms of active TB and risk for 
exposure to TB  
 Body weight  
 TB questionnaire  
 Record 12 -lead ECG  
 
Change #36  
Section 8.2.7 Week 16 Visit  (±3 days relative to Baseline)  
The following have been deleted from the bulleted list:  
 Physical exam including evaluation of signs and symptoms of active TB and risk for 
exposure to TB  
 Body weight  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 188 of 206  Collection of blood and urine samples for the following clinical laboratory tests should be 
obtained prior to dosing:  
 Immunophenotyping (participating centers only)  
 Record 12 -lead ECG  
 TB questionnaire  
 
Change #37  
Section 8.3.1 Week 20 Visit (±3 days relative to Baseline)  
The following have been added to the bul leted list:  
 Collection of blood and urine samples for the following clinical laboratory tests should be 
obtained prior to dosing:  
 Hematology and biochemistry  
 
Change #38  
Section 8.3.2 Week 24 Visit (±3 days relative to Baseline)  
The following have been del eted from the bulleted list:  
 Collection of blood and urine samples for the following clinical laboratory tests should be 
obtained prior to dosing:  
 Urinalysis and electrolytes  
 Photographs of skin and nails (participating centers only)  
 
Change #39  
Sections 8 .3.3 Week 28 Visit (±3 days relative to Baseline) and 8.3.6 Week 40 Visit (±3 days 
relative to Baseline)  
The following has been added to the bulleted list:  
 Photographs of skin and nails (participating centers only)  
 
Change #40  
Sections 8.3.3 Week 28 (±3 da ys), 8.3.4 Week 32 (±3 days), 8.3.5 Week 36 (±3 days), 8.3.6 
Week 40 (±3 days), 8.3.7 Week 44 (±3 days), 8.3.8 Week 48 (±3 days), and 8.3.9 Week 52 (±3 
days)  
Has been changed to:  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 189 of 206 Sections 8.3.3 Week 28 ( ±3 ±7 days), 8.3.4 Week 32 ( ±3 ±7 days), 8.3.5 Week 36 (±3 ±7 
days), 8.3.6 Week 40 ( ±3±7 days), 8.3.7 Week 44 ( ±3 ±7 days), 8.3.8 Week 48 ( ±3 ±7 days), 
and 8.3.9 Week 52 ( ±3 ±7 days)  
 
Change #41  
Section 8.3.5 Week 36 Visit (±3 days relative to Baseline)  
The following has been deleted from the bulleted list: 
 Photographs of skin and nails (participating centers only)  
 
Change #42  
Section 8.3.8 Week 48 Visit (±7 days relative to Baseline)  
The following has been deleted from the bulleted list:  
 TB questionnaire  
 
Change #43  
Section 8.5 Safety Follow -Up Visit ( 20 weeks after last dose, -3 days/+7 days)  
Has been changed to:  
Section 8.5 Safety Follow -Up Visit (20 weeks after last final  dose, -3 days/+7 days  ±7 days ) 
 
Change #44  
Section 9  ASSESSMENT OF EFFICACY  
The PASI, BSA, IGA, scalp IGA, mNAPSI, and pp -IGA sho uld be performed by the 
Investigator, another delegated physician, or an appropriately qualified medical professional 
(based on local requirements) who has had documented training on how to perform these 
assessments correctly. Preferably, the same assessor  should evaluate the subject at each 
assessment.  
Has been changed to:  
The PASI, BSA, IGA, scalp IGA, mNAPSI, and pp -IGA should be performed by the 
Investigator, another delegated physician, or an appropriately qualified medical professional 
(based on local  requirements) who has had documented training on how to perform these 
assessments correctly. Preferably, the  The same assessor should evaluate the subject at each 
assessment.  
 
Change #45  
Section 9.10 Patient Global Assessment of psoriasis, second and thir d paragraphs  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 190 of 206 The Patient Global Assessment of PSO will be performed as part of the patient symptoms diary 
from baseline through the Initial Treatment Period ; the assessment is to completed within a +3 
day completion window at each of the visits specified in Table 5 -1. 
During the double -blind Maintenance Treatment Period, this assessment will be completed 
within a +3 day completion window at the visits specified in Table 5 -1. 
Has been changed to:  
The Patient Global Assessment of PSO will be performed as part of the patient symptoms diary 
from baseline  Screening  through the Initial Treatment Period ; the assessment is to completed 
within a +3 day completion window at each of the visits specified in T able 5 -1. 
During the double -blind Maintenance Treatment Period, this assessment will be completed  
within a +3 day completion window  at the visits specified in Table 5 -1. 
 
Change #46  
Section 9.11 Patient Symptom Diary responses, second paragraph  
The ePRO di ary will also administer the patient global assessment of PSO as noted above 
appropriate anchor items at the end of every study week. The ePRO diary software will be 
programmed such that the subjects will be given a window of opportunity to complete the eP RO 
diaryeach evening. The data collected on the ePRO diary will be uploaded to a central server 
database and will be 21 CFR Part 11 compliant. Appropriate GCP procedures (including 
subject/site training and testing) will be performed at the study sites.  
Has been changed to:  
The ePRO diary will also administer the patient global assessment of PSO as noted above 
appropriate anchor items at the end of every study week. The ePRO diary software will be 
programmed such that the subjects will be given a window of  opportunity to complete the ePRO 
diary each evening . The data collected on the ePRO diary will be uploaded to a central server 
database and will be 21 CFR Part 11 compliant. Appropriate GCP procedures (including 
subject/site training and testing) will be p erformed at the study sites.  
 
Change #47  
Section 9.12 PASE questionnaire  
The PASE questionnaire is a self -administered tool to screen for active PsA in patients with PSO 
(Husni et al, 2014). The questionnaire consists of 15 items that are divided into a 7 -item 
symptoms subscale and an 8 -item functions subscale. Standardized responses are based on 5 
categories relating to agreement (strongly agree [1], agree [2], no idea [3], disagree [4], and 
strongly disagree [5]).  
Has been changed to:  
The PASE questionn aire is a self -administered tool to screen for active PsA in patients with PSO 
(Husni et al, 2014). The questionnaire consists of 15 items that are divided into a 7 -item 
symptoms subscale and an 8 -item functions subscale. Standardized responses are based o n 5 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 191 of 206 categories relating to agreement ( strongly agree [ 15], agree [ 24], no idea [3],  disagree [ 42], 
and strongly disagree [ 51]).  
 
Change #48  
Section 9.16 Photographs  
At certain clinical sites, representative photographs of the changes in skin and nail appe arance 
will be captured. Subjects will have full body (anterior and posterior views) and nail photographs 
taken. Photographs will be anonymized.  
Has been changed to:  
At certain clinical sites, representative photographs of the changes in skin and nail appearance 
will be captured. Subjects will have full body (anterior and posterior views) and nail  
photographs taken. Only those subjects with nail disease at Baseline wil l have nail 
photographs taken. Only those subjects with palmoplantar disease at Baseline will have 
photographs of their palms or soles of their feet taken. Only those subjects scalp disease at 
Baseline will have scalp photographs taken.  Photographs will be  anonymized.  
 
Change #49  
Section 10 Assessment Of Pharmacokinetic/ Pharmacodynamic/ And Pharmacogenomic 
Variable(s)  
Section 10.1 Pharmacokinetic and pharmacodynamic variables  
Blood samples for measurement of PK assessments (Section 4.4) will be collected a t the time 
points specified in the schedule of study assessments (Table 5‒1).  
At dosing visits, blood samples will be drawn prior to dosing, and will be drawn at the same time 
of the sampling for clinical laboratory tests. The time and date of collection w ill be recorded in 
the eCRF.  
Instructions pertaining to sample collection, processing, storage, labeling, and shipping are 
provided in the laboratory manual for this study. Detailed information on sample analysis will be 
provided in a bioanalytical report.  
Pharmacokinetic samples from subjects receiving ustekinumab will not be analyzed, but stored 
for potential future PK analysis and anti -drug antibody determination.  
At participating centers, immunophenotyping will be assessed by flow cytometry using 
fluorescent -activated cell sorting on whole blood of T -cells, B -cells, natural killer cells, and T -
helper subsets.  
Has been changed to:  
Section 10 Assessment Of Pharmacokinetic And Pharmacogenomic Variable(s)  
Section 10.1 Pharmacokinetic variables  
Blood s amples for measurement of PK assessments (Section 4.4) will be collected at the time 
points specified in the schedule of study assessments (Table 5‒1).  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 192 of 206 At dosing visits, blood samples will be drawn prior to dosing, and will be drawn at the same time 
of the  sampling for clinical laboratory tests. The time and date of collection will be recorded in 
the eCRF.  
Instructions pertaining to sample collection, processing, storage, labeling, and shipping are 
provided in the laboratory manual for this study. Detailed information on sample analysis will be 
provided in a bioanalytical report.  
Pharmacokinetic samples from subjects receiving ustekinumab will not be analyzed, but stored 
for potential future PK analysis and anti -drug antibody determination.  
At participating centers, immunophenotyping will be assessed by flow cytometry using 
fluorescent -activated cell sorting on whole blood of T -cells, B -cells, natural killer cells, and 
T-helper subsets.  
 
Change #50  
Section 12.1.4  Pregnancy  
 The subject should immediately stop the intake of the IMP or be down -titrated as instructed 
at the PEOT visit.  
A pregnancy becomes an SAE in the following circumstances: miscarriage, abortion (elective or 
spontaneous), unintended pregnancy after hormonal contraceptive failure (if the hormona l 
contraceptive was correctly used), ectopic pregnancy, fetal demise, or any congenital 
anomaly/birth defect of the baby. Those SAEs must be additionally reported using the 
Investigator SAE Report Form.  
Have been changed to:  
 The subject should immediately  stop the intake of the IMP or be down -titrated as 
instructed at the PEOT visit . 
A pregnancy becomes an SAE in the following circumstances: miscarriage, elective  abortion 
(elective or spontaneous abortion when medically indicated (e.g. when pregnancy is 
endangering life or health of woman or when fetus will be born with severe abnormalities ), 
unintended pregnancy after hormonal contraceptive failure (if the hormonal contraceptive was 
correctly used), ectopic pregnancy, fetal demise, or any congenital anom aly/birth defect of the 
baby. Those SAEs must be additionally reported using the Investigator SAE Report Form.  
 
Change #51  
Section 12.2 Laboratory measurements  
Table  12-2: Laboratory measurements  
Hematology  Chemistry  Urinalysis dipsticka 
Basophils  Calcium  pH 
Eosinophils  Chloride  Albumin (protein)  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 193 of 206 Table  12-2: Laboratory measurements  
Hematology  Chemistry  Urinalysis dipsticka 
Lymphocytes  Magnesium  Glucose  
Atypical lymphocytes  Potassium  Blood  
Monocytes  Sodium  Leukocyte esterase  
Neutrophils  Glucose  Nitrite  
Hematocrit  BUN  Urine dipstick for pregnancy testingb 
Hemoglobin  Creatinine  Urine drug screend 
MCH  ALP   
MCHC  AST   
MCV  ALT   
Platelet count  GGT   
RBC count  Total bilirubin   
WBC count  LDH   
 Serum pregnancy testingb  
Has been changed to:  
Table  12-2: Laboratory measurements  
Hematology  Chemistry  Urinalysis dipsticka 
Basophils  Calcium  pH 
Eosinophils  Chloride  Albumin (protein)  
Lymphocytes  Magnesium  Glucose  
Atypical lymphocytes  Potassium  Blood  
Monocytes  Sodium  Leukocyte esterase  
Neutrophils  Glucose  Nitrite  
Hematocrit  BUN  Urine dipstick for pregnancy testingb 
Hemoglobin  Creatinine  Urine drug screend 
MCH  ALP   
MCHC  AST   
MCV  ALT   
Platelet count  GGT   
RBC count  Total bilirubin   
WBC count  LDH   
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 194 of 206 Table  12-2: Laboratory measurements  
Hematology  Chemistry  Urinalysis dipsticka 
 Serum pregnancy testingb  
 
Change #52  
Section 12.2.1  Evaluation of PDILI  
Rechallenge with a substance potentially causing drug -induced liver injury is dangerous, may be 
fatal, and must not occur.  
Has been changed to:  
Rechallenge with a substance potentially causing drug -induced liver injury is dangerous, 
may be fatal, and must not occur.  
 
Change #53  
Section 12.2.1.2.1  IMP restart/rechallenge (if applicable)  
Rechallenge with a substance potentially causing drug -induced liver injury is dangerous, may be 
fatal, and must not occur.  
Has been changed to:  
Section 12.2.1.2.1  IMP restart/rechallenge (if applicable)  
Rechallenge with a substance potentially causing drug -induced liver injury is dangerous, 
may be fatal, and must not occur.  Rechallenge with IMP can occur only if ALL of the 
following requirements are met:  
 The results of additional testing and monitoring des cribed in Section 12.2.1.3 and 
Section  12.2.1.4 confirm a nondrug -related cause for the abnormal hepatic laboratory 
parameters and any associated symptoms (ie, a subsequent alternative diagnosis fully 
explains the hepatic findings).  
 The subject has shown clear therapeutic benefit from the IMP.  
 Subject’s ALT or AST elevations do not exceed ≥5xULN.  
 Subject’s total bilirubin is <2xULN.  
 Subject has no signs or symptoms of hypersensitivity or hepatitis.  
 The rechallenge is approved by the UCB responsible physician, DMC, and a 
hepatologist. The hepatologist must be external to UCB but may be a member of the 
DMC. It is recommended that the hepatologist be a local hepatology expert or the 
hepatologist treating the subject.  
 Subject agrees to the Investigator -recommended monitoring plan.  
Change #54  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 195 of 206 Section 12.3.1 Assessment and management of TB and TB risk factors  
b. High risk of acquiring TB infection:  
 Known exposure  to another person with active TB infection within the 3 months prior to 
Screening.  
Has been cha nged to:  
b. High risk of acquiring TB infection:  
 Known close  exposure  to another person with active TB infection within the 3 months 
prior to Screening.  
 
Change #55  
Section 12.3.1.1 Tuberculosis assessment by IGRA  
During conduct of the study, the TB assess ment by IGRA (QuantiFERON TB GOLD is 
recommended) will be performed as described in Table 5 -1 for all subjects.  
Has been changed to:  
During conduct of the study, the TB assessment by IGRA (QuantiFERON TB GOLD  test is 
recommended) will be performed as described in Table 5 -1 for all subjects.  
 
Change #56  
Section 12.3.1.3 Tuberculosis questionnaire, last paragraph  
Subjects with a latent or active TB infection must be withdrawn from the study.  
Has been deleted:  
Subject s with a latent or active TB infection must be withdrawn from the study.  
 
Change #57  
Section 12.3.1.4 Tuberculosis management, second paragraph  
During the study, subjects who develop evidence of LTB infection or active TB must 
immediately stop further administration of IMP and will be referred to an appropriate TB 
specialist (pulmonologist or infectious disease specialist) for further evaluation. Evidence of 
LTB infection is defined as subject’s IGRA test converts to positive or indeterminate (and 
confi rmed indeterminate on repeat), or the subject’s questionnaire or history and physical 
indicates that TB infection or exposure may have occurred. Evidence of active TB includes, in 
addition to the aforementioned tests, signs and symptoms of organ involvemen t. In either 
situation, the subject should be carefully assessed by a TB specialist for active TB. Subjects 
diagnosed with active TB or LTB infection should be withdrawn from the study and receive 
appropriate TB or prophylaxis therapy.  
Has been changed to:  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 196 of 206 During the study, subjects who develop evidence of LTB infection or active TB must 
immediately stop further administration of IMP and will be referred to an appropriate TB 
specialist (pulmonologist or infectious disease specialist) for further evaluation.  Evidence of 
LTB infection is defined as subject’s IGRA test converts to positive or indeterminate (and 
confirmed indeterminate on repeat), or the subject’s questionnaire or history and physical 
indicates that TB infection or exposure may have occurred. Ev idence of active TB includes, in 
addition to the aforementioned tests, signs and symptoms of organ involvement. In either 
situation, the subject should be carefully assessed by a TB specialist for active TB. Subjects 
diagnosed with active TB or LTB infecti on should be withdrawn from the study and receive 
appropriate TB or prophylaxis therapy.  
 
Change #58  
Section  12.3.2 Pregnancy testing  
The Screening Visit serum pregnancy testing results must be negative and received and reviewed 
prior to randomization. A n egative urine pregnancy test result should be obtained immediately 
prior to each administration of IMP and at all subsequent post -dosing visits. Pregnancy tests 
should be administered to all female subjects of childbearing potential, regardless of their us e of 
birth control.  
Has been changed to:  
The Screening Visit serum pregnancy testing results must be negative and received and reviewed 
prior to randomization. A negative urine pregnancy test result should be obtained immediately 
prior to each administrati on of IMP and at all subsequent post -dosing visits  at the visits 
specified in Table 5 -1. Pregnancy tests should be administered to all female subjects of 
childbearing potential, regardless of their use of birth control.  
 
Change #59  
Section 13.3.1.1 Electronic Health Record extraction pilot  
It is anticipated that a selection of data points (Demography, Medical History, Concomitant 
Medications, and potentially Vital Signs) will be collected via the subjects’ Electronic 
Healthcare Record (EHR) at specif ic sites as part of a small EHR Pilot. Retrieve Form for Data 
Capture (RFD) will be used to extract the selected data points from the EHR and imported into 
the EDC system. An archive of selected data points, at the time of extraction, will be stored at 
the sites.  
Has been deleted:  
Section 13.3.1.1 Electronic Health Record extraction pilot  
It is anticipated that a selection of data points (Demography, Medical History, Concomitant 
Medications, and potentially Vital Signs) will be collected via the subjects’ E lectronic 
Healthcare Record (EHR) at specific sites as part of a small EHR Pilot. Retrieve Form for 
Data Capture (RFD) will be used to extract the selected data points from the EHR and 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 197 of 206 imported into the EDC system. An archive of selected data points, at th e time of extraction, 
will be stored at the sites.  
 
Change #60  
Section 14.1 Definition of analysis sets  
The Full Analysis Set (FAS) will consist of all randomized subjects that received at least 1 dose 
of the IMP and have a valid measurement of the co -prim ary efficacy variables at Baseline.  
Has been changed to:  
The Maintenance Set will consist of all subjects who have received at least 1 dose of active 
IMP (bimekizumab or ustekinumab) in the Maintenance Treatment Period.  
The Full Analysis Set (FAS) will c onsist of all randomized subjects that received at least 1 dose 
of the IMP and have a valid measurement for each  of the co -primary efficacy variables at 
Baseline.  
The Pharmacodynamics Per -protocol Set (PD -PPS) will consist of all randomized subjects 
who re ceived at least 1dose of the IMP and provided at least 1 PD measurement post -dose 
without important protocol deviations affecting the measurement.  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 198 of 206 Change #61  
Section 14.2  General statistical considerations  
Figure  14-1: Sequence of testing  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 199 of 206 .Has been changed to:  
Figure  14-1: Sequence of testing  
 
 
Change #62  
Section 14.4 Subgroup analyses  
Subgroup analyses will be performed on the primary and secondary efficacy variables that are 
part of the fixed sequence testing procedure described in Secti on 14.3. The following variables 
for subgroup analyses will be defined: age, gender, disease duration, region, weight, body mass 
index (BMI), prior systemic chemotherapy or photochemotherapy, prior biologic exposure, prior 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 200 of 206 systemic therapy of any kind, Bas eline disease severity, and antibody positivity. These 
summaries will be based on imputed data (NRI) and will include descriptive statistics only.  
Has been changed to:  
Subgroup analyses will be performed on the primary and secondary efficacy variables that are 
part of the fixed sequence testing procedure described in Section 14.3. The following variables 
for subgroup analyses will be defined: age, gender, disease duratio n, region, weight, body mass 
index (BMI) , prior systemic chemotherapy or photochemotherapy  phototherapy , prior 
biologic exposure, prior systemic therapy of any kind, Baseline disease severity, and antibody 
positivity. These summaries will be based on imput ed data (NRI) and will include descriptive 
statistics only.  
 
Change #63  
Section 14.5.2 Pharmacokinetic/pharmacodynamic analyses  
The relationship between efficacy response (PASI/IGA) and bimekizumab plasma concentration 
will be explored via graphical and a model based (PK -PD) approach quantify the time course of 
dose/exposure response. In addition, the relationship between safety and exposure will also be 
explored. The data will be combined with that from other bimekizumab trials in psoriasis for a 
pooled, c ross trial analysis. The details of this analysis will be described in a data analysis plan, 
and the analysis itself will be reported separately from the Clinical Study Report (CSR). 
Candidate biomarkers may include, but are not limited to: IL -17A/IL -17F p athway signaling and 
PSO biology (eg, IL -17A, IL -17F, IL -23, IL -6, TNF, DC -STAMP, and circulating osteoclast 
precursors). The details of the model and the approach will be specified in a data analysis plan.  
Pharmacodynamic variables will be analyzed for al l subjects in the PD -PPS.  
Has been changed to:  
Section 14.5.2 Pharmacokinetic /pharmacodynamic  analyses  
The relationship between efficacy response (PASI/IGA) and bimekizumab plasma 
concentration will be explored via graphical and a model -based (PK -PD) appr oach to 
quantify the time course of dose/exposure response. In addition, the relationship between 
safety and exposure will also be explored. The data will be combined with that from other 
bimekizumab trials in psoriasis for a pooled, cross trial analysis. The details of this analysis 
will be described in a data analysis plan, and the analysis itself will be reported separately 
from the Clinical Study Report (CSR). Candidate biomarkers may include, but are not 
limited to: IL -17A/IL -17F pathway signaling and PSO biology (eg, IL -17A, IL -17F, IL -23, 
IL-6, TNF, DC -STAMP, and circulating osteoclast precursors) (not applicable in Japan). 
The details of the model and the approach will be specified in a data analysis plan.  
Pharmacodynamic variables will be analyzed f or all subjects in the PD -PPS.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 201 of 206 Change #64  
Section 14.6 Handling of protocol deviations  
Important protocol deviations are deviations from the protocol which potentially could have a 
meaningful impact on study conduct, or on the primary efficacy, key safety,  or PK/PD outcomes 
for an individual subject.  
Has been changed to:  
Important protocol deviations are deviations from the protocol which potentially could have a 
meaningful impact on study conduct, or on the primary efficacy, key safety, or PK /PD 
outcomes  for an individual subject.  
 
Change #65  
Section 17 References  
The following reference has been deleted:  
Bretz F, Maurer W, Brannath W, Posch M. A graphical approach to sequentially rejective 
multiple test procedure. Statistics in Medicine. 2009;28:586 -604. 
 
18.4 Protocol Amendment 4  
Rationale for the amendment  
The purpose of this amendment was to update the secondary and “other” efficacy variables to be 
consistent with the wording in the statistical analysis plan (SAP). The secondary and “other” 
efficacy variable s for the scalp IGA response, and the “other” efficacy variable for the IGA 
response were updated to clarify that the response required “at least a 2 -category improvement 
from Baseline,” as it is described in the SAP.  
For the Patient Symptom Diary, the sec ondary and “other” efficacy variables were updated from 
“change from Baseline” to “response” on the items of itch, pain, and scaling in order to align the 
protocol with the planned responder analyses described in the SAP which define clinically 
meaningful thresholds of change for defining treatment response, rather than change from 
Baseline. The hierarchy figure (Figure 14.1) was also updated to reflect this change. There is no 
change to the frequency of diary assessments or how the diary assessments are pe rformed.  
The name and contact information of the Clinical Project Manager  was also changed.  
Change #1  
Clinical Project Manager  
Name:   
Address:  UCB Biosciences, 8010 Arco Corporation Drive, Raleigh, NC 27617  
Phone:   
Fax:  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 202 of 206 Has been changed to:  
Name:   
Address:  UCB Biosciences, 8010 Arco Corporation Drive, Raleigh, NC 27617  
Phone:   
Fax:  
Change #2  
Section 4.2.1  Secondary efficacy variables  
The following bullets:  
 Change from Baseline in the Patient Symptom Diary responses for itch, pain, and scaling at 
Week  16 
 Scalp IGA response (Clear or Almost Clear ) at Week 16 for subjects with scalp PSO at 
Baseline  
Have been changed to:  
 Change from Baseline in the  Patient Symptom Diary responses for itch, pain, and scaling at 
Week  16 
 Scalp IGA response (Clear or Almost Clear with at least a 2-category improvement from 
Baseline ) at Week 16 for subjects with scalp PSO at Baseline  
Change # 3 
Section 4.3.1  Other efficacy variable(s)  
The following bullet s: 
 IGA response (Clear)  
 Change from Baseline in the Patient Symptom Diary responses  
 Scalp -specific Investigator’s Global Assessment (scalp IGA) response (Clear or Almost 
Clear) for subjects with scalp PSO at Baseli ne 
Has been changed to:  
 IGA response (Clear with at least a 2 -category improvement from Baseline )  
 Change from Baseline in the  Patient Symptom Diary responses  
 Scalp -specific Investigator’s Global Assessment (scalp IGA) response (Clear or Almost 
Clear  with at least a 2-category improvement from Baseline ) for subjects with scalp PSO 
at Baseline  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 203 of 206 Change #4  
Section 9.11  Patient Symptom Diary responses  
A third paragraph has been added:  
The Patient Symptom Diary responses for itch, pain, and scaling at Week 1 6 will be 
computed based on the responder definition as well as the absolute and percent change 
from Baseline. Each of the Patient Symptom Diary response scores included in the 
statistical testing procedure (itch, pain, and scaling) will be characterized i n terms of the 
cumulative percent of subjects demonstrating a pre -specified point improvement at 
Week16. The threshold for the Patient Symptom Diary  response score of itch, pain, and 
scaling is 2.39, 1.98, and 2.86, respectively. The responder analysis wil l be limited to the 
subjects with a Baseline Patient Symptom Diary  response score at or above the applicable  
threshold score (ie , at least 2.39, 1.98, and 2.86 for itch, pain, and scaling, respectively).  
Change #5  
Figure 14 1:  Sequence of testing  
  
BL=Baseline;  IGA=Investigator’s Global Assessment; PASI=Psoriasis Area Severity Index; PSD=Patient Symptom 
Diary; PSO=psoriasis  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 204 of 206 Has been changed to:  
 
BL=Baseline;  IGA=Investigator’s Global Assessment; PASI=Psoriasis Area Severity Index; PSD=Patient Sympt om 
Diary; PSO=psoriasis  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 205 of 206 19 DECLARATION AND SIGN ATURE OF INVESTIGATO R 
I confirm that I have carefully read and understood this protocol and agree to conduct this 
clinical study as outlined in this protocol, according to current Good Clinical Practice and local  
laws and requirements.  
I will ensure that all subinvestigators and other staff members read and understand all aspects of 
this protocol.  
I have received and read all study -related information provided to me.  
The objectives and content of this protocol as well as the results deriving from it will be treated 
confidentially, and will not be made available to third parties without prior authorization by 
UCB.  
All rights of publication of the results reside with UCB, unless other agreements were made in a 
separa te contract.  
Investigator:  
 
   
Printed name    Date/Signature  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0009  
   
Confidential  Page 206 of 206 20 SPONSOR DECLARATION  
I confirm that I have carefully read and understand this protocol and agree to conduct this 
clinical study as outlined in this protocol and according to current Good Clinical Practice.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
Approval Signatures
Name: ps0009-protocol-amend-4
Version: 1 . 0
Document Number: CLIN-000134866
Title: PS0009 Protocol Amendment 4
Approved Date: 23 May 2019
Document Approvals
Approval
Verdict: ApprovedName: 
Capacity: Clinical
Date of Signature: 22-May-2019 19:51:04 GMT+0000
Approval
Verdict: ApprovedName: 
Capacity: Clinical
Date of Signature: 22-May-2019 19:54:05 GMT+0000
Approval
Verdict: ApprovedName: 
Capacity: Clinical
Date of Signature: 23-May-2019 05:35:09 GMT+0000
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 